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INTRODUCTION
To give the reader an idea of what pediatric headache - and especially pediatric migraine 
- entails, and to illustrate its various aspects and consequences, a case history is presented 
of a young boy who was referred by his general practitioner to the author of this thesis.      
At	referral	Paul	was	eight	years	old	and	had	already	been	suffering	from	severe	and	debilitating	
headaches	(one	or	two	per	week)	for	more	than	three	years.	The	headache	had	a	throbbing	
character,	was	 located	 in	his	 forehead,	did	not	 radiate	 to	his	neck	and	 shoulders,	 and	was	
frequently	accompanied	by	nausea,	vomiting,	and	 increased	sensitivity	 to	 light	and	sound.	
During	a	headache	attack	he	was	unable	to	carry	out	any	tasks	or	duties.	A	headache	attack	
would	 last	several	hours.	Paul	described	the	pain	as	severe.	Typically,	Paul	would	go	to	bed	
and,	preferably,	fall	asleep.	After	waking	up	he	would	feel	much	better.	
Paul	 did	 not	 suffer	 from	 reversible	 visual	 or	 sensory	 symptoms	 or	motor	weakness	 before,	
during	or	after	the	headache	attacks.	His	mother	would	occasionally	give	him	paracetamol	
(500	mg)	as	a	suppository,	which	provided	some	relief	from	the	pain	but	not	from	the	other	
symptoms.
Because	of	the	headaches	he	frequently	missed	school	and	was	unable	to	engage	in	sports	or	
outdoor	activities	with	his	friends.	Consequently,	his	school	grades	dropped	and	he	completely	
stopped	playing	soccer	 in	his	 junior	 team.	 In	addition,	his	parents	were	under	considerable	
strain	 because	 they	 frequently	 had	 to	miss	work	 to	 take	 care	 of	 Paul,	 and	were	 extremely	
worried	about	him	-	especially	about	the	cause	of	his	headaches.	His	father	was	afraid	that	
Paul	was	suffering	from	a	severe	brain	disease.	
Eventually,	the	parents	pointed	out	that	because	Paul	had	stopped	playing	soccer	and	could	
not	do	any	other	outdoor	activities,	he	spent	a	lot	of	time	watching	TV.	Generally,	he	went	to	
bed	at	about	eight	o’clock	but	did	not	sleep	until	as	late	as	nine	or	ten	o’clock	because	he	was	
playing	computer	games.	They	also	found	that	Paul	was	becoming	increasingly	withdrawn,	
had	fewer	contacts	with	friends,	and	occasionally	seemed	worried	and	‘down’.								
The	physical	and	neurological	examinations	revealed	no	abnormalities.	Paul	was	of	average	
height	and	weight	for	his	age,	and	had	normal	blood	pressure.	Ophthalmologic	examination	
did	not	reveal	any	signs	of	papiloedema	or	a	refraction	disorder.	
Paul	was	diagnosed	as	suffering	from	migraine	without	aura.	He	and	his	parents	were	informed	
about	the	diagnosis	and	were	relieved	that	Paul	was	not	suffering	from	a	severe	brain	disease.
He	was	treated	with	diclofenac	(50	mg)	and	domperidon	(30	mg)	suppositories	symptomatically.	
Paul	and	his	parents	were	instructed	not	to	use	both	of	the	drugs	more	than	once	a	day,	and	
not	more	than	three	times	a	week.	They	were	also	advised	not	to	use	other	analgesics	or	any	
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other	 symptomatic	medications.	 In	addition,	 they	were	given	 some	basic	 ’life	 rules’	 to	help	
improve	Paul’s	 sleeping	pattern	and	were	advised	 to	encourage	Paul	 to	 start	 some	 form	of	
physical	exercise,	preferably	outdoor	activities.	
Six	weeks	later	Paul	was	seen	for	a	follow-up	consultation.	In	that	period	he	had	suffered	only	
one	 headache	 attack	 and	 had	 been	 successfully	 treated	with	 diclofenac	 and	 domperidon	
suppositories.	The	parents	reported	that	Paul	was	sleeping	much	better	after	they	had	removed	
the	computer	from	his	room	and	let	him	walk	the	dog	for	about	30	minutes	before	he	went	to	
bed.	The	only	migraine	attack	that	Paul	had	suffered	had	been	preceded	by	a	night	with	less	
sleep	than	usual,	because	he	had	attended	a	friend’s	party.	The	parents	wondered	whether	the	
migraine	attack	had	been	triggered	by	this	one	night	of	less	sleep,	or	whether	this	was	just	a	
coincidence.	
This case history illustrates many aspects of pediatric headache and raises relevant 
questions from a clinical, parental and patient viewpoint.     
First of all - the diagnosis. Paul is suffering from unilateral headache attacks with a pulsating 
quality, accompanied by nausea, vomiting, photofobia and phonofobia, together with 
avoidance of any routine physical activity. In addition, the pain is described as severe. 
Because Paul has no aura symptoms, and his physical and neurological examinations 
are normal, the headache is diagnosed as migraine without aura in accordance with the 
ICHD-II criteria1. 
Second, this case history shows that Paul’s migraines have a profound impact on both his 
life and that of his parents. Paul’s school grades deteriorated because of frequent absence 
due to migraine - and he stopped playing soccer. Moreover, his parents are worried 
because they often miss work to take care of Paul, and also fear that Paul is suffering from 
a severe disease - thus increasing the tension in the family.  
Due to the headache attacks, Paul has, more or less, adopted a different lifestyle. However, 
it is questionable whether this lifestyle is considered suitable by the clinician and the 
parents, or even by Paul himself. In other words, is Paul coping in an adequate and 
acceptable way? One is more likely to answer ‘no’, because even with this new lifestyle 
Paul does not suffer less from the headaches, perhaps he even suffers more. However, to 
answer this question in an objective way we need to measure the burden of headache 
before and then after adaptation to his new lifestyle. The question then arises whether we 
should assess the burden of headache by merely measuring the frequency and intensity 
of the headache attacks – or are other options available?  
It is well known that the burden of migraine in adults and children is high, and that well-
being and ability to function are affected in several life domains, such as school or work 
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performance, mental health and social activities2,3. An important outcome for measuring 
the burden of a disease is ‘quality of life’ (QoL), which reflects the impact of the disease 
and treatment on a subjective evaluation by the patient (or, in the case of children, by the 
parents) of the patient’s physical functioning and emotional well-being4-8.  
Studies examining QoL in children with headache and migraine are either population-
based8-10  or hospital-based8,11-13. In both types (but particularly in hospital-based studies), 
children with headache are shown to have significantly lower QoL scores than healthy 
children. Compared to children with chronic illness (such as rheumatic disorders 
or cancer) their QoL is similar with respect to impairments in school and emotional 
functioning12. All these hospital-based studies were performed in tertiary pediatric 
headache centers, providing information from a selected group of children with migraine 
(referred from general hospitals by pediatricians or neurologists), and they explored only 
a limited number of life domains of the children themselves. No hospital-based studies 
have explored QoL in children with migraine in general hospitals or in general pediatric, 
neurological or pediatric neurological practices, thus raising the question how QoL is 
affected in children with headache referred to these latter types of hospitals and practices. 
It is also unknown if and how and to what extent the child’s headache influences the life 
of the parents and family members. 
Thirdly, Paul’s headaches seem to affect his mental state. He has become more withdrawn, 
has less social contacts, and sometimes appears worried and ‘down’. This might indicate 
that he is becoming depressed. The raises the question whether this is a consequence 
of the headache attacks, or whether the headaches are a symptom of an underlying 
psychological or psychiatric disorder. 
Clinical and population studies in children have shown a relationship between headache 
and psychopathology; in these studies various outcome measurements were used. 
Behavioral problems and psychological functioning were measured in subgroups of 
children suffering from different types of headache14,15 or were compared with those 
of healthy children16-21, with children suffering from chronic fatigue22 or from recurrent 
pain due to other disorders23. One study had a longitudinal design24, but most studies on 
psychological functioning in children with headache used a cross-sectional design. To date, 
no systematic review has explored the occurrence and manifestations of psychological 
dysfunctioning and/or psychiatric comorbidity in childhood migraine. 
Because a substantial proportion of children with headache or migraine seem to 
demonstrate some form of psychological dysfunctioning or psychiatric comorbidity, 
the question arises whether (after referral to a specialist) these children should have a 
consultation with a child psychologist or child psychiatrist. Another question to be 
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considered is whether the psychological dysfunctioning or psychiatric comorbidity might 
be positively influenced by an intervention directed at reducing headache attacks. If this 
is the case, such an intervention should be implemented early on and referral to a child 
psychologist/psychiatrist should take place at a later stage of treatment. However, in 
children with migraine, there are no intervention studies directed at decreasing headache 
attacks that have assessed the effect on psychological (dys)functioning or psychiatric 
comorbidity as the main outcome. This implies that this aspect of childhood migraine is 
largely uncharted.			
With regard to treatment of childhood migraine a wide range of intervention studies 
have been performed: both symptomatic (i.e. interventions aimed at decreasing the 
pain and/or other symptoms of  migraine once the attack has started) and prophylactic 
(i.e. interventions aimed at preventing headache attacks in migraineurs), and both 
pharmacological and non-pharmacological. At the start of the research leading to this 
thesis, no systematic review of the literature describing and assessing all treatment 
modalities in children with migraine had been performed; therefore, no evidence-based 
recommendations could be made and no guidelines could be designed. From a clinical 
viewpoint, conducting such a review of intervention studies is highly relevant.   
In addition, with regard to treatment, the question arises which treatment modalities 
are scientifically proven effective in terms of improving headache attacks and have 
demonstrated a decrease of the burden, especially since some treatment modalities 
have the potential of adverse effects and therefore can increase the burden of the 
children involved whilst at the same time decreasing it because of the improvement of 
the headache25-27. From a clinical, parental and patient viewpoint the question of how to 
measure the combination of the beneficial effects of the intervention in combination with 
(possible) adverse effects is highly relevant, especially when considering the young age of 
these patients and their concomitant inability to verbalize abstract concepts such as a net 
result of ‘beneficial and adverse effects’. The use of QoL as outcome, preferably measured 
on a broad diversity of life domains, might provide an answer to this important question. 
The few studies that used QoL as measure of outcome in children with migraine have 
shown that an intervention which successfully decreases the headache symptoms, has a 
concomitant beneficial effect on QoL27,28. In these studies the pediatric Migraine Disability 
Scale (pedMIDAS) was used as QoL questionnaire, providing information on a relatively 
limited number of life domains: i.e. absence or limited performance in school, homework 
or chores and in social activities (including sports). Until now, these studies have been 
performed only in tertiary pediatric headache centers. 
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Treatment of migraine not only encompasses symptomatic or prophylactic treatment, 
but also the detection and elimination of migraine triggers and improvement of sleep 
quality. However, prospective studies on the effect of poor sleep quality or decreased 
sleep duration as a migraine trigger in children are scarce. This means that we still need 
to explore how, and to what extent, sleep deprivation and poor sleep quality might 
provoke headache attacks in children with migraine. For Paul, an improvement was seen 
after starting proper symptomatic treatment combined with following simple life rules to 
increase sleep quality and resume physical exercise. At his follow-up consultation he had 
experienced only one headache attack - and this was preceded by a night of less sleep 
than usual. The parents enquired whether this one night of less sleep could be the main 
trigger for the attack: the answer to this question is not yet fully elucidated.
All the questions outlined above are of relevance for the clinician, the parents and the 
children themselves. In the present thesis we have attempted to answer some of them 
from a clinical-scientific point of view.  
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THE CURRENT THESIS
Perspectives and goals 
The first aim of the work presented in this thesis is to describe and evaluate all currently 
used  treatment modalities for children with migraine. For this, our group of collaborators 
(mainly from the Dept. of General Practice, Erasmus Medical Center) performed a systemic 
review of all symptomatic and prophylactic treatment modalities (both pharmacological 
and non-pharmacological) in children with migraine. This resulted in three publications 
describing the results of our review, and enabling us to make evidence-based 
recommendations about symptomatic and prophylactic treatments in children and 
adolescents with migraine25,26,29. Based on the results of this review we concluded that there 
is a lack of evidence-based treatment modalities in childhood migraine, and that both 
evidence-based and non-evidence-based treatment modalities may have considerable 
adverse effects25,26,29. For example, anti-epileptics are widely used for migraine prophylaxis 
in children and adolescents with migraine. Although these drugs may have a beneficial 
effect on headache frequency and intensity, they may also have a negative effect on 
mood, cognition or behavior27. However, the net result of this combination is difficult 
to determine. From this perspective, recommendations were made for future studies to 
use QoL, measured on a broad number of life domains (and possibly other outcomes) 
to detect this net result of beneficial and adverse effects. This is of particular relevance 
for children who are too young to adequately describe their improvements on the one 
hand and their complaints on the other, let alone to subsequently provide reasoned 
judgment about the overall effect of treatment25,26. Therefore, we decided to perform an 
evidence-based prophylactic intervention study in children with migraine with QoL as the 
secondary outcome parameter, and with migraine frequency, intensity and duration as 
the primary outcome parameters.
Subsequently, it was decided to perform an exploratory study in children with primary 
headache (referred to the outpatient pediatric department of a general hospital) with the 
purpose of measuring QoL at referral on a broad range of life domains. The Child Health 
Questionnaire (CHQ) was used as the QoL outcome parameter. This is a generic QoL 
measurement tool, originally developed by Landgraf and colleagues30 and translated and 
validated in Dutch by Raat and colleagues6,7.  After completion of this study, it was decided 
to use the CHQ as QoL outcome in the prophylactic intervention study in children with 
migraine. 
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Based on a literature search exploring the occurrence and manifestations of psychological 
(dys)functioning and/or psychiatric comorbidity in children with migraine in clinical 
studies, it was decided also to use psychological functioning as secondary outcome 
parameter for the intervention study. This was primarily to be able to observe whether an 
intervention designed to decrease headache attacks in children with migraine, would also 
have a concomitant beneficial effect on psychological functioning. The Child Behaviour 
Check List (CBCL) was chosen as outcome measure for psychological functioning because 
this was the most widely used outcome measure in the descriptive studies emerging 
from the literature search. The CBCL was developed by Achenbach and colleagues31 and 
translated and validated in Dutch by Verhulst and colleagues32. 
However, a comprehensive systematic review of the occurrence and manifestations of 
psychological (dys)functioning and/or psychiatric comorbidity in children with migraine 
in clinical studies	was lacking. Therefore, we decided to perform a systemic literature 
search on this topic which would allow us to make evidence-based recommendations for 
its diagnosis and treatment.
With regard to the choice of the prophylactic intervention itself, very few evidence-
based prophylactic intervention studies have been performed in children with 
migraine26. However, our attention was drawn to riboflavin (vitamin B2), which was used 
as a prophylactic agent in studies on adults with migraine, including two open-label 
studies33,34 and two randomized controlled trials35,36. In these latter trials, riboflavin proved 
to be effective and with minimal adverse effects. Therefore, we considered it of clinical 
interest to perform a placebo-controlled trial in children with migraine with riboflavin as 
the active agent. At the start of this intervention study, no other trials were registered to 
investigate the effect of riboflavin in children with migraine. 
Finally, having decided to perform a placebo-controlled, cross-over trial in children with 
migraine, we considered it of clinical importance to design a prospective study (within 
the context of this trial) to evaluate sleep deprivation as a potential	causative factor for 
headache attacks in childhood migraine. The effect of resting and sleeping on headache 
symptoms, after the start of a headache attack, was also explored.
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Outline of the thesis
Chapter	2 presents the systematic literature review of all pharmacological prophylactic 
treatments of migraine in children. This review was conducted as part of a more 
comprehensive systematic review of all pharmacological and non-pharmacological 
treatment modalities in childhood migraine. After describing the search strategy, study 
selection, methodological quality of the studies and method of data extraction, the 
effectiveness of the different interventions are compared. Finally, the results are discussed 
and recommendations are made for pharmacological prophylactic treatment modalities 
in childhood migraine, as well as for future pharmacological prophylactic intervention 
studies in children with migraine.
Chapter	3 presents the systematic literature review of the prevalence and manifestations 
of psychiatric comorbidity and psychological functioning in children with migraine. After 
describing the study protocol, evaluation data on the quality and outcome of the included 
studies are presented, emphasizing the evidence in relation to psychological functioning 
in children with migraine. The results are discussed, evidence-based conclusions are 
drawn, and recommendations are made for clinical practice.       
Chapter	4 presents a clinical descriptive study on the generic quality of life (QoL) in children 
with headache, referred to an outpatient pediatric department of a general hospital. The 
procedure, selection criteria and rationale for the use of the Child Health Questionnaire 
(CHQ) as outcome for measuring QoL are described. Demographic information is presented 
for the children with primary headache, and for the control groups of healthy children 
and the children with asthma and attention deficit hyperactivity disorder (ADHD). CHQ 
scores are reported for all investigated groups, which are then compared with each other. 
Conclusions are drawn and implications for future research are discussed.
Chapter	5 describes the placebo-controlled, randomized, double-blind, crossover trial in 
children with migraine using riboflavin (vitamin B2) as verum medication. The rationale 
for selecting riboflavin as prophylactic intervention is presented, and comparable 
intervention studies in adult migraineurs with riboflavin as the acting agent are described. 
After presenting baseline information on demographics and clinical characteristics of 
the children, data are presented on the effect of riboflavin compared with placebo on 
the primary outcome measures, i.e. headache frequency and intensity, and duration 
of headache attacks. The results of this study are discussed in the light of comparable 
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studies in adults and children. Evidence-based conclusions are drawn with regard to the 
beneficial effects of riboflavin on headache parameters, as well as its adverse effects, in 
children with migraine.
In Chapter	 6 the effect of riboflavin on generic QoL, measured with the CHQ, and 
psychological functioning, measured with the Child Behaviour Check List (CBCL), is 
evaluated in children with migraine. An overview of the literature on QoL as outcome 
measure in children with headache or migraine is presented. Also presented is a systematic 
review of psychological functioning and/or psychiatric comorbidity as outcome measure 
in intervention studies on childhood migraine. After describing the methodology of 
our study, data are presented on the effect of riboflavin, compared with placebo, on the 
outcome measures CHQ and CBCL. The  results are then discussed and conclusions are 
drawn. In addition, the advantages and disadvantages of the use of QoL and psychological 
functioning as outcome measures in intervention studies in children with headache or 
migraine are discussed.
Chapter	7 investigates the effect of sleep deficit (defined as more than 1 hour sleep less 
than usual) in the preceding night before a headache attack in children with migraine, 
as well as the effect of resting and sleeping after the start of the headache attack. This 
study was designed within the context of the placebo-controlled trial with riboflavin 
as described in Chapters 5 and 6. The effect of a preceding sleep deficit on headache 
symptoms are compared with headache attacks without a preceding sleep deficit and, 
subsequently, with the effect of resting and sleeping on headache symptoms. Results are 
discussed in the context of the available literature on this subject, conclusions are drawn 
and recommendations are made for future studies.
Chapter	8	constitutes a general discussion on the main findings of the work presented 
in this thesis. Finally, recommendations are made for future descriptive and intervention 
studies in childhood migraine.
Chapter 1
22
REFERENCES
1. Headache Classification Committee of the International Headache Society. The International Classification 
of Headache Disorders 2nd edition (ICHD II). Cephalalgia 2004:24:suppl. 1:1-160.
2. Leonardi M, Steiner T, Scherer A, Lipton RB. The global burden of migraine: measuring disability in 
headache disorders with WHO’s Classification of Functioning, Disability and Health (ICF). J Headache 
Pain 2005;6:429-440.
3. D’Amico D, Usai S, Grazzi L, Rigamonti A, Solari A, Leone M, Bussone G. Quality of life and disability in 
primary chronic daily headaches. Neurol Sci 2003;24:S97-S100.
4. Bandell-Hoekstra I, Abu-Saad HH, Passchier J, Knipschild P. Recurrent headache, coping, and quality of life 
in children: a review. Headache 2000;40:357-370.
5. World Health Organization. Constitution of the World Health Organization basic documents. Geneva, 
Switzerland: World Health Organization 1948.
6. Raat H, Botterweck AM, Landgraf JM, Hoogeveen WC, Essink-Bot ML. Reliability and validity of the short 
form of the child health questionnaire for parents (CHQ-PF28) in large random school based and 
general population samples. J Epidemiol Commun Health 2005;59:75-82.
7. Raat H, Bonsel GJ, Essink-Bot ML, Landgraf JM, Gemke RJ. Reliability and validity of comprehensive health 
status measures in children: The Child Health Questionnaire in relation to the Health Utilities Index. J 
Clin Epidemiol 2002;55:67–76.
8. Kernick D, Campbell J. Measuring the impact of headache in children: a critical review of the literature. 
Cephalalgia 2009;29:3-16. 
9. Van Duijn NP, Brouwer HJ, Gooskens RH. Kinderen met hoofdpijn (Children with headache). Medisch 
Contact 2000;26:971-974.
10. Langeveld JH, Koot HM, Loonen MC, Hazebroek-Kampschreur AA, Passchier J. A quality of life instrument 
for adolescents with chronic headache. Cephalalgia 1996;16:183-196.
11. Powers SW, Patton SR, Hommel KA, Hershey AD. Quality of life in pediatric migraine: characterization of 
age-related effects using PedsQL. Cephalalgia 2004;24:120-127.
12. Powers SW, Patton SR, Hommel KA, Hershey AD. Quality of life in childhood migraines: clinical impact 
and comparison to other chronic illnesses. Pediatrics 2003;112:e1-5.
13. Nodari E, Battistella PA, Naccarella C, Vidi M. Quality of life in young Italian patients with primary 
headache. Headache 2002;42:268-274.
14. Rossi LN, Cortinovis I, Menegazzo L, Menini S, Carnelli V. Behaviour during attacks and assessment of 
intensity in primary headaches of children and adolescents.  Cephalalgia 2006;26:107-112.
15. Passchier J, Orlebeke JF. Headaches and stress in schoolchildren: an epidemiological study. Cephalalgia 
1985;5:167-176. 
16. Guidetti V, Mazzei G, Ottaviano S, Pagliarini M, Paolella A, Seri S. The utilization of the Rorschach test in a 
case-controlled study. Cephalalgia 1986;6:87-93.
17. Mazzone L, Vitiello B, Incorpora G, Mazzone D. Behavioural and temperamental characteristics of 
children and adolescents suffering from primary headache. Cephalalgia 2006;26:194-201. 
18. Just U, Oelkers R, Bender S, Parzer P, Ebinger F, Weisbrod M, Resch F. Emotional and behavioural problems 
in children and adolescents with primary headache. Cephalalgia 2003;23:206-213.
19. Pakalnis A, Gibbons J, Colvin A. Comorbidity of psychiatric and behavioral disorders in pediatric 
migraine. Headache 2005;45:590-596.
20. Anttila P. Sourander A, Metsahonkala L, Aromaa M, Helenius H, Sillanpaa M. Psychiatric symptoms in 
children with primary headache.  J Am Acad Child Adolesc Psychiatr 2004;43:412-419.
21. Vannata K, Getzoff EA, Powers SW, Noll RB, Gerhardt CA, Hershey AD. Multiple perspectives on the 
psychological functioning of children with and without migraine. Headache 2008;48:994-1004.
Introduction
23
Ch
ap
te
r 1
22. Smith M, Martin-Herz S, Womack W, Marsigan J. Comparative study of anxiety, somatization, functional 
disability and illness attribution in adolescents with chronic fatigue or migraine. Pediatrics 2003;111:e376-
81.
23. Galli F, D’Antuono G, Tarantino S, Viviano F, Borrelli O, Chirumbolo A, Cucchiara S, Guidetti V. Headache and 
recurrent abdominal pain: a controlled study by the means of the Child Behaviour Checklist (CBCL). 
Cephalalgia 2007;27:211-9.
24. Guidetti V, Galh F, Fabrizi P, Giannantoni AS, Napoli L, Bruni O, Trillo S. Headache and psychiatric 
comorbidity: clinical aspects and outcome in an 8-year follow-up study. Cephalalgia 1998;18:455-62.
25. Damen L, Bruijn J, Verhagen AP, Berger MY, Passchier J, Koes BW. Symptomatic treatment of migraine in 
children: a systematic review of medication trials. Pediatrics 2005; 116(2):e295-302.
26. Damen L, Bruijn J, Verhagen AP, Berger MY, Passchier J, Koes BW. Prophylactic treatment of migraine in 
children. Part 2. A systematic review of pharmacological trials. Cephalalgia 2006;26(5):497-505.
27. Hershey AD, Powers SW, Vockell AL, LeCates S, Kabbouche M. Effectiveness of topiramate in the 
prevention of childhood headaches. Headache 2002;42:810-818. 
28. Hershey AD, Powers SW, Vockell AL, Lecates SL, Ellinor PL, Segers A, Burdine D, Manning P, Kabbouche MA. 
Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. 
Headache 2007;47:73-80.
29. Damen L, Bruijn J, Koes BW, Berger MY, Passchier J, Verhagen AP. Prophylactic treatment of migraine in 
children. Part 1. A systematic review of non-pharmacological trials. Cephalalgia 2006;26(4):373-383.
30. Landgraf JM, Maunsell, Speechley KN, Bullinger M, Campbell S, Abetz L, et al. Canadian-French, German 
and UK versions of the Child Health Questionnaire: methodology and preliminary item scaling 
results. Qual Life Res 1998;7:433-445.
31. Achenbach TM, Edelbrock CS. Behavioral problems and competencies reported by parents of normal 
and disturbed children aged four through sixteen. Monogr Soc Res Child Dev 1981;46:1-82.
32. Verhulst F, van der Ende J, Koot H. Manual for  the CBCL/4-18 (Dutch edition). ISBN 90-75584-03-2.
33. Schoenen J, Lenaerts M, Bastings E. High-dose riboflavin as a prophylactic treatment of migraine: 
results of an open pilot study. Cephalalgia 1994;14:328-329.
34. Boehnke C, Reuter U, Flach U, Schuh-Hofer S, Einhäupl K, Arnold G. High-dose riboflavin treatment is 
efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur J Neurol 2004;11:475-
477.
35. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis: a 
randomized controlled trial. Neurology 1998;50:466-470. 
36. Sándor P, Áfra J, Ambrosini A, Schoenen J. Prophylactic treatment of migraine with ß-blockers and 
riboflavin: differential effects on the intensity dependence of auditory evoked cortical potentials. 
Headache 2000;40:30-35.

Ch
ap
te
r 2
Chapter 2
Prophylactic treatment of migraine in children. Part 2. 
A systematic review of pharmacological trials
Léonie Damen, Jacques Bruijn, Arianne Verhagen, Marjolein Berger, Jan Passchier, 
Bart Koes
Cephalalgia	2006;26:497-505
Chapter 2
26
ABSTRACT 
Objective: To assess the efficacy of pharmacological prophylactic treatments of migraine 
in children.  
Methods: Databases were searched from inception to June 2004 and references were 
checked. We selected controlled trials on the effects of pharmacological prophylactic 
treatments in children with migraine. We assessed trial quality using the Delphi list and 
extracted data. Analyses were carried out according to type of intervention.
Results:	A total of 20 trials were included. Headache improvement was significantly higher 
for flunarizine compared to placebo (RR 4.00 [95% CI 1.60; 9.97]). There is conflicting 
evidence for the use of propranolol.	 Nimodipine, clonidine, L-5HTP, trazodone and 
papaverine showed no effect when compared to placebo. All medications were well-
tolerated and adverse events showed no significant differences.
Conclusions:	 Flunarizine may be effective as prophylactic treatment for migraine in 
children. Because of the small number of studies and the methodological shortcomings, 
conclusions regarding effectiveness have to be drawn with caution.
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INTRODUCTION
Migraine is the most common cause of chronic recurrent headache in school children. 
Prevalence of migraine increases with age, ranging from 1.4% to 5% in young children up 
to 11.6% in adolescents (15-18 years) and the ratio of women to men diverges to become 
about 2:1 after puberty1-3. The International Headache Society has recently revised its 
diagnostic criteria and classification system4. The changes are that migraine may last less 
than 72 hours, may be bifrontal, and that phonophobia and photophobia may not always 
be present. 
Treatment of paediatric migraine has been the subject of debate for many years. 
Prophylactic pharmacological treatment could be considered when headache frequency 
exceeds four episodes per month and/or the attacks are so severe or prolonged that they 
interfere with school or normal activities. Drugs commonly used for migraine are calcium 
antagonists, beta-blockers and pizotifen.
To our knowledge, two systematic reviews including prophylactic treatments have been 
performed on migraine in children5.6. One review included 17 behavioural treatment 
studies and 24 prophylactic drug studies of migraine in children5. They concluded that 
behavioural therapies seemed more effective than prophylactic drug regimens, but they 
excluded 35% of the behavioural treatment studies and 17% of the drug studies, which 
they considered to be methodologically inadequate or lacking statistical information. 
Not all studies analysed had control groups and different study designs were used. 
The systematic review of Victor and Ryan6 included 20 studies of which 3 studies were 
published in a congress book. They identified one single study each of propranolol and 
flunarizine showing efficacy as prophylactics of paediatric migraine. 
The present systematic review distinguishes itself from these reviews by evaluating the 
literature systematically using up-to-date methodology recommended by the Cochrane 
Collaboration7, reporting according to the Quality Of Reporting Of Meta-analyses 
(QUOROM) statement and by including the most recent literature up to June 2004. In 
this article, we present a systematic review of controlled trials concerning the efficacy of 
pharmacological prophylactic treatments of migraine in children. The authors have also 
reviewed the results of non-pharmacological prophylactic treatments. This is the subject 
of a separate article (part 1).  
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METHODS
Search strategy 
Medline, Embase, PsycInfo, Web of Science and Cinahl were searched from inception to 
June 2004 using the terms ‘migraine’, ‘headache’, ‘cephalgia’, ‘cephalalgia’, ‘child*’, ‘infant’, 
‘teenage’, ‘adolescent’ or ‘p(a)ediatric’ together with the search strategy for identifying 
randomised (RCT) and clinical controlled trials (CCT) described by Robinson and 
Dickerson8. The Cochrane Controlled Trials Register, Cochrane Library, issue 2 2004, was 
searched using the words ‘migraine’, ‘headache’, ‘cephalgia’, ‘cephalalgia’, ‘child*’, ‘infant’, 
‘teenage’, ‘adolescent’ or ‘p(a)ediatric’. Additional strategies for identifying trials included 
searching the reference lists of review articles and included studies. 
Study selection 
Only RCTs and CCTs including pharmacological prophylactic interventions used in the 
treatment or management of migraine conducted among children (age less than 18 
years), with criteria designed to distinguish migraine from other types of headache, were 
selected for our review. The use of a specific set of diagnostic criteria (e.g. IHS 1988)9,10 
was not required, but migraine diagnoses had to be based on at least some of the 
distinctive features of migraine, e.g. headache attack lasts 2-48 hours, unilateral location, 
pulsating quality, moderate to severe intensity, aggravation by routine physical activity, 
nausea and/or vomiting, photophobia and phonophobia. Studies with at least one of 
the following headache (HA) outcome measures were included: intensity, frequency, 
duration or improvement. Rescue medication was defined as additional medications 
different to study medication permitted in non-responders, usually limited to the habitual 
medications a person uses to treat their migraine headache. No language restriction was 
applied. 
Two authors (LD, JB) independently screened titles and abstracts of studies identified by 
the literature search for eligibility. Potentially relevant studies were retrieved as full papers 
and again independently reviewed by two authors (LD, JB). Disagreements regarding the 
inclusion of trials were resolved through consensus when possible, or by arbitration of a 
third author (AV).
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Methodological quality and data extraction
Two authors (LD and JB or AV) independently assessed the methodological quality of the 
included trials using the Delphi list11. The Delphi list is a generic criteria list developed 
by international consensus and consists of the following 9 items: 1) randomisation; 
2) adequate allocation concealment; 3) groups similar at baseline; 4) specification of 
eligibility criteria; 5) blinding of outcome assessor; 6) blinding of care provider; 7) blinding 
of patient; 8) presentation of point estimates and measures of variability; 9) intention-
to-treat-analysis. One extra item was added: 10) withdrawal / dropout rate (>20% or 
selective dropout) unlikely to cause bias because it was found relevant for these studies. 
All selected methodological criteria were scored as yes ( = 1), no ( = 0) or don’t know ( 
= 0). The quality score was computed by counting the number of positive scores, with 
equal weights applied on all items. In case of a disagreement between the two authors, 
consensus was used to resolve disagreement. When consensus could not be reached, a 
third author made the final decision (JB or AV). 
Extraction of data from the original reports was performed by one author (LD) and checked 
by a second (AV). Disagreements were resolved by consensus. Extracted information 
included (if available) demographic data, detailed description of the intervention and 
control (i.e. dose given, study duration), outcome measures and information on adverse 
effects. 
Data-analysis
We calculated standard mean differences (SMD) with 95% confidence interval (CI) for 
continuous outcomes or relative risks (RR) with 95% CI in case of dichotomous variables. 
RR above 1 and a SMD above 0 represent a better outcome for the first mentioned 
intervention group. For all data we include data only on those whose results are known 
(available case analysis). 
In case of crossover trial ideally we would like to restrict our analysis to first period data 
only, or, in case of a sufficient wash out period and no carry over effect, data of both 
periods could be combined. In this review we analysed the crossover trials as if they were 
parallel-group trials, because most data did not permit analysis of paired between patient 
data. If a carry-over effect was found and data were reported by period, then the analysis 
was restricted to first-period data only. 
A qualitative analysis was performed using a rating system with levels of evidence12. 
The evidence was judged to be strong when multiple (two or more) high quality RCTs 
produced generally consistent findings. Results were considered consistent if 75% or 
more of the studies reported similar results on the same outcome measure. It was judged 
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to be moderate when one high quality RCT and / or multiple (two or more) low quality 
RCTs and / or CCTs produced generally consistent findings. Evidence was considered to be 
limited when only one low quality RCT and / or CCT existed and conflicting if the findings 
of existing trials were inconsistent. No evidence was considered when no RCTs or CCTs 
were found or when the authors provide no sufficient data for analysis. We regarded trials 
with methodological quality scores of 6 or more as of high quality12. 
RESULTS
Search results
A total of 3492 publications were identified by our broad and sensitive search strategy 
(see Flow chart). Finally a total of 16 RCTs and 4 CCTs were included in this review, of which 
11 studies used a crossover design (see flow chart). 
Description of studies
Full details of the included studies are presented in Table 1. 
Participants
The number of included participants in each trial ranged from 19 to 118	(mean 44 ± 21 
patients), with a total of 887 patients included in this review. Most studies were small; out 
of 40 study arms 12 included less than 20 subjects, while eight included over 50 subjects. 
The mean percentage of participants who dropped out was 14.5% (range 0-43.9%). The 
mean age of participants was 10.7	± 1.3 years	(range 3-18 years). Overall, the percentage 
of girls was generally the same as boys (mean 48.8%; range 30.8-68.6%). Two trials used 
the criteria of the International Headache Society (9), two studies used the Ad Hoc criteria 
to classify migraine, six studies used the Valhquist definition while the remaining studies 
used varying definitions (see table 1).	
Interventions
The interventions used could be divided into placebo comparisons and drug-drug 
comparisons. Regarding placebo, comparisons were evaluated for nimodipine13, 
flunarizine14,15, propranolol16-18, timolol19, clonidine20,21, pizotifen22, L-5-hydroxytryptophan 
(L-5HTP)23,24, trazodone25, magnesium oxide26, and papaverine27. Regarding the different 
drugs, comparisons were made between flunarizine and propranolol28, flunarizine and 
acetylsalicylic acid29, flunarizine and dihydroergotamine30, pizotifen 0.5 mg and 1.0 mg31, 
and pizotifen and lisuride32.
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Outcome measures
All studies used headache diaries to assess outcomes. Using this diary amongst others HA 
frequency, intensity and duration were scored on a Likert-scale. In most studies (11 out of 
20) a measure of clinical improvement was calculated. In these studies an improvement 
was regarded as being clinically relevant when the patients’ headache declines by 50% or 
more. This score is presented as ‘HA improvement’ in Table 1 and is our primary outcome 
measure. When this outcome measure was not available, we used mainly headache 
frequency. 
Methodological quality
The quality score (with positive items in parenthesis) is presented in the ‘Study quality’ 
section of Table 1. The median score for methodological quality was 5 with a range of 
1-7. Using a cut-off point of 6 out of 10 criteria, eight studies (40%) were considered to 
be of high quality. The most prevalent methodological shortcomings were a concealed 
randomisation method (unclear 79%), the intention-to-treat analysis (unclear 28%, 
negative 72%) and blinding of the care provider (unclear 63%). 
Effectiveness of pharmacological prophylactic treatment
1. Placebo comparisons
Calcium-antagonists
In one crossover study13 nimodipine was compared to placebo. During the first treatment 
period no significant differences were found concerning HA frequency and number of 
adverse events. None of the patients complained of serious side effects except for mild 
abdominal discomfort during the early days of nimodipine treatment (17%), which 
disappeared spontaneously without altering dosage. Two studies14,15 compared flunarizine 
with placebo, in which one study reported on HA improvement14. At three months we 
found that HA improvement was significantly higher for flunarizine compared to placebo. 
The number of adverse events was not significant different: drowsiness, gastrointestinal 
complaints, weight gain and fatigue. 
There is limited evidence that flunarizine is more effective than placebo.
Anti-hypertensive medications
Three high quality studies compared propranolol to placebo16-18. Two studies reported on 
HA improvement, showing inconsistent results17,18 and two on adverse events16,17. Adverse 
events mentioned were increased appetite, abdominal pain, worsening of headache and 
were not significantly different between groups. One small study compared timolol to 
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placebo, but no data were available to calculate effect estimates19. One high quality20 and 
one low quality study21 compared clonidine to placebo, in which only the low quality study 
reported on HA intensity and both studies on adverse events. We found no significant 
differences in HA intensity or the number of adverse events. Adverse events mentioned 
for clonidine were fatigue and nausea.
There is conflicting evidence for the use of propranolol, and no evidence is found in favour 
of the use of timonolol and clonidine.
Serotonergic drugs
One high quality crossover study22 compared pizotifen to placebo, but no data were 
available to calculate effect estimates. Only one patient mentioned excessive weight 
gain while on pizotifen. Two studies23,24 compared L-5HTP to placebo, in which only one 
reported on HA improvement24. We found no significant differences in HA improvement 
or in HA index. In the study of Longo et al.23 adverse events were not specified per 
medication. One high quality crossover study25 compared trazodone to placebo and 
reported no significant differences in HA frequency during the first period. None of the 
patients complained of any serious side effects.
We found no evidence for or against the use of pizotifen, L-5HTP or trazodone.
Other medications
One high quality study compared magnesium oxide with placebo, but no data were 
available to calculate effect estimates26. Adverse events were not significantly different 
between magnesium oxide and placebo: diarrhoea or soft stools. One small study compared 
papaverin to placebo and found no significant differences for HA improvement27.
2. Drug-drug comparisons
All drug-drug comparisons were made in single low quality studies of which three 
were rather small and reported no significant differences between both drugs on HA 
improvement, HA frequency or adverse events. Adverse events were all minor and 
included fatigue, sleepiness, wait gain or abdominal pain.
DISCUSSION
Based on the available literature, we found limited evidence that flunarizine is more 
effective than placebo.	 There is conflicting evidence from two studies for the use of 
propranolol. Nimodipine, clonidine, L-5HTP, trazodone and papaverine showed no HA 
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improvement or efficacy in HA reduction of frequency attacks compared to placebo. 
Available studies on drugs like timolol, pizotifen and magnesium oxide compared to 
placebo reported no sufficient data to calculate effect estimates. 
Although systematic reviews offer the least biased method of summarising research 
literature, our results must be interpreted with consideration of the quality of evidence 
from which they were obtained. First, we decided not to contact the authors for additional 
information, because 19 of the 20 trials included in this review were published before 
1994 and most authors would be difficult to find. Secondly, our inclusion criteria greatly 
reduced the number of studies selected. Positive results for the use of prophylactic 
treatments in children and adolescents have frequently emerged from open-label 
or uncontrolled studies33-39. Third, the methodological shortcomings of many of the 
currently available studies limit conclusions about the effectiveness of pharmacological 
prophylactic treatments.	 These shortcomings include an unconcealed randomisation 
method, inadequate statistical analysis (intention-to-treat analysis), and most studies 
suffered from the lack of (reported) credible blinding of the care provider. Finally, most 
treatments have only been evaluated in 1 or 2 studies with small number of patients, 
which limits the generalisability of the findings. 
Commonly described drugs such as pizotifen and anti-epileptic drugs have not been 
adequately studied in controlled studies. Calcium antagonists and anti-hypertensive 
drugs have been well studied, but larger and better trials are still required in children. 
Therefore we strongly recommend performing large high quality RCTs evaluating most 
frequently offered pharmacological prophylactic treatments, because at the moment no 
firm conclusions can be drawn based on the available literature.
One of the reasons most studies show no significant differences is that it is difficult for any 
prophylactic treatment to show additional benefit taking the favourable natural course of 
childhood migraine into account. Furthermore, it may also be due to the small sample sizes 
of most studies or the outcome measure “HA improvement”, which was a main outcome 
measure in most studies. It indicated that only people with over 50% improvement are 
considered clinically improved, which is a large improvement. The Philadelphia panel 
advises cut-off scores for clinically relevant differences in muscular skeletal diseases of 15% 
improvement40. Headache improvement and adverse events are two outcome measures 
frequently used in the included trials. Although most studies described the adverse events 
as mild and save, the simple description of the kind and number of adverse events often 
gives insufficient insight into the severity and appreciation of the adverse events for a 
Chapter 2
34
child. Therefore, we suggest that other outcome measures like quality of life, satisfaction 
of child and/or parents, and repeated administration should also be used as an outcome 
measure in studies involving treatment of migraine in children. 
In conclusion, this review shows that there is a clear need of high quality research 
evaluating pharmacological prophylactic treatment of children with migraine. Favourably 
high quality studies should be performed and reported according to the Consolidated 
Standards of Reporting of Trials (CONSORT) statement to improve the quality of trials 
reports. Headache clinical improvement should be used as the primary outcome measure, 
but lower cut-of points for recovered and not recovered are recommended. Quality of life 
and satisfaction of child and/or parents should also be used as an outcome measure in 
studies involving pharmacological prophylactic treatment of children with migraine. 
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Flow chart: Quorum statement flow diagram
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Psychopathology in children and adolescents with migraine in 
clinical studies: a systematic review of the literature
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ABSTRACT
Background: In the last decades, numerous population-based and hospital-based studies 
have demonstrated a relationship between migraine or headache and psychopathology 
in children.
Objective: To describe and assess all clinical studies on the prevalence and manifestations 
of psychological functioning and psychiatric comorbidity in children with migraine, and 
to provide recommendations for its diagnosis and treatment.
Methods: A literature search was made in Medline, Embase, PsycINFO and the Cochrane 
database to identify clinical studies that assessed psychological functioning and/or 
psychiatric comorbidity in children with migraine. Trial quality was assessed according to 
a standardized and validated set of criteria. 
Results: Seven studies met the inclusion criteria. Evidence assessment was performed using 
the best-evidence synthesis method of Slavin. Based on this method, we found strong 
evidence that children with migraine in a clinical setting do not exhibit more withdrawn 
behaviour, do not have more thought problems, do not have more social problems 
and do not exhibit more delinquent or aggressive behaviour than healthy children. 
Furthermore, there is strong evidence that children with migraine have more somatic 
complaints and exhibit  more  internalizing behaviour which is, given the construct of the 
outcome measure used, a consequence of the nature of their disease rather than a sign 
of psychological dysfunctioning. Finally, compared with healthy children, there is limited 
evidence that children with migraine in a clinical setting are more frequently diagnosed 
with oppositional defiant disorder and are not more frequently diagnosed with ADHD, 
conduct disorder, dysthymia and depression.
Conclusions: Based on this review, we conclude that children with migraine at referral to 
a specialist do not exhibit more psychological dysfunctioning, and (to a lesser extent) do 
not exhibit more psychiatric comorbidity compared with healthy controls.  
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INTRODUCTION
Migraine is a common disorder in childhood. Its prevalence is influenced by sex and age 
and is reported to range from 3 to 15%1. Migraine in children is characterized by attacks 
of intense, throbbing, unilateral or bilateral headache, often accompanied by nausea, 
vomiting, photophobia and phonophobia2. 
As early as 1937 Harold G. Wolff presented the first extensive paper on psychological 
functioning in migraineurs, including a chapter addressing possible psychological 
maladjustments in childhood as well as case reports on psychological dysfunctioning 
in children and adolescents with migraine3. Since then numerous population-based 
and hospital-based reports have been published demonstrating a relationship between 
migraine/headache and psychopathology in children. A variety of measurement tools are 
used in these studies to investigate psychological functioning and psychiatric comorbidity 
in children with headache or migraine. 
In order to produce evidence-based recommendations for diagnostic procedures and 
treatment related to psychological functioning and psychiatric comorbidity in children 
with migraine, we reviewed the evidence by performing a literature search for studies 
conducted in a clinical setting. The aim of this review was to describe and assess all clinical 
studies on the prevalence, manifestations and treatment of psychological functioning and 
psychiatric comorbidity in children with migraine in order to provide recommendations 
for its diagnosis and treatment. 
METHODS
Search strategy
We searched Medline, Embase, PsychInfo and the Cochrane database from inception to 
February 2009 using the terms “migraine”, “headache”, “cephalgia”, “cephalalgia”, “child*”, 
“infant”, “teenage”, “adolescent”, “p(a)ediatric”, “juvenile”, “psychiatric”, “psychiatric disorder”, 
“psychiatric comorbidity”, “psychiatric comorbid disorder”, “depression”, “anxiety”, 
“behavioural problem”, “behavioral problem”, “psychological”, “psychological disorder”, 
“psychological comorbidity” and “psychological comorbid disorder”. 
Additional strategies for identifying trials included searching the reference lists of the 
included studies for outcome assessment.
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Study selection
We selected only descriptive studies concerning psychological functioning or psychiatric 
comorbidity in clinically-treated children with migraine (≤ 18 years old). Only clinical 
studies were included. Studies on children in the general population were not included, 
with the exception of those that performed a separate analysis for clinically-treated 
children with migraine. The diagnosis of migraine had to be made with criteria designed 
to distinguish migraine from other types of headache. The use of a specific set of 
diagnostic criteria (e.g. the ICHD-II2, the International Headache Society (IHS) criteria4 and 
the criteria of the Ad Hoc Committee on the Classification of Headache5) was not required, 
but migraine diagnoses had to be based on the distinctive features of migraine and had 
to be described in the methods section of the study, e.g. headache attack lasts 2-48 h, 
unilateral or bilateral location, pulsating quality, moderate to severe intensity, aggravation 
by routine physical activity, nausea and/or vomiting, photophobia and phonophobia. 
A separate analysis describing the psychological functioning or eventual psychiatric 
comorbidity of all included subjects in a standardized, transparent and reliable manner 
was also necessary for inclusion*. Review articles were included only when a meta-
analysis had been performed. A final criterion for study selection was publication in the 
English language. 
Two authors (JB and HL) independently screened the titles and abstracts of the studies 
identified by the literature search for eligibility. All potentially relevant studies were 
retrieved as full papers and then again independently reviewed by two authors (JB and 
HL). Any disagreements were resolved through consensus when possible, or by arbitration 
of a third author (JP).
* For example, in a study concerning children with clearly described criteria for the diagnosis migraine, a comorbid 
diagnosis of anxiety disorder or depression solely by consultation of a child psychologist or psychiatrist without 
specifying the criteria upon which this diagnosis was based, was considered as insufficient for inclusion.
Study quality assessment
The quality of each study was assessed according to a standardized and validated set of 
criteria based on the protocols of the Cochrane Database of Systematic Reviews as used 
in randomized controlled trials6-12 and modified to cover the case-control design of the 
studies included in this review.
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1. Comparison group(s). The presence of at least one comparison group, preferably a 
sample of healthy children from the same region as the children with headache or 
migraine. 
2.   Sample size. Based on power analysis (α = 0.05 (two-tailed), power = 0.80, Cohen’s d = 8, 
i.e. a large difference between the groups), a sample size of more than 25 participants 
per comparison group was required.
3.  Sample selection. A random selection strategy should be employed.
4. Design.The investigation should be case-controlled and based on quantitative 
information.
5. Outcome measures. These should be standardized, reliable and valid and cover the 
child’s psychological functioning and/or its eventual psychiatric comorbidity. 
6. Statistical analyses. Hypothesis testing using appropriate statistical analyses should be 
performed on the most important outcome measures.
These six criteria were assessed and scored independently by two investigators (JB 
and HL). A score of 1 (criterion met) or 0 (criterion not met) was used, leading to a total 
maximum score of 6 points per study. Inter-reviewer disagreement was primarily solved 
by discussion. When necessary, arbitration of a third author (JP) was used to resolve 
disagreement. This led to a uniform score on all included articles. Scores of 0 to 3 points 
were taken to indicate studies of low quality, and scores of 4 to 6 studies of high quality6-12.
Outcome assessment
Because only seven studies met the selection criteria and a broad diversity of outcome 
measures was used, a meta-analysis (whereby statistical data of the studies are pooled 
and tested between groups), could not be performed. Instead, a best-evidence synthesis 
method13 (as used in other systematic reviews10,11,12,14) was applied. This consists of four 
levels of scientific evidence: 
1. Strong evidence: more than one relevant high-quality study with generally consistent 
outcomes. 
2. Moderate evidence: one relevant high-quality study and one (or more) relevant low-
quality study(ies) with generally consistent outcomes.
3. Limited evidence: one relevant high-quality study or more than one relevant low-
quality studies with generally consistent outcomes.
4. Inconclusive evidence: one relevant low-quality study, no relevant studies, or studies 
with inconsistent outcomes.
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Relevant is defined as using appropriate outcome measures for psychological functioning 
or psychiatric comorbidity. A “generally consistent outcome” is defined as a situation in 
which 75% of the studies agree on the result that there are no differences between case 
and control (comparison) groups on outcome measures, or 75% of the studies agree 
on the result that there are definite differences between case and control (comparison) 
groups on outcome measures10-14.
RESULTS
Search results
The results of our search strategy are presented in Fig 1. Seven studies were included 
that concerned psychological functioning and/or psychiatric comorbidity in children or 
adolescents with migraine in a clinical setting. 
Description of studies
Table I summarizes the seven studies15-21. 
Participants
In the seven studies, the number of children with migraine ranged from 5 to 67 (mean 
38) children, with a total of 268 children included in this review. Their ages ranged from 
7.5 to 16.5 years; however, this complete age range occurred in only one study with 5 
partcipants17. In the remaining studies the age range was 8.3 to 15.3 years. Of all children, 
the mean age was 11.7 years, indicating that most children in the studies were pre-
pubertal. Of the seven studies, two16,21 used the ICHD criteria2 to classify migraine, three18-20 
used the IHS criteria4, one study15 used the Prensky criteria22 and another study17 used the 
Silberstein criteria23.  
Outcome measures
A total of 26 different outcome measures were used. These were: the State-Trait Anxiety 
Inventory for Children (STAIC)15, Revised Children’s Manifest Anxiety Scale (RCMAS)15, 
Children’s Self-Report Psychiatric Rating Scale (CSPRS)15, Coddington’s Life Events Scale 
for Children (LES-C)15, Coddington’s Life Events Scale for Adolescents (LES-A)15, Matthew 
Youth Test for Health17,  KidCope17, Type A achievement17, Type A agression17, Parent-rated 
disability17, Child-rated disability17, Rorschach test18, Thematic Appreciation Test (TAT)18, 
Blacky Pictures Test (BPT)18, Wechsler’s Intelligence Scale for Children (WISC)18, Wechsler’s 
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Adult Intelligence Scale (WAIS)18, Multidimensional Anxiety Scale for Children (MASC)19, 
Conner’s Parent Rating Scale (CPRS)19, Emotionality, Activity, Sociability and Shyness Scale 
for Childhood (EAS)19, Child Symptom Inventory 4th edition (CSI-4)20, Adolescent Symptom 
Inventory 4th edition (ASI-4)20, Loneliness and Social Dissatisfaction Questionnaire (LSDQ)21, 
Self Perception Profile for Children (SPPC)21, and Roberts Apperception Task for Children 
(RATC)21. 
These outcome measures were not used across the studies, but in single studies only. 
The Children’s Depression Inventory (CDI) was used in two studies19,21 and the Child 
Behaviour Check List (CBCL) was used in four studies16,17,19,21. 
The outcome measures were mostly questionnaires to be completed by the parents 
of the children or by the children themselves. In two studies17,18 a psychodiagnostic 
interview with a child psychologist or child psychiatrist was part of the investigation. The 
comparative data are presented in Table I. 
Study quality assessment
The assessment of the six methodological aspects and the quality standard of each study 
are presented in Table II.  All studies used comparison groups; five studies had a sufficient 
sample size (i.e. more than 25 per comparison group)15,16,19,20,21. The median score for 
methodological quality was 3.1 (range 0-4) whereas 6 was the maximum score possible. 
Five studies had a quality score of 415,16,19,20,21. One study had a quality score of 018 and 
one study of 217. Using a cut-off point of 3 or more as a high-quality study, five studies 
were considered as such15,16,19,20,21. None of the studies had a quality score of 5 or 6; this 
was due to criteria 3 and 4 with regard to sample selection and design, respectively. Only 
if the sample selection was randomized and the design case-controlled and based on 
quantative information, was a score of 1 given. In none of the included studies was this 
the case. 
Outcome assesment
Outcome assessment of the seven studies proved difficult due to the broad diversity of 
outcome measures used. Outcome measures in five studies focused on psychological 
functioning of the children with migraine15-21, whereas two studies explicitly focused on 
psychiatric comorbidity18, 20. In four studies16-19 psychological functioning or psychiatric 
comorbidity in three groups of children with different types headache, or children with 
other pain-related disorders, were compared with each other; this latter group included 
two low-quality studies17, 18 with no healthy control group. The other two studies16,19 were 
of high quality and did include healthy controls. Three high-quality studies15,20,21 included 
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only children with migraine and healthy controls. For practical purposes, for this review 
we decided to assess evidence only on the outcome measures that compared children 
with migraine with healthy children. 
For the study of Cooper et al.15, no significant differences were found between children 
with migraine and healthy children on anxiety scores as measured on the STAIC and 
RCMAS, and on the outcome measure CSPRS, LES-C and LES-A. 
In the study of Galli et al.16 a significant difference was found on the CBCL subscales 
Attention problems and Somatic complaints and on the combined scale Internalizing 
behaviour, in favour of healthy children. No significant differences were found between 
children with migraine versus healthy children on the other CBCL scales.
In the study of Gladstein et al.17 three small groups of children with transformed migraine 
(n = 5), new persistent daily headache (n = 13), and children with both migraine and 
tension type headache (n = 15) were compared. No significant differences were found 
on the outcome measures Matthew Youth Test for Health, KidCope, Type A aggression, 
Parent-rated disability and Child-rated disability between children with transformed 
migraine versus children with new persistent daily headache and versus children with both 
migraine and tension-type headache. Only on the outcome measure Type A achievement 
was a significant difference found between children with transformed migraine versus 
children with new persistent daily headache and children with both migraine and tension-
type headache, in favour of the latter two groups. 
In the study of Lanzi et al.18 three small groups of children with migraine with aura (n 
= 13), migraine without aura (n = 8) and children with chronic tension-type headache 
(n = 9) were compared using various tests and a psychodiagnostic interview resulting 
in a psychodynamic classification as “neurotic organization”, “borderline organization” 
and “white relation”. This psychodynamic classification was used as outcome measure. 
In addition to the low number of participants in each group, no statistical analysis was 
performed to compare the outcomes.  
Mazzone et al.19 found no significant differences between children with migraine and 
healthy children on the outcome measures CPRS, EAS Emotionality and EAS Shyness. 
However, significant differences on anxiety scores and social functioning between 
children with migraine versus healthy children were found on the outcome measure 
MASC and on the outcome measure EAS Sociability, respectively, in favour of the healthy 
children. In addition, a significant difference was found on depression scores in children 
with migraine versus healthy children as measured on the CDI, in favour of the healthy 
children. Furthermore, significant differences were found between children with migraine 
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versus healthy children using the CBCL as outcome measure on the scales of Internalizing 
and Externalizing behaviour and Total score, in favour of the healthy children. A significant 
difference was also found between children with migraine and healthy children with 
regard to pathological internalizing scores (severe enough for referral to a child psychiatrist 
or child psychologist), in favour of the healthy children. Pathological externalizing and 
pathological total scores, as measured on the CBCL, showed no significant difference 
between children with migraine and healthy children. No CBCL subscale analysis was 
described19. 
Pakalnis et al.20 found significant differences in the diagnosis of oppositional defiant 
disorder (ODD) and above average T-scores of CSI symptoms of conduct disorder (CD), 
ODD and generalized anxiety disorder (GAD) in children with migraine versus healthy 
children, in favour of healthy children. No significant differences were found in the 
diagnosis of ADHD, CD, dysthymia and depression between children with migraine versus 
healthy children although scores were above normative means.
Finally, Vannatta et al.21 found no significant differences between children with migraine 
and healthy children on outcome measures of the LSDQ, all subscales of the SPPC, and all 
subscales of the RATC.	In their study, the CBCL was also used to measure psychological 
functioning.	Both the mother as well as the father of all children with migraine and all 
healthy controls completed the CBCL questionnaires separately. Consequently, separate 
analyses were performed, referred to as the ‘mother’s report’ and ‘father’s report’. A 
significant difference was found between children with migraine versus healthy children 
in both the mother’s and father’s report on the subscale of Somatic complaints, in favour 
of the healthy children. In addition, the mother’s report showed a significant difference in 
favour of healthy children on the scale Internalizing behaviour and the subscale Anxious/
depressed, but the father’s report did not. On all other CBCL scales, neither the reports 
of the mothers nor those of the fathers revealed any significant differences between the 
children with migraine and the healthy children.
Five of the seven included studies were eligible for assessing evidence with regard to 
psychological functioning in children with migraine15,16,17,19,21, and two studies were 
eligible for assessing evidence with regard to psychiatric comorbidity18,20.
With regard to the first group, four of the five studies were of high quality15,16,19,21 and one 
of low quality17. This latter study included only 5 children with transformed migraine; 
moreover, no comparison was made with healthy controls. In addition, the authors 
used migraine criteria as defined by Silberstein23, which differ considerably from the IHS 
criteria4 and ICHD-II criteria2 which were used in the three of the four high-quality studies. 
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Therefore, because the evidence from this study17 can not realistically be compared with 
the other studies, we decided to assess the four other studies for evidence and describe 
the outcome measures separately (Table III). 
For the purpose of presenting evidence in a systematic manner, we decided to divide the 
available outcome measures into eight outcome fields in accordance with the scales as 
used in the CBCL, i.e. withdrawn, somatic complaints, anxious/depressed, social problems, 
thought problems, attention problems, delinquent behaviour, aggressive behaviour and 
internalizing and externalizing behaviour, of which the latter two are used only in the CBCL. 
We decided to allocate the non-CBCL outcome measures over these outcome fields based 
on their characteristics. Consequently, the outcome measures STAIC, RCMAS, CDI, MASC, 
EAS Emotionality, RATC Anxiety and RATC Depression were allocated to the outcome field 
anxious/depressed since all these outcome measures are used to measure signs of anxiety 
and/or depression in children. Two distinct outcome fields of ‘anxiety’ and ‘depression’ 
were not made because, had we done so, the CBCL outcome measure Anxious/depressed 
would have to be excluded since this CBCL subscale does not make this distinction. 
We allocated the outcome measure EAS Shyness to the outcome field withdrawn, the 
outcome measure EAS Sociability, RATC Rejection and LSDQ to the outcome field social 
problems, and the outcome measure RATC Aggression to the outcome field aggressive 
behaviour. We were unable to allocate the outcome measures CSPRS, LES-C, LES-A, CPRS, 
EAS Activity and SPPC to any specific outcome field. Furthermore, assessing evidence on 
a number of outcome fields was complicated because the different outcome measures 
yielded contradictory results. Therefore, we decided to assess evidence on all outcome 
measures within one outcome field. We specifically decided that 75% of the outcome 
measures within one outcome field should give equivalent results to provide conclusive 
evidence. 
Based on this methodology and according to the criteria of the best-evidence synthesis 
method13, there is strong evidence that children with migraine in a clinical setting do not 
exhibit more withdrawn behaviour, do not have more thought problems, do not have 
more social problems and do not exhibit more delinquent or aggressive behaviour than 
healthy children. Furthermore, based on the same criteria, there is strong evidence that 
children with migraine have more somatic complaints and show more internalizing 
behaviour. Finally, there is inconclusive evidence that children with migraine have 
more signs of anxiety or depression, have more attention problems, and exhibit more 
externalizing behaviour than healthy children. 
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Of the studies focusing on psychiatric comorbidity in children with migraine, one of the 
two selected studies was of high quality20 and the other of low quality18. This latter study 
included three small groups of children with migraine with aura (n = 13), without aura (n  = 
8), or with chronic tension-type headache (n = 9). Furthermore, no statistical analysis was 
performed and there was no comparison with healthy children. Therefore, we decided 
to assess the first study20. Consequently, according to the criteria of the best-synthesis 
method13, there is only limited evidence that children with migraine in a clinical setting 
more frequently have ODD and higher than average T-scores for CSI symptoms of ODD, 
CD and GAD as compared with healthy children. Furthermore, there is limited evidence 
that children with migraine in a clinical setting are not more frequently diagnosed with 
ADHD, CD, dysthymia and depression and do not have higher above average T-scores of 
CSI symptoms of ADHD, depression and anxiety compared with healthy children.
DISCUSSION and RECOMMENDATIONS 
This is the first systematic review to investigate psychological functioning and psychiatric 
comorbidity in children with migraine in clinical studies. In contrast with previous 
reviews26,27, in the present study the methodological quality and strength of evidence of 
the reviewed studies were assessed in a systematic manner using a standardized set of 
criteria.
Based on this review, the conclusion seems justified that there is no or only inconclusive 
evidence that children with migraine in a clinical setting show more problems in 
psychological functioning and, to a lesser extent, do not exhibit more psychiatric 
comorbidity in comparison with healthy children. Only with respect to somatic complaints 
and internalizing behaviour there is strong evidence that children with migraine have 
more problems than healthy children. With regard to somatic complaints, this conclusion
is based on the relevant CBCL subscale score in two studies16,21. This subscale contains eight 
questions of which three concern the symptoms of headache, nausea and vomiting28,29 
which are the hallmarks of migraine in children. Since in both studies16,21 no correction for 
migraine-associated symptoms took place in the subscale Somatic complaints, the
included children are inclined by the nature of their disease to have a high score on this 
subscale. 
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Fig. 1 Flow chart showing the results of the search strategy
* Initially 6 studies were included for outcome assessment. After searching the reference 
lists of these included studies, one additional study was found eligible for outcome 
assessment.
   
 
 
 
 
Full articles retrieved for more detailed evaluation (n = 34) 
Studies included for outcome assessment (n = 7*) 
Studies excluded: 
 • Not a clinical study (n = 3)    
 • No separate analysis for migraine (n = 9) 
• No separate analysis for psychological functioning 
and/or psychiatric comorbidity (n = 7) 
 • No comparison with other children (n = 1) 
 • Review article (n = 1) 
 • Not in the English language (n = 4) 
 • Untraceable (n = 3)  
Studies excluded on the basis of title and abstract: not clinical 
studies and/or no diagnosis of migraine in children (≤ 18 years) 
and/or no psychological functioning or psychiatric comorbidity  
(n = 627) 
Potentially relevant studies identified and screened for retrieval (n = 661) 
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Table III: Evidence table of psychological functioning in children with migraine in high-quality 
clinical studies 
Outcome field Cooper 
et al.15
Galli et 
al.16
Mazzone et al.19  Vannatta et al21 Evidence
Withdrawn CBCL = EAS Shyness = CBCL = Strong 
Somatic complaints CBCL + CBCL + Strong 
Anxious/depressed STAIC =
RCMAS =
CBCL = CDI +
MASC +
EAS Emotionality =
CDI =
CBCL =/+*
RATC Anxiety =
RATC Depression =  
Inconclusive 
Social problems CBCL = EAS Sociability + CBCL =
LSDQ =
RATC Rejection =
Strong
Thought problems CBCL = CBCL = Strong 
Attention problems CBCL + CBCL = Inconclusive
Delinquent 
behaviour
CBCL = CBCL = Strong 
Aggressive 
behaviour
CBCL = CBCL =
RATC Agression =
Strong 
Internalzing CBCL + CBCL + CBCL =/+* Strong 
Externalizing CBCL = CBCL + CBCL = Inconclusive
=  no significant difference between children with migraine vs. healthy children
+  significant difference between children with migraine vs. healthy children in favour of healthy children
*  in father’s CBCL report =, in mother’s CBCL report + 
Moreover, the CBCL subscale Somatic complaints is one of the three subscales that
together form the Internalizing behaviour score (the other two being the subscale 
Withdrawn and the subscale Anxious/depressed). Since in both studies16,21 the subscale 
Withdrawn showed no significant difference between children with migraine and healthy 
children, and in one study16 the subscale Anxious/depressed showed no significant 
difference between children with migraine and healthy children and in the other study 
only in the mother’s report a significant difference between children with migraine and 
healthy children in favour of healthy children was revealed21, the conclusion seems justified 
that the deviant Internalizing behaviour score in children with migraine (as described by 
Galli et al.16 and Mazzone et al.19) and in the mother’s report (as described by Vannatta 
et al.21) is mainly due to the nature of the disease in children with migraine and not the 
consequence of psychological dysfunctioning due to the migraine itself. 
Although we are able to offer some evidence on several aspects of psychological functioning 
and psychiatric comorbidity in children with migraine, the investigations reported so 
Chapter 3
58
far have limitations and problems that impair the generalizability of the findings. Thus, 
our classification of the studies into high-quality and low-quality studies, and the other 
methodological aspects, should be interpreted with the following restrictions in mind.
First of all, very strict criteria were used for the final inclusion of relevant studies. We 
included only clinical studies and any population studies were excluded. This means that a 
number of methodologically sound and relevant studies were excluded. For example, the 
studies of Just et al.30 and Andrasik et al.31 were excluded because the patient sample was 
not, or only partially, clinically based and a separate analysis for the clinical sample was 
not included. In addition several well-designed clinical studies were excluded because 
a separate analysis for children or adolescents with migraine, or a separate analysis for 
psychological functioning or psychiatric comorbidity, was lacking. Furthermore, we 
excluded studies which were not published in the English language, thereby potentially 
excluding other relevant studies.
Second, a broad diversity of 26 different outcome measures was used in the seven 
selected studies, of which only two were used across some studies (CBCL and CDI), thereby 
complicating comparison of outcome measures between studies. For this reason we 
decided to allocate different outcome measures to so-called outcome fields with the aim 
to assess the evidence provided by the high-quality studies of psychological functioning 
in children with migraine. In doing so, we were not able to allocate the outcome measures 
CSPRS, LES-C, LES-A, CPRS, EAS Activity and SPPC to a specific outcome field and therefore 
excluded them from final evidence assessment, potentially causing bias. 
Third, another limitation concerns the comparison groups used in the reviewed studies. 
In the study of Cooper et al.15 a comparison group of ‘best friend’ controls was used, 
potentially causing bias because no concealed randomization was used. In fact, in all of 
the included studies no concealed randomization was used with regard to the children 
with migraine or the control group. 
Fourth, all included studies have relatively small sample sizes (for children with migraine 
as well as for healthy children), rarely exceeding 50 persons. Only the study of Galli et al.16, 
included 70 children with migraine, and the study of Mazzone et al.19 included 67 healthy 
children. Comparing such relatively small groups might also be a potential cause for bias. 
Fifth, four different sets of criteria for diagnosing migraine in children were used 
(Silberstein23, Prensky22, IHS4, ICHD-II2), potentially complicating comparison of the patient 
groups and outcomes. However, the Silberstein and Prensky criteria were used in only two 
single studies (Cooper et al.15 and Gladstein et al.17), one of which was of low quality17. The 
other five studies either used the IHS criteria (Lanzi et al.18, Mazzone et al.19 and Pakalnis 
et al.20) or the ICHD-II criteria (Galli et al.16 and Vannatta et al.21). This makes comparison of 
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outcome measures in these five studies feasible since the ICHD-II criteria are based on the 
IHS criteria. 
Sixth, the study of Vanatta et al.21 demonstrated that fathers and mothers of children 
with migraine complete the questionnaires in different ways, which can cause substantial 
differences in outcome. This may also be a potential cause for bias in the other selected 
studies.
Finally, none of the included studies used a random selection strategy and a case-
controlled design, meaning that the quality score could not exceed 4, whereas the highest 
score possible was 6. 
CONCLUSIONS
There is strong evidence that children with migraine in a clinical setting do not exhibit 
more withdrawn behaviour, do not have more thought problems, do not have more social 
problems  and do not exhibit more delinquent or aggressive behaviour than healthy 
children. Furthermore, there is strong evidence that children with migraine have more 
somatic complaints and exhibit internalizing behaviour which is, given the construct of 
the outcome measure used, a consequence of the nature of their disease rather than a 
sign of psychological dysfunctioning. There is inconclusive evidence that children with 
migraine have more signs of anxiety and depression, have more attention problems, 
and exhibit more externalizing behaviour than healthy children. Finally, there is limited 
evidence that children with migraine in a clinical setting are more frequently diagnosed 
with oppositional defiant disorder and are not more frequently diagnosed with ADHD, 
conduct disorder, dysthymia and depression compared with healthy children. 
However, in the presence of evident psychological or psychiatric co-morbidities, 
appropriate mental health referral may have beneficial results regarding treatment and 
long-term management of the migraines. This should also be an area that warrants closer 
investigation in the future20.
More clinical studies are needed to further explore psychological functioning and 
psychiatric comorbidity in children with migraine using the same outcome measures with 
relatively large samples and using appropriate statistical testing. For clinical practice, in 
general, it does not seem necessary to refer a child with migraine to a child psychologist 
or a child psychiatrist, but only if clinical features or behavior warrant such referral.
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ABSTRACT 
Background: Knowledge on the quality of life of children with headache is lacking. Until 
now only a few studies in this field have provided information on a limited number of life 
domains.
Objective. To assess the quality of life on a comprehensive number of life domains in 
children with primary headache presenting at an outpatient paediatric department in a 
general hospital. 
Methods.  From October 2003 until October 2005 all children who were referred to the 
outpatient paediatric department because of primary headache were investigated 
by protocol. A thorough history was taken and a general physical and neurological 
examination was performed. The International Headache Society (IHS) criteria were 
used for classification. Quality of life (QoL) was measured using the Dutch version of the 
Child Health Questionnaire (CHQ-PF50 Dutch edition) and compared with data from a 
previously investigated cohort of healthy children from the same region, and with data 
from a cohort of children from the USA with asthma or with ADHD, investigated with the 
CHQ-PF50.
Results. A total of 70 primary headache patients were included in the study (25 with 
tension type headache, 36 with migraine, 7 with chronic tension type headache, 2 with 
both tension type headache and migraine). Their mean age was 10.6 years (range 4 to 17 
years); 37 children were male. On all but 1 subscale (self-esteem) the QoL of the children 
with primary headache was decreased compared with the cohort of healthy children, 
especially on the domains of mental health, parental impact time, and family cohesion. 
Compared with the cohort of children with asthma the QoL was significantly worse for 
our headache group on 7 subscales and significantly better on 1 subscale (general health 
perception). Compared with the cohort of children with ADHD the QoL was significantly 
worse on 6 subscales but significantly better on 3 subscales. There were no significant 
differences on any QoL subscale between children with tension type headache and 
children with migraine.  
Conclusions. The QoL in children with primary headache presenting at the outpatient 
paediatric department of a general hospital seems to be considerably diminished. No 
difference in QoL was found between children with tension type headache and those with 
migraine.
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INTRODUCTION
Headache is a common problem, not only in adults but also in adolescents and even 
in children. The prevalence of headache and migraine in children is age and gender 
dependent. Sillanpää reported a prevalence of headache of 50.5% for boys and 49.5% for 
girls at 7 years of age, and a prevalence of migraine of 2.9% and 2.5%, respectively1. At age 
14 years, the prevalence of headache is 48.6% and 51.4%, and for migraine the prevalence 
is 6.4% and 14.8% for boys and girls, respectively1. 
In the Netherlands 15% of children aged 6 to16 years suffers from at least two episodes of 
headache each month2; only 30% of these children is seen by a physician. In most cases the 
parents give the child a simple analgesic, put the child to bed, or take other measures to 
give the child some rest. If the child is seen by a physician, it is usually a general practitioner 
(GP). Children with migraine are more inclined to consult a physician than children with 
tension type headache (TTH); this is because children with migraine have more alarming 
symptoms and treatment by the parents with the measures mentioned above is often 
insufficient. A relatively small percentage of the children with headache seen by the GP is 
referred to a specialist who can be a paediatrician, neurologist or paediatric neurologist. 
Children with migraine tend to be overrepresented in the group of children referred2.   
An important outcome measure for effectiveness of treatment is Quality of Life (QoL), 
which reflects the impact of disease and treatment on a subjective evaluation by the 
patient (or, in the case of children, by the parents) of the patient’s physical functioning and 
emotional well-being3-5,9. QoL studies in children with headache and migraine are either 
population based2,9,10 or hospital based11,12,16. In both types of study, but particularly in 
the hospital-based ones, children with headache had significantly lower QoL scores than 
healthy children. Compared to children with chronic illness (such as rheumatic disorders 
or cancer) their QoL was similar with respect to impairments in school and emotional 
functioning. All the hospital-based studies were conducted in tertiary headache 
centres11,12,16; these studies indicate that children with headache have a comparable QoL 
to children with a chronic illness. 
The present study aimed to measure the QoL in children with primary headache presented 
in an outpatient paediatric department in a general (non-academic) hospital to obtain 
information on the severity of headache as perceived by the children and their family. It is 
of clinical interest to compare the QoL in children with migraine with that in children with 
TTH. In addition, we compared the QoL in children with migraine and TTH with that in the 
normal population. It was hypothesized that the children with primary headache would 
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report a lower QoL than healthy children.
In the QoL studies performed in tertiary headache centers, the QoL in children with primary 
headache was comparable to that in children with chronic illnesses such as cancer or 
rheumatic disorders11,12,16. As attention deficit hyperactivity disorder (ADHD) and asthma 
are also conditions such as headache, but not as severe as cancer and rheumatic disorders, 
we found it of additional clinical interest to compare the QoL in children with primary 
headache with that in children with one of these two chronic afflictions. Therefore, we 
decided to compare our data with a cohort of children with asthma and ADHD in the USA 
who were previously investigated with the same QoL questionnaire. It was tested whether 
there is a significant difference in their QoL compared with that of children with primary 
headache.
MATERIAL and METHODS
Patients
A consecutive series of 70 children referred (between October 2003 and October 2005) 
because of primary headache complaints by their GP to the outpatient Department of 
Paediatrics of the Vlietland Hospital participated prospectively in this study after informed 
consent was obtained. Headache diagnosis and classification were obtained using the 
criteria of the International Headache Society (IHS)13. 
With regard to the control group, the study population consisted of 353 schoolchildren in 
grades 3 to 8 (aged 5-13 years) at three representative elementary schools in Rotterdam, 
the Netherlands9. In both the headache and control group we used the original database 
for statistical analysis. The ADHD cohort consisted of 83 children who were treated at the 
behavioural neurology clinic at Sargent College, Boston University, USA7,18,19,20. Finally, 
the QoL data of the asthma cohort were collected from a baseline pharmaceutical study 
among 158 children with asthma in the USA7.  In both the ADHD and asthma group we 
could only use the summarized published data for statistical analysis in this study.   
Procedure
In case of the children with primary headache, a thorough history was taken and a 
complete physical and neurological examination was performed. The Dutch version of the 
Child Health Questionnaire (CHQ-PF50 Dutch edition)9 was handed over to the parents or 
guardians; they were asked to complete it at home and return it at the next visit. For both 
children and adolescents the parents filled in the questionnaire, which is understandable 
Quality of life in children with primary headache in a general hospital
67
Ch
ap
te
r 4
given the cognitive developmental level of the included children (11 years or less) 
that does not permit the abstract formal thinking required for answering quality of life 
questions. To obtain uniformity in the way the answers were given, we also asked the 
parents of children older than 12 years to complete the questionnaires. No rewards or 
other response-increasing policies were applied. To ensure accuracy, the questionnaire 
was reviewed at the next visit at the outpatient department. At that occasion, if the forms 
were not returned completely filled out or not filled out at all, the parents or guardians 
were asked to complete the form during the visit. All questionnaires were filled out 
completely without any dropouts. All parents were able to read and write Dutch. The 
data were stored in a database. Only children with primary headache as defined by the 
International Headache Society (IHS) criteria13  were included. Children with secondary 
headache were excluded. There were no other exclusion criteria.
With regard to the control group, the teachers of each class distributed the health 
questionnaires to the children, to be handed over by them to their parents (or guardians). 
The children were required to return the forms within two weeks. No rewards or other 
response-increasing policies were applied. The two criteria for eligibility for analysis were: 
1) the parent’s ability to read and write Dutch, and 2) at least an 80% response on the CHQ 
items9.
The QoL data of the children with ADHD were gathered using two modes of administration 
(in site completion and mail-out/mail back) at the behavioural neurology clinic where 
they were treated. A diagnosis of ADHD as defined by DSM-III-R criteria was the primary 
eligibility criterion7,18,19,20. The eligibility criteria in the asthma cohort were: 1) suffering 
from asthma in accordance with the American Thoracic Society definition of asthma, and 
2) using asthma pharmacotherapy daily for at least 3 months prior to screening7.   
Measures
We decided to measure QoL with the CHQ because this questionnaire has already been 
administered in chronically ill children7-9.  The CHQ was translated into Dutch in 2001 
according to international guidelines8,9,14,15. This translated version has previously been 
validated; the internal consistency [(Cronbach alpha on average 0.72 for the domains 
(range 0.39-0.96)] appeared to be adequate and the test-retest reliability good9. This 
version was further validated by measuring the QoL in 353 healthy Dutch schoolchildren 
from the same region in which the present study was performed9; this latter validation 
study provided the data on the QoL in healthy children.
The CHQ-PF50 comprises 50 items over 11 multi-item scales or domains, and two single-
item questions7-9. The life domains not only give insight in the QoL of the child itself, but 
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also in the impact of the disease of the child on his or her parents and family (see Table 
1 for the separate subscales). Each CHQ domain consists of 3 to 6 items with 4, 5 or 6 
possible responses per item. According to the CHQ User’s Manual, the domain item scores 
have to be recoded, recalibrated and finally summed. The final score may range from 0 
(worst possible health state) to 100 (best possible health state)7. 
Statistical Analysis
Analyses were performed using the statistical programme SPSS for Windows, for which the 
syntax was developed with help of the CHQ User’s Manual7. The QoL data of the children 
with primary headache were compared with the QoL data of the control group, and with 
the statistics from the cohort of children with asthma or with ADHD as given in the CHQ 
manual7,18,19,20. To test for differences, two-way ANCOVA and one-way ANOVA were used, 
respectively.
RESULTS
Demographics
This study evaluated 70 children (37 male, 33 female). Their age ranged from 4 to 17 years, 
the mean age was 10.6 years (SD ± 3.2 years), and 72.8% of them were aged between 8 
and 14 years. Headache diagnosis based on the IHS criteria was TTH only (n = 25), migraine 
only (n = 36), and chronic tension type headache (n = 7). Two children had both migraine 
and TTH. The control group included 353 children; their age ranged from 5 to 13 years of 
age. The mean age was 8.8 years (SD ± 1.9 years); 52% were girls9.
The ADHD cohort consisted of 83 children. Their age ranged from 6 to 13 years, the mean 
age was 11 years (SD ± 2.3 years) and 81% was male7,18,19,20. The asthma cohort consisted 
of 158 children with an age range from 4 to 11 years and a mean age of 9 years; 69% was 
male7. 
CHQ Scores
Children with primary headache compared with healthy children
Table 1 presents the means and standard deviations (SD) for each subscale of the CHQ for 
children with primary headache compared with healthy children, using ANCOVA analysis 
with adjustment for gender and age. On all subscales there was a significant difference 
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(p<0.05) between the children with primary headache and the healthy controls, with the 
exception of the domain self-esteem (p = 0.34).
Table 1 CHQ-PF50: Children with primary headache compared with healthy children, and with 
children with asthma or with ADHD
QoL-subscales Primary headache
(n = 70)
Healthy children
(n = 353)
Asthma
(n = 178)
ADHD
(n = 83)
mean sd mean sd mean sd mean sd
Global Health 61.8 20.9 85.8* 20.6 na na na na
Physical Functioning 82.0 10.0 98.9* 9.3 85.5 10.3 96.7# 12.2
Role/Emotional/
Behavioural
83.3 13.3 97.4* 12.7 91.3# 15.1 68.7# 30.0
Role/Physical 70.2 20.0 95.5* 20.6 86.5# 19.4 96.8# 14.7
Bodily Pain 55.6 19.2 85.6* 18.6 75.5# 20.3 85.1# 19.4
Behavior 57.6 13.3 78.4* 13.1 72.4# 15.7 54.5 17.3
Mental Health 36.6 14.9 81.1* 14.4 78.1# 12.3 66.8# 15.6
Self-Esteem 77.3 11.7 78.8 11.4 82.4# 14.6 62.6# 19.5
General Health Perception 65.9 16.2 82.6* 15.5 56.3# 17.7 81.7# 19.0
Parental Impact Emotional
77.0 16.7 86.3* 16.3 71.1 21.7 58.5# 18.8
Parental Impact Time 30.1 15.8 93.9* 15.7 81.6# 19.1 72.9# 21.8
Family Activities 83.6 14.2 91.3* 13.8 na na 62.1# 24.1
Family Cohesion 38.7 20.9 71.9* 20.6 na na na na
*significant difference (p< 0.05; two-sided) measured by two-way ANCOVA test
#significant difference (p< 0.05; two-sided) measured by one-way ANOVA test
QoL, quality of life; sd, standard deviation; ADHD, attention deficit hyperactivity disorder; na, not available
Children with primary headache compared with children with chronic illness
Table 2 presents the means and standard deviations for each subscale of the CHQ for 
children with primary headache compared with the cohort of children with asthma or 
with ADHD, respectively. In the groups of children with asthma and ADHD the scores were 
not adjusted for demographic variables (e.g. proportion of males and females and age 
distribution) because we did not have the original databases at our disposal.
Children with migraine compared with children with tension type headache
Table 2 presents the means and standard deviations for each subscale of the CHQ for 
children with migraine and with TTH. Excluded from this analysis were the children 
with chronic tension type headache or with two diagnoses. No significant differences 
were found between TTH and migraine on either subscale using ANCOVA analysis after 
adjustment for gender and age.   
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Table 2 CHQ-PF50: Children with migraine compared with TTH 
QoL subscales Migraine
(n =36)
TTH
(n =25)
mean sd mean sd
Global Health* 61.1 27.6 72.3 28.5
Physical Functioning* 81.3 22.2 82.0 22.5
Role/Emotional/Behavioural* 78.8 24.6 85.3 24.0
Role/Physical* 64.8 31.2 71.1 31.0
Bodily Pain* 51.7 21.6 59.2 21.0
Behaviour* 55.6 13.2 58.3 13.0
Mental Health* 34.1 22.8 37.4 22.5
Self-Esteem* 73.6 13.8 79.6 13.5
General Health Perception* 65.9 19.2 64.8 19.0
Parental Impact Emotional* 76.4 18.6 76.7 18.0
Parental Impact Time* 32.8 25.8 28.2 24.5
Family Activities* 81.4 17.4 89.5 17.0
Family Cohesion* 34.6 22.8 37.6 22.5
* no significant difference (p= ns; two-sided) measured by two-way ANCOVA test
QoL, quality of life; sd, standard deviation; TTH, tension type headache
DISCUSSION
The QoL in our group of children with primary headache is significantly decreased on 12 of 
the 13 life domains of the CHQ compared with a group of healthy children from the same 
region after adjustment for gender and age. This is in agreement with our hypothesis and 
the studies of Powers and Nodari in which children with primary headache reported a 
lower QoL on all subscales compared with a cohort of healthy children11,12,16.  No data 
were available regarding the presence of headache among the control group of children. 
Nevertheless, as the exclusion of these patients would have rendered the differences in 
QoL between our patient and control group even larger than found, this would not have 
influenced our conclusions. 
QoL research in children is a rapidly expanding area and reports on the impact of various 
chronic diseases on paediatric and adolescent QoL are beginning to appear12. We 
measured QoL with a validated Dutch version of the CHQ9. The CHQ is not disease-specific; 
it provides information on a broad range of 13 life domains, whereas other clinical studies 
examined only six or nine domains7,8,9,11,12,16. The CHQ also gives insight into the burden 
placed on the family and parents of the child with primary headache, which is missing in 
the QoL measurement tools in other clinical studies as the PedsQL11,12 and the QLH-Y16. 
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From this study, the conclusion seems justified that a child with primary headache, severe 
enough to consult a specialist, places a heavy burden on its parents and brothers and 
sisters.
The data from this study allow us to conclude that the QoL of children with headache is 
very poor, with particular impact on the domains of mental health, parental impact time 
and family cohesion. The question arises whether this is the consequence of the headache 
of the child itself, or whether the headache is a consequence of the poor QoL. To address 
this question, longitudinal headache studies in children are needed with headache 
frequency and intensity as a primary outcome measure, and QoL as a secondary outcome 
measure, to evaluate how both outcome measures influence each other.
In contrast to most of the above-mentioned clinical studies, we measured QoL in children 
with TTH as well as with migraine11,12,16. Only Nodari et al.16 have measured QoL with TTH 
and migraine in a tertiary headache centre using the Quality of Life in Youth Questionnaire 
(QLH-Y). This latter questionnaire was originally developed by Langeveld et al.10 and was 
translated and validated for the Italian population; because there was no analysis tailored 
to the children with TTH and migraine, it was not possible to detect differences in QoL 
between them. In the present study we included 26 children with TTH and 36 children 
with migraine; no significant differences in QoL were found between them on any 
subscale after adjustment for gender and age. The average difference on the 13 variables 
in terms of Cohen’s d between migraine and TTH patients was 0.15. In order to detect a 
difference of this size at a nominal level of significance α = 0.05 (two-sided) and β = 0.20, 
the sample size required is 845 patients in both migraine and TTH patients. Assuming 
that the 13 variables can be adequately represented in two dimensions, the actual level 
of significance was α = 0.025 (two-sided).  Therefore, conclusions about the absence of 
differences in QoL between children with migraine and TTH have to be drawn with caution 
because of the low number of children in both groups and, consequently, the low power 
of this comparison. Nevertheless, we speculate that the absence of differences might be 
due to the system of health care in the Netherlands in which the GP is the key person 
in referring the child to an outpatient paediatric department. We believe that the most 
important factor in referral is this physician’s perception of the burden placed on the child 
and its family as induced by the headache. Thus, it is not so much the type of headache 
that is the reason for referral, but rather the severity of the headache and its impact on the 
QoL of the child and its family.        
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We compared the QoL in children with primary headache with that of children in the 
USA with asthma or with ADHD. Due to absence of data on the subscale of global health 
and family cohesion, a comparison on these domains was not possible for children with 
asthma or with ADHD. Also, because there were no data on the subscale of family activities 
in the children with asthma, a comparison on this domain was also not possible.
In seven subscales (i.e. role/emotional/behavioural, role/physical, bodily pain, behaviour, 
mental health, self-esteem, and parental impact time) the QoL of the children with 
primary headache was significantly lower than that of children with asthma; on the 
subscales physical functioning and parental impact emotional no significant differences 
were found. On the subscale of general health perception, QoL was significantly higher in 
children with primary headache. Therefore, we conclude that QoL of children with primary 
headache is in general lower than in children with asthma.
The QoL of children with ADHD was on six subscales (i.e. physical functioning, role/
physical, bodily pain, mental health, general health perception and parental impact time) 
significantly higher than in children with primary headache. The QoL of the subscales 
role/emotional/behavioral, self esteem, parental impact emotional and family activities 
was significantly higher in children with primary headache than in children with ADHD. 
There was no significant difference on the subscale behaviour between the groups. We 
conclude that QoL in children with primary headache is in general worse than in children 
with ADHD but is better with regard to impact on the family. Because of the different 
origins and cultural background of the children, and possible differences in the meaning 
of the items due to the different languages, any conclusions about the differences in 
QoL between children’s primary headache on the one hand, and asthma and ADHD on 
the other, have to be drawn with caution. Also, the different clinical setting and the time 
elapsed since the study on QoL of children with asthma was performed (in 1994) may be 
of relevance. Furthermore, adjustment for differences in the demographic character of the 
samples was not possible because we did not have the original databases at our disposal. 
We have compared the QoL data of the boys in the headache group with the QoL data of 
the ADHD and asthma sample as both samples contained a relatively high percentage of 
boys (81 vs. 69%). We found no marked differences in comparison with the QoL data of 
the whole headache group. Therefore, we cautiously conclude that adjustment for gender 
in the ADHD and, to a lesser extent, in the asthma sample, will not substantially influence 
the original (ANOVA) data. 
To gain more insight into the impact of different types of headache, a QoL study using the 
same questionnaire should be performed in children with ADHD, asthma and headache 
from the same outpatient department.
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Finally, we believe that QoL is an important concept, not only to gain insight in the effect 
that a disease has on the emotional and physical well-being of a child and the impact on 
its family, but also to gain insight in the dynamic aspects of the disease or the response 
to treatment. There is a lack of longitudinal studies with QoL as outcome measure in the 
field of primary headache in children. More longitudinal studies with QoL as outcome 
measure are needed to gain more insight in the dynamic aspects of primary headache 
in children and especially on the relation between headache and QoL. With respect to 
treatment, every treatment or intervention has in general not only expected beneficial 
effects, but also adverse effects. Most intervention studies in this field (primary headache 
in children) usually describe the adverse effects as mild and safe. However, the simple 
description of the kind and number of adverse effects gives insufficient insight into the 
severity and appreciation by the child17, combined with the beneficial effects of the 
intervention. QoL in these studies, measured on a broad range of life domains, combined 
with primary outcome measures as headache frequency and intensity, can provide this 
insight. Therefore we recommend that more QoL studies in this field should be performed, 
not only descriptive but also dynamic assessments, in which QoL is used as an outcome 
measure in intervention and longitudinal studies.   
CONCLUSIONS
Headache is a common problem in childhood. The present study shows that in children 
with primary headache referred to a paediatric outpatient department of a Dutch 
general hospital, the QoL is considerably lower than the QoL of healthy controls. Also, we 
conclude from this study that a child with primary headache places a considerable burden 
on its parents and family. Within the group of children with primary headache, the QoL 
of children with TTH is similar to that in children with migraine. There are indications that 
primary headache in children affects QoL in a broader spectrum of life domains and to a 
larger degree than does asthma or ADHD.  
ACKNOWLEDGEMENTS    
The authors thank all the children and their parents who participated in this study. Special 
thanks go to the pediatricians in the Vlietland Ziekenhuis for their support and referral of 
the patients: Coby Langendoen M.D., Lia van Wijk M.D., Bert den Exter M.D., Arjan Pijning 
M.D., Esther Hentzen M.D., Brigitte de Bie M.D. and Evelyne van Boeckel M.D.   
Chapter 4
74
REFERENCES 
1. Sillanpaa M; Changes in the prevalence of migraine and other headaches during the first seven 
schoolyears. Headache 1983;23:15-9.  
2. Van Duijn N.P.  et al; Kinderen met Hoofdpijn (Children with Headache); Medisch Contact 2000;26:971-4. 
3. Bandell-Hoekstra I, Abu-Saad HH, Passchier J, Knipschild P. Recurrent headache, coping, and quality of life 
in children: a review. Headache 2000;40:357-70.
4. World Health Organization. Constitution of the World Health Organization Basic Documents. Geneva, 
Switzerland: World Health Organization 1948.
5. Raat, H., Botterweck AM, Landgraf JM, Hoogeveen WC, Essink-Bot ML. Reliability and validity of the short 
form of the child health questionnaire for parents (CHQ-PF28) in large random school based and 
general population samples. J Epidemiol Commun Health 2005;59:75-82
6. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996;334:205-11. 
7. Landgraf JM, Abetz L, Ware JE. The CHQ User´s Manual. Second Printing. Boston, MA. Health Act, 1999.  
8. Landgraf JM, Maunsell, Speechley KN, Bullinger M, Campbell S, Abetz L, et al. Canadian -French, German 
and UK versions of the Child Health Questionnaire: methodology and preliminary item scaling 
results. Qual Life Res 1998;7:433-45.
9. Raat H, Bonsel GJ, Essink-Bot ML, Landgraf JM, Gemke RJ. Reliability and validity of comprehensive health 
status measures in children: The Child Health Questionnaire in relation to the Health Utilities Index. J 
Clin Epidemiol 2002;55:67-76.
10. Langeveld JH, Koot HM, Loonen MC, Hazebroek-Kampschreur AA, Passchier J. A quality of life instrument 
for adolescents with chronic headache. Cephalalgia 1996;16:183-96.
11. Powers SW, Patton SR, Hommel KA, Hershey AD. Quality of life in pediatric migraine: characterization of 
age-related effects using PedsQL. Cephalalgia 2004;24:120-7. 
12. Powers SW, Patton SR, Hommel KA, Hershey AD. Quality of life in childhood migraines: clinical impact 
and comparison to other chronic illnesses. Pediatrics 2003;112:e1-e5. 
13. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. 
Headache Classification Committee of the International Headache Society.  Cephalalgia 1988;8 (suppl. 7):1-
96. 
14. Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life 
measures: literature review and proposed guidelines. J Clin Epidemiol 1993;46:1417-32.
15. Ware JE, Keller SD, Gandek B, Brazier JE, Sullivan M. Evaluating translations of health status questionnaires. 
Methods from the IQOLA project. International Quality of Life Assessment. Int J Technol Assess Health Care 
1995;11:525-51. 
16. Nodari E, Battistella PA, Naccarella C, Vidi M. Quality of life in young Italian patients with primary 
headache. Headache 2002;42:268-74.     
17. Damen L, Bruijn JK, Verhagen AP, Berger MY, Passchier J, Koes BW. Symptomatic treatment of migraine in 
children: a review of medication trials. Pediatrics 2005;116(2):e295-302.  
18. Landgraf JM, Ware JE, Schor E, Davies AR, Rossi-Roh K (1993a, June 27). Comparison of health status 
profiles for children with medical conditions: preliminary psychometric and clinical results form the 
Children’s Health and Quality of Life Project. Paper presented at 10th Annual Meeting of the Association 
for Health Services Research, Washington D.C.
19. Landgraf JM, Ware JE, Schor E, Davies AR, Rossi-Roh K (1993b, June 6) Health profiles in children with 
psychiatric and other medical conditions. Paper presented at 9th World Congress of Psychiatry, Rio de 
Janeiro, Brazil.
20. Landgraf JM, Ware JE, Rossi-Roh K (1993) Measuring the Relative Health and Well-Being of Children with 
Attention Deficit Hyperactivity Disorder. Results from the Children’s Health and Quality of Life Project. 
(Final report to Ciba Geigy, Inc., Project MCS#447). Boston, MA: The Health Institute, New England Medical 
Center.
Ch
ap
te
r 5
Chapter 5
Medium dose ribofl avin as a prophylactic agent in children 
with migraine: a preliminary placebo-controlled, randomized, 
double-blind, crossover trial 
Jacques Bruijn, Hugo Duivenvoorden, Jan Passchier, Heiko Locher, Natascha Dijkstra, 
Willem-Frans Arts
Cephalalgia	2010	(e-Pub	ahead	of	print)
Chapter 5
76
Medium dose riboflavin as a prophylactic agent in children with migraine: a placebo-controlled, randomized, double-blind trial
ABSTRACT 
Background: Riboflavin seems to have a promising effect on migraine in adults. The present 
study examines whether riboflavin has a prophylactic effect on migraine in children. 
Objective: To investigate whether riboflavin in a dosage of 50 mg per day has a prophylactic 
effect on migraine attacks in young children.
Methods: This randomized, placebo-controlled, double-blind, crossover trial included 
42 children (6 to 13 years) with migraine of which 14 children were also suffering from 
tension-type headache. Following a 4-week baseline period, all children received placebo 
for 16 weeks then riboflavin for 16 weeks (or vice versa) with a washout period of 4 weeks 
in between. The primary outcome measure was reduction in mean frequency of migraine 
attacks and tension-type headache in the last 4 weeks at the end of the riboflavin and 
placebo phase, compared with the preceding baseline or washout period. Secondary 
outcome measures were mean severity and mean duration of migraine and tension-type 
headaches in the last 4 weeks at the end of the riboflavin and placebo phase, compared 
with the preceding baseline or washout period.
Results: No significant difference in the reduction of mean frequency of migraine attacks 
in the last month of treatment was found between placebo and riboflavin (p = 0.44). 
However, a significant difference in reduction of mean frequency of headaches with a	
tension-type  phenotype was found in favour of the riboflavin treatment (p = 0.04). 
Conclusions:  In this group of children with migraine, there is no evidence that 50 mg	
riboflavin has a prophylactic effect on migraine-attacks. We found some evidence that 50 
mg riboflavin may have a prophylactic effect on interval headaches that may correspond 
to mild migraine attacks or tension type headache attacks in children with migraine.  
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INTRODUCTION
Migraine is a common disorder in adolescents and children. The prevalence of headache 
and migraine is age and gender dependent. Sillanpaa reported a prevalence of migraine 
for boys and girls at 7 years of age of 2.9% and 2.5%, respectively; at age 14 years the 
prevalence of migraine was 6.4% and 14.8% for boys and girls, respectively1. 
The efficacy of both pharmacological and non-pharmacological interventions in children 
and adolescents with migraine has been studied extensively2-5. Some interventions in the 
field of symptomatic treatment of migraine in children have been proven effective, such as 
sumatriptan nasal spray, ibuprofen and acetaminophen2,5. In the prophylactic treatment 
of migraine in children and adolescents, until now only flunarizine is an evidence-based 
effective drug, and probably also topiramate4-6. Adverse effects have been reported in 
both treatments. In addition, flunarizine is not available in the USA and both flunarizine 
and topiramate cannot be prescribed to children or adolescents in most European 
countries4-6. Other treatment modalities in this field (which are not evidence based) are 
antihypertensive medications, antidepressants, serotonergic drugs, 5-HT2-antagonists 
(such as pizotifen or methysergide) and antiepileptic drugs. However, in all of these agents 
adverse effects have been described4,5. Thus, there is a need for high-quality research to 
evaluate pharmacological prophylactic treatment that has minimal or no adverse effects 
in children and in adolescents with migraine. 
From this perspective we were interested to examine riboflavin (vitamin B2). Riboflavin is a 
co-factor for the mitochondrial oxidative phosphorylation (OXPHOS) as it is the precursor 
for the flavin compounds necessary for the transfer of electrons in the mitochondrial 
energy cascade. In vivo studies have detected an impairment of OXPHOS in adult 
migraineurs between attacks7-9. Supra-physiological doses of riboflavin might be helpful 
in reducing this impairment. In patients with mitochondrial encephalopathy with lactic 
acidosis and stroke-like episodes, a subgroup had a reduced frequency of migraine attacks 
during treatment with riboflavin10. Therefore, riboflavin has been used as a prophylactic 
agent in studies on adults with migraine, including two open-label studies11,14 and two 
randomized controlled trials12,13. In these latter trials, riboflavin was proven effective 
with minimal adverse effects. These adverse effects were diarrhoea (1 of 43 adults with 
migraine treated with riboflavin) and polyuria (1 of 43 adults with migraine treated with 
riboflavin)12,13.  A common and harmless side effect of riboflavin is a bright yellow/orange 
discolouration of the urine.
At the time of the present study, no other trials were registered to investigate the effect 
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of riboflavin in children with migraine. Therefore, we decided to perform a placebo-
controlled, randomized trial in children with migraine using riboflavin as the acting agent. 
MATERIAL and METHODS
A 40-week, randomized, double-blind, crossover design was used to examine the effect 
of riboflavin compared with placebo in young children with migraine. The study was 
conducted in two hospitals in the Netherlands. The children were prospectively recruited 
between October 2005 and March 2008, and the trial was completed in December 2008. 
The children were referred by general practitioners (in the region of Schiedam/Vlaardingen) 
and by paediatricians, neurologists and paediatric neurologists in the greater Rijnmond 
region in the Netherlands. 
All potentially referring physicians received an information letter about this trial. The 
children were assessed at the outpatient paediatric department of the Vlietland Hospital 
(in Schiedam/Vlaardingen) by the principal investigator (JB), and at the department of 
paediatric neurology of the Erasmus Medical Centre (EMC, Rotterdam) by the principal 
investigator (JB) and the co-investigators (ND and WFA).
Parental informed consent, and informed consent from children aged 12 years, was 
obtained. Headache diaries were composed in advance of the trial. The study was 
approved by the Medical Ethics Committees of the EMC and the Vlietland Hospital.   
Patients
The inclusion criteria were: 
1) age 6 to 13 years: we deliberately chose this age group because only a limited number
     of evidence-based interventions on this group are available2-5
2) migraine with or without aura according to the ICHD II criteria15
3) a frequency of two or more headache attacks per month
The exclusion criteria were:
1) epilepsy or other serious neurological disease
2) diseases of the liver or kidneys, and gastro-intestinal, metabolic or cardiovascular disease
3) use of other prophylactic medication for migraine within 1 month of the trial
4) use of other prophylactic treatment for migraine during the trial
5) inability to comply with the requirements of the trial, and/or inability to speak and 
     read Dutch
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Procedure and intervention
The pharmacy department of the EMC manufactured placebo and riboflavin capsules, the 
latter containing 50 mg riboflavin. To ensure the double-blind design, carotene 100 mg 
was used as placebo. Both carotene and riboflavin give an orange discolouration of the 
urine. A PubMed search confirmed the absence of evidence that carotene has any effect 
on headache frequency or intensity in children. 
After a baseline period of 4 weeks, children were randomised in phase 1 to receive either 
one capsule containing placebo or 50 mg riboflavin daily for 16 weeks. Children were 
instructed to swallow the capsule at breakfast. Following a wash-out period of 4 weeks, 
in phase 2 the children received either one capsule containing placebo daily for 16 weeks 
if they had received riboflavin in phase 1, or one capsule of 50 mg riboflavin daily for 16 
weeks if they had received placebo in phase 1. Treatment allocation was concealed from 
the participants and investigators for the duration of the study. The hospital pharmacists 
guarded the randomization key. To evaluate blinding, at the last visit parents were asked 
which treatment they believed that their child had received in which phase, and the 
reasons for their assumptions.
All children were primarily diagnosed with migraine by paediatric neurologists (JB or WFA). 
A thorough history was taken, and a complete neurological and physical examination 
was performed including measurement of blood pressure, body weight, height and skull 
circumference.
If the child was eligible for inclusion, the child and their parents were informed about 
all aspects of the trial and asked for their consent. They were informed that they could 
end their participation at any time during the trial without having to give any reason. 
No rewards or other response-enhancing policies were applied. A two-week period was 
allowed for the child/parents to consider possible participation in the study.
The parents of the children were asked to keep a detailed headache diary during all stages 
of the study. This headache diary documented every headache attack, including: the date, 
the severity of the headache on a 4-point Likert scale, its location(s), duration and nature 
(pulsating or non-pulsating), possible aggravation by routine physical activity, associated 
symptoms such as nausea or vomiting, and the presence or absence of photophobia or 
phonophobia or fever. The diaries were based on the ICHD-II criteria in order to enable 
classification of each headache attack as a migraine attack, tension-type headache, 
headache probably due to an (ear-nose-throat) infection, or a headache attack not 
fulfilling the ICHD-II criteria of any of these. Parents also completed questionnaires on 
behavioural problems and life dimensions of the children for a different research focus 
(not reported here).  
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All parents and children received information regarding childhood migraine, and all 
children were treated symptomatically according to state-of-the-art evidence-based 
guidelines5,16.  This meant that, in case of a migraine attack, they received acetaminophen 
and ibuprofen orally or rectally, and sumatriptan nasal spray if they were 12 years old. 
Children were given simple instructions on how to improve sleep duration and quality, i.e. 
to stop the intake of caffeine, and decrease the amount of time spent watching television 
or computering to a maximum of 2-3 hours a day.
Appointments with parents were made at the end of each stage. At each appointment 
the headache diary of the preceding stage was given by the parents to the paediatric 
neurologists (JB or WFA), and in return a new headache diary for the following stage 
was handed over to the parents. During the trial, halfway in both phase 1 and phase 2, 
paediatric neurologist JB or co-investigator ND, would hold a telephone conversation 
with the parents.    
At each visit and each telephone appointment, the parents were consistently asked about 
any possible adverse effects of the medication. This was documented in the personal file 
of the child. To improve compliance during both phases of the study, parents and child 
were asked to bring the remaining tablets with them at each visit.
Three months after the conclusion of the trial all parents and children received a letter 
informing them when their child had received riboflavin or placebo, and the preliminary 
conclusions of the trial. 
Outcome measures
The outcome measures were reduction in the mean frequency, mean severity and mean 
duration of migraine and tension-type headache in the last four weeks at the end of phase 
1 and of phase 2 compared with the baseline and washout period, respectively. 
Any adverse effects were documented and compared.
Statistical Analysis
Sample size calculations were based on a clinically relevant difference of 0.60 standard 
deviation (sd) between the riboflavin and placebo condition in favour of riboflavin with 
regard to migraine frequency in accordance with the data of the randomized controlled 
trial by Schoenen et al12. In addition, based on a crossover design, an α of 0.05 (two-
sided) and a statistical power of 0.80, a minimum number of 20 patients was required to 
participate in the trial. To allow for dropouts 30 patients were initially enrolled, which was 
later extended to 42 to also allow for exploratory analysis.  
Statistical analysis was performed according to the intention-to-treat principle. 
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As measures of central tendency, the means (for continuous data) and percentages (for 
categorical data) were estimated. In case of continuous data, the sd was used as measure 
of dispersion. To evaluate the effect of riboflavin on the outcome variables the t-test for 
independent observations was applied17. All statistical testing took place at the 0.05 level 
of significance. 
We planned an exploratory analysis with regard to the effect of riboflavin vs. placebo 
on tension-type headache. We also planned an exploratory analysis in children with 
a relatively high baseline headache attack frequency vs. children with a relatively low 
baseline headache attack frequency. 
RESULTS
Demographics 
A total of 57 children were assessed for eligibility; 15 patients were not enrolled because 
they did not meet the inclusion criteria, or met one or more exclusion criteria, or because 
the parents or child refused to participate in the trial (Fig. 1).
Of the 42 children that were randomized, 20 were randomized to receive riboflavin during 
phase 1 and placebo during phase 2, whereas 22 children received placebo during phase 
1 and riboflavin during phase 2. In this latter group, during the placebo phase, one child 
was lost to follow-up, the parents of two children withdrew their consent for further 
participation, and one patient proved to be suffering from headache due to medication 
overuse, discovered after careful study of her baseline headache diary. Both treatment 
groups had comparable demographic and migraine features (Table 1). Of the 20 children 
who were randomized to receive riboflavin in the first and placebo in the second phase, 
10 (50%) were also suffering from tension-type headache. Of the 22 children who were 
randomized to receive first placebo and riboflavin in the second phase, 4 (18%) were also 
suffering from tension-type headache.  
Outcome data
The outcome data are summarized in Tables 2a and 2b. No significant difference in the 
reduction of the mean frequency of migraine attacks in the fourth and last month of 
treatment was found between placebo and riboflavin (p = 0.44). However, we did find a 
significant difference in the reduction of the mean frequency of attacks of tension-type 
headache in favour of the riboflavin treatment (p = 0.04). 
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Fig. 1: The CONSORT* flow diagram showing the flow of participants.  
*CONSORT indicates Consolidated Standard of Reporting Trials. 
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 (n = 57) 
Excluded (n = 15) 
· not meeting inclusion criteria (n = 2) 
· presence of exclusion criteria (n = 3) 
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     Enrollment (n = 42) 
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Allocated to riboflavin 
            (n = 18) 
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Allocated to placebo 
         (n = 20) 
phase 2: 16 weeks 
Wash-out (n = 20):  
        4 weeks 
Wash-out (n = 18):   
       4 weeks 
Discontinued intervention (n = 4) 
· refusal of further participation (n = 2) 
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Table 1: Baseline demographic and clinical characteristics 
Characteristic riboflavin-placebo
(n = 20)
placebo-riboflavin
(n = 22)
Age in years (mean ± sd)
 
9.91 ± 1.89 9.50 ± 1.63
Male 12 (60%) 12 (54%)
Migraine with aura 9 (45%) 8 (36%)
Other headache types:
   Nil other than migraine
   Tension-type headache
   Headache by ENT infection
   Other
8 (40%)
10 (50%)
1 (5%)
3 (15%)
15 (68%)
4 (18%)
0 (0%)
2 (9%)
Family history of migraine 16 (89%) 19 (95%)
Years since onset of migraine 
    (mean ± sd) 3.06 ± 1.73 2.80 ± 2.14
Number of migraine attacks per month 
(mean ± sd) 3.60 ± 3.10 3.48 ± 5.41
Duration of migraine attacks in hours 
(mean ± sd) 2.45 ± 1.19 2.57 ± 1.54
Migraine prophylaxis used 
    in the past 2 (10%) 4 (18%)
Use of paracetamol as   
   symptomatic treatment 13 (65%) 17 (77%)
Use of ibuprofen as   
   symptomatic treatment 4 (20 %) 6 (27%)
Use of sumatriptan as   
   symptomatic treatment 4 (20%) 5 (23%)
sd, standard deviation
No significant difference was found in change or reduction of mean intensity of migraine 
attacks and tension-type headache attacks in the fourth and last month of treatment 
between placebo and riboflavin (p = 0.18 and did not apply, respectively). Also, no 
significant difference was found in change or reduction of mean duration of migraine 
attacks and tension-type headache attacks in the fourth and last month of treatment 
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between placebo and riboflavin (p = 0.15 and did not apply, respectively). 
Analysis for a period or carry-over effect was performed on all outcome measures but 
proved to be inconclusive. 
An exploratory analysis of attack frequency in children with a relatively high baseline 
frequency of 5 or more attacks per month, and in children with 4 or less attacks per month 
at baseline, revealed no significant differences in both of these categories between 
riboflavin and placebo with regard to migraine prophylaxis (p = 0.36 and p = 0.29, 
respectively).  
During the trial no adverse effects were reported by parents or children; this was recorded 
in the patient files in both the riboflavin-placebo and the placebo-riboflavin group.
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DISCUSSION
With regard to prophylaxis of migraine attacks, there was no significant difference in the 
mean migraine frequency per 4 weeks (p = 0.44) or mean intensity of migraine attacks (p 
= 0.18) or mean duration of migraine attacks (p = 0.15) in the last four weeks of treatment 
between riboflavin and placebo. It could be argued that this result might be due to the 
fact that we had no upper limit for attack frequency as an exclusion criterion. In children, a 
high frequency of migraine or headache attacks, especially with an attack frequency of 15 
headache attacks per month or more (the main diagnostic criterion for chronic migraine/
headache), is often indicative of resistance to pharmacological prophylactic treatment18. 
Therefore, we also performed a separate exploratory analysis of attack frequency in 
children with a relatively high baseline frequency (5 or more attacks per month), and in 
children with a relatively low baseline frequency (4 or less attacks per month). In both of 
these categories no significant differences were found between riboflavin and placebo 
with regard to migraine prophylaxis.
Our conclusions are in line with those of MacLennan et al. who investigated 48 children with 
migraine aged 5 to 15 (mean 11.1 ± 2.1) years with a higher dosage of 200 mg riboflavin 
per day in a placebo-controlled, double-blind, randomized trial with a parallel group 
design19. This latter trial also reported no differences between riboflavin and placebo for 
primary or secondary outcome variables with regard to migraine prophylaxis. The trial of 
MacLennan et al. had an upper limit exclusion criterion of 8 migraine attacks per month. 
They recommended performing future studies with a crossover design, or with larger 
sample sizes. The fact that both our crossover study and that of MacLennan et al. showed 
no proof of effectiveness of riboflavin as a prophylactic agent in children with migraine is 
in contrast to the riboflavin studies conducted among adults with migraine11-14.   
The strength of our study is the double-blind, randomized, placebo-controlled, crossover 
design, which gives more statistical power than a parallel design. Of the 4 dropouts during 
the study, all were in the placebo-riboflavin group and dropped out during the placebo 
phase. It can be argued that this might be due to the lower effect of placebo compared 
with riboflavin. However, analysis of the other children in the riboflavin-placebo group 
showed a slightly better (non-significant) response to the placebo phase compared with 
the riboflavin phase.  
A weakness of our study, on the other hand, could be the 50 mg per day dosage of riboflavin. 
Riboflavin has been used as a therapeutic agent in various mitochondrial diseases in 
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children and adolescents, such as the NADH-CoQ Reductase Deficient Myopathy and the 
Mitochondrial Encephalopathy and Stroke studies10,20. In these latter studies riboflavin 
was given in doses approximately 100-fold higher than the normal dietary intake, e.g. 
between 100 and 300 mg per day. These dosages were well tolerated without adverse 
effects (except for nausea) and sometimes yielded striking improvement20. 
Before the start of our study, three trials in adults with migraine (all using 400 mg riboflavin 
per day) had suggested a dosage of 100-200 mg per day for children12-14. However, shortly 
before the start of our trial, Maizels et al. demonstrated no significant difference between 
a combination of high-dose riboflavin, magnesium and feverfew in comparison with 
a low dose (25 mg) of riboflavin acting as placebo in adults with migraine, suggesting 
an equivalent effect of low-dose riboflavin versus high-dose riboflavin21. Therefore, we 
decided to treat our 6 to 13-year-old patients with a dosage of 50 mg riboflavin, which is 
relatively low compared with the dosage used in mitochondrial diseases and in riboflavin 
studies in adults with migraine. 
On the other hand, if one assumes that children have a much higher metabolic rate than 
adults, the maximum dosage of riboflavin in children should be even higher than in 
adults to obtain a similar effect. From this perspective, our attention was drawn to the 
recent publication of Condò et al.24 which describes a retrospective open-label study in 41 
children or adolescents with migraine who were treated with 200 mg or 400 mg riboflavin 
on a daily basis for three to six months. In that study, 68.4% of the included children had 
a reduction of 50% or more in the frequency of all headache attacks. Statistical analysis 
showed no significant differences between frequency/intensity responders for a 200 or 
400 mg/day dose. However, in that study no placebo group was included and treatment 
was not concealed, which are essential factors for assessing study quality.
Another point for discussion could be the duration of 16 weeks of each treatment period, 
and the analysis that was limited to the last 4 weeks of both phases of the study. This 
set-up was based on the original riboflavin trial of Schoenen et al. among adults with 
migraine. In that study, the maximal effect of riboflavin was seen in the fourth month of 
treatment12. 
In addition, the relatively small number of participants might be a factor explaining the 
negative results of our trial. However, our power estimation was according to standard 
criteria. Future studies using a randomized controlled parallel group design according to 
IHS guidelines, should employ a larger sample size. 
One can also argue that, based on the low percentage of children receiving migraine 
prophylaxis in both the riboflavin-placebo and the placebo-riboflavin group (10% and 
18%, respectively), the effectiveness of riboflavin was less significant due to the limited 
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severity of the headache symptoms in the included children. However, in our opinion 
these low percentages of migraine prophylaxis at inclusion do not mean that the severity 
of symptoms was less significant. First of all, the included children were relatively young (6-
13 years) and migraine has a relatively low prevalence in pre-pubertal children compared 
with adolescents and adults. Therefore, most children in our study had a relatively short 
history of migraine. Secondly, most children were included after their first consultation 
with a specialist to whom they were referred by the general practitioner (GP) because 
of their headache; in the Dutch healthcare system the GP is the key person for referral to 
a specialist. Referral to, or consultation with a specialist is advised in the national Dutch 
guidelines for GPs if there is a need for prescribing symptomatic or prophylactic treatment 
in children with migraine. Finally, an earlier study from our group showed that the quality 
of life is very poor in children with migraine and tension-type headache at their first visit 
to one of the two hospitals which were also used for inclusion and follow-up procedures 
in the present study25; this suggests that GPs in the Netherlands tend to refer only children 
with a high burden of headache or migraine. It is for these reasons that most of the children 
in the present study did not receive prophylactic treatment, and not because of limited 
severity of their headache symptoms. 
 
A final drawback is that, in all trials among children with migraine (both for acute treatment 
and migraine prophylaxis), a high placebo response made it difficult to prove the efficacy 
of a verum drug22. This will also apply to our study, especially since all children were 
given simple instructions about improving sleep quality and duration, stopping intake of 
caffeine, and decreasing the amount of time spent watching television or computering 
(besides receiving state-of-the-art evidence-based symptomatic treatment), which 
undoubtedly increased the placebo response in all the included children.
In addition, an interesting hypothesis that might explain our negative findings is related 
to the mitochondrial DNA make-up of our patients. 
A recent pharmacogenetic study in adults with migraine showed that patients with 
non-H mitochondrial DNA haplotype respond better to treatment with riboflavin than 
patients with H-mitochondrial DNA haplotype23. To investigate if this is a significant 
factor, mitochondrial DNA analysis should be performed and the presence of non-H or 
H-haplotype mitochondrial DNA should be taken into account in the analysis of our data. 
In summary, with regard to effectiveness, based on our present study, the study of Condò 
et al.24 and the study of MacLennan et al.19, we conclude that, at this moment, there is 
inconclusive evidence for the effectiveness of riboflavin on migraine attacks in children or 
adolescents with migraine.      
Chapter 5
90
Medium dose riboflavin as a prophylactic agent in children with migraine: a placebo-controlled, randomized, double-blind trial
With regard to safety, in our present study none of the included children experienced 
adverse effects. In the study of Condò et al.24, two patients experienced vomiting and 
increased appetite, respectively, during riboflavin treatment. This was most likely 
unrelated to the use of riboflavin. In the study of MacLennan et al.19, none of the children 
on riboflavin experienced adverse effects. Therefore, one can now conclude that riboflavin 
in dosages up to 400 mg daily for a period of several months can be safely used in children 
with migraine.
Finally, we found some evidence that riboflavin may have a prophylactic effect on tension 
type headache in children with migraine.
Unfortunately, due to the low numbers of patients involved, calculation of significant 
differences between placebo and riboflavin as a prophylactic agent in tension-type 
headache with regard to the secondary outcome variables (mean intensity of headache 
attacks and mean duration of headache attacks) was not possible. 
A prophylactic effect of riboflavin on tension-type headache has not yet been described 
either in adults or in children11-14,19,24. In these latter studies, headache frequency or 
migraine frequency was used as outcome variable and there was no separate analysis 
regarding tension-type headache or (other) non-migraine headache attacks.
Based on our study one might argue that a medium dose of riboflavin has a prophylactic 
effect on tension-type headache in children. From that perspective, one has to bear in 
mind that the tension-type headaches in our study were an accompanying phenomenon 
in children with migraine as their main primary headache. Also, at baseline the total 
number of children with both migraine and tension-type headache in both groups 
(riboflavin-placebo and placebo-riboflavin) was low, especially in the placebo-riboflavin 
group (50% and 18%, respectively).
In addition, one can speculate about the nature of accompanying tension-type headaches 
in children with migraine, especially since the Spectrum Study of Lipton et al. provides 
evidence that all headache attacks in adults with migraine more or less represent a 
spectrum of migraine headaches26. If one assumes that this is also the case in children, 
based on the present study one might conclude that riboflavin in a low dose reduces mild, 
but not severe, headaches in migrainous children. Therefore, caution is required when 
drawing conclusions about the prophylactic effect of riboflavin on tension-type headache 
in children. However, this is the first study giving indications that riboflavin can diminish 
tension-type headache in children with migraine compared with a placebo intervention. 
To investigate if riboflavin indeed has a primary effect on tension-type headache in 
children or adults, more placebo-controlled, randomized, double-blind trials need to be 
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performed in children or adults with primary tension-type headache with and without 
migraine. 
CONCLUSIONS
The present study shows that riboflavin in a dosage of 1 dd 50 mg has no effect on 
migraine prophylaxis in young children with migraine compared with placebo. 
Currently, there is inconclusive evidence that riboflavin has a prophylactic effect on 
migraine attacks in children. However, in this study we give evidence that riboflavin may 
have a prophylactic effect on interval headaches that may correspond to mild migraine 
attacks or tension-type headaches in children with migraine. More studies are needed 
to investigate whether the same prophylactic effect of riboflavin on migraine as seen in 
adults can be achieved in children. More studies are also needed to investigate the effect 
of riboflavin on tension-type headache, both in children and adults with and without 
migraine. 
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ABSTRACT 
Background: Several descriptive clinical studies have reported poor quality of life (QoL) 
and psychological dysfunctioning in children with migraine at referral to a specialist. 
QoL has been used as outcome in a few intervention studies in children with migraine. 
Psychological (dys)functioning has not yet been used as outcome in intervention studies 
in childhood migraine. The present study examines whether a treatment directed at 
reducing headache attacks in children with migraine has a concomitant improving effect 
on QoL and psychological functioning.
Objective: To investigate whether riboflavin in a dosage of 50 mg per day has a favourable 
effect with regard to improving QoL and psychological functioning in children with 
migraine.  
Methods: This randomized, placebo-controlled, double-blind, crossover trial included 
42 children (6-13 years) with migraine. Following a 4-week baseline period, all children 
received placebo for 16 weeks then riboflavin for 16 weeks (or vice versa) with a washout 
period of 4 weeks in between. The outcome measures were QoL as measured with the 
Child Health Questionnaire (CHQ-PF50) and psychological functioning as measured with 
the Child Behaviour Checklist (CBCL) at the end of the riboflavin and placebo phase, 
compared with the preceding baseline or washout period. 
Results: Riboflavin had no superior effect versus placebo in children with migraine with 
regard to improvement of QoL and psychological functioning on all investigated life 
domains and psychological subscales. At baseline the QoL was significantly worse on all 
13 life domains compared with healthy controls. At baseline all CBCL scores were within 
the range of healthy controls with the exception of thought problems, somatic complaints 
and internalizing behaviour; the deviant scores on the latter two probably result from the 
migraine itself and are not a sign of psychological dysfunction. Throughout the trial there 
was an improvement on 11 of the 13 QoL domains and on all of the CBCL scales, leading to 
normalization of scores on the QoL domains mental health, self-esteem, parental impact 
emotional and parental impact time, and on all of the CBCL scales with the exception of 
somatic complaints.    
Conclusions:  In children with migraine QoL at referral to a specialist is poor, not because 
of psychological dysfunctioning but due to the disease itself. QoL and psychological 
functioning can be used as outcome in intervention studies on children with migraine. 
Compared with placebo, riboflavin has no superior effect on improvement of QoL and 
psychological functioning. 
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INTRODUCTION
Quality of life (QoL) and psychological functioning are important and related concepts 
in headache research, both in adults and children. QoL reflects the impact of disease 
and treatment based on a subjective evaluation by the patient (or, in the case of young 
children, by the parents) of their physical functioning and emotional wellbeing1 whereas 
behavioural and psychiatric problems form an important outcome reflecting a key 
dimension within QoL, i.e. psychological functioning and wellbeing. In the past, when 
QoL measures were not available for children, behavioural problems have even been used 
as a proxy measure for QoL2.
Several clinical studies have explored QoL in children with headache or migraine. In 
general, QoL measurement scales are divided into generic and disease-specific ones. 
Disease-specific QoL scales are designed for one specific group of patients and are used 
to detect changes induced by therapeutic interventions. Generic QoL questionnaires are 
applicable to all populations and diseases and are used to compare outcomes between 
them3,4. These questionnaires have up to 50 questions representing a maximum of 13 
life domains, including the impact of headache on daily activities, cognitive functioning, 
social activities and emotional wellbeing, as well as on domains like physical functioning, 
self-esteem, bodily pain and the impact of headache on the patient’s parents and family5-9. 
In general, these studies indicate that, compared with healthy children, children with 
headache or migraine have significantly lower QoL scores on all investigated life domains5-9. 
Compared to children with chronic illness (such as rheumatic disorders or cancer) their 
QoL is similar with respect to impairments in school and emotional functioning6. 
We previously investigated a group of children with primary headache (presenting at an 
outpatient department of a general hospital) using the generic Child Health Questionnaire 
(CHQ-PF50)9. The QoL in the group of children with primary headache was considerably 
lower than that of healthy controls on all of the 13 investigated life domains, with the 
exception of the domain self-esteem. Moreover, we found that a child with primary 
headache places a considerable burden on its parents and family. The QoL of children with 
tension type headache was similar to that of children with migraine. Furthermore, primary 
headache in children affected QoL in a broader spectrum of life domains and to a larger 
degree than does asthma or ADHD9.  QoL has also been used as outcome in population 
studies among adolescents with headache; in these studies, an inverse correlation was 
found between QoL and severity of headache symptoms10,11.  
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Studies in children with migraine indicate that an intervention that successfully decreases 
the burden of headache in these children has a concomitant beneficial effect on QoL12,13. In 
these latter studies the pedMIDAS was used as QoL questionnaire, providing information 
on a relatively limited number of life domains.       
With regard to psychological functioning and psychiatric comorbidity, clinical and 
population studies have shown a relationship between headache and psychopathology 
in children. In these studies, various measurement tools were used. 
Behavioural problems and psychological functioning were measured in subgroups of 
children suffering from different types of headache14,15 or were compared with healthy 
children16-21, children suffering from chronic fatigue22 or recurrent pain due to other 
disorders23. One study had a longitudinal design24, but most studies on psychological 
functioning in children with headache used a cross-sectional design. Because a substantial 
proportion of children with headache demonstrate psychological dysfunctioning, the 
question arises whether this can be influenced by an intervention directed at reducing 
headache attacks. To our knowledge, no intervention studies in children with headache 
or migraine have assessed psychological (dys)functioning or psychiatric comorbidity as 
outcome variable. 
To address this question about the interdependency of migraine on the one hand, and 
psychological functioning and psychiatric comorbidity on the other, we performed a 
literature search to assess and describe the evidence from pharmacological randomized 
controlled trials (RCTs) and pharmacological clinical controlled trials (CCTs) concerning 
the relationship between headache and psychological (dys)functioning and/or psychiatric 
comorbidity in children with migraine. Four databases were searched (Medline, PsycINFO, 
Embase, Cochrane) which identified 2,007 potential trials. All these were screened on title 
and abstract for possible relevance, selecting only RCTs or CCTs in children/adolescents 
(aged 0-18 years) with migraine, with criteria designed to distinguish migraine from 
other types of headache, and with psychological (dys)functioning and/or psychiatric 
comorbidity as primary or secondary outcome variable. Based on these criteria only one 
article emerged25. This latter article describes a CCT comparing nadolol with topiramate 
as prophylactic therapy in adults and adolescents with migraine. The mean age of the 
participants was 37 years (range 16-56 years) and no separate analysis was made for 
adolescents. However, based on the mean age (and age range) of the patients we assume 
that few adolescents were included and that such an analysis would offer little value in 
terms of evidence to answer our research question. 
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In conclusion, the present literature search provided no evidence-based information on 
the relationship between headache on the one hand, and psychological (dys)functioning 
and/or psychiatric comorbidity on the other, in children with migraine in clinical 
intervention studies. 
To establish whether reduction in migraine attacks is associated with changes in QoL, 
and psychological or psychiatric symptoms and signs during and after treatment, we 
performed a placebo-controlled, randomized, double-blind, crossover trial to investigate 
riboflavin as prophylactic agent in children with migraine with headache parameters, 
generic QoL and psychological functioning as outcome variables. 
Our first aim was to investigate whether riboflavin has a superior effect compared with 
placebo in prophylaxis of migraine attacks in children: the results of this latter study have 
already been published26. The present study examines the effects of riboflavin treatment 
on generic QoL and psychological functioning in children with migraine. 
MATERIAL and METHODS
A 40-week, randomized, double-blind, crossover design was used to compare the effects 
of riboflavin with placebo in young children with migraine. The detailed methodology has 
already been reported26. Parental informed consent was obtained; for children aged ≥12 
years this was supplemented with their own personal consent. The Ethical Review Board 
of the participating hospitals approved the study. 
Patients
Inclusion criteria were:
1) age 6-13 years
2) migraine with or without aura in accordance with the ICHD II criteria27 
3) frequency of two headache attacks per month or more
Exclusion criteria were:
1)    epilepsy or other serious neurological disease
2) diseases of the liver, kidneys, gastro-intestinal, metabolic or cardiovascular 
disease
3) use of other prophylactic medication for migraine within 1 month of the trial
4) use of other prophylactic treatment for migraine during the trial
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Procedure
All children were prospectively recruited between October 2005 and March 2008; they 
were assessed at the outpatient paediatric department of a general hospital and at the 
paediatric neurology outpatient department of a university hospital.
At the first visit, the parents or caretakers were asked to complete the Child Health 
Questionnaire (CHQ-PF50, Dutch edition)9,28 and the Child Behaviour Checklist (CBCL)29 
in its validated Dutch version30 at home and return them before the start of the trial. 
Subsequent CHQ-PF50 and CBCL questionnaires were completed by the parents at the 
end of the first trial phase, the washout phase, and at the end of the second trial phase.  
Intervention
The trial was performed with one dose of 50 mg riboflavin daily as the intervention 
drug and with one dose of placebo daily in a crossover design as described earlier26. All 
children were also treated symptomatically according to state-of-the-art evidence-based 
guidelines31. This meant that, in case of a migraine attack, they received acetaminophen 
and ibuprofen orally or rectally, and sumatriptan nasal spray if they were aged 12 years 
and older. 
Children were randomized in a double-blind manner to receive 16 weeks placebo or 
riboflavin in phase 1. After a washout period of 4 weeks, the child received 16 weeks 
placebo in phase 2 if it had received riboflavin in phase 1, and 16 weeks riboflavin in phase 
2 if it had received placebo in phase 1 (Fig. 1). 
Outcome measures
The primary outcome measure was reduction in the mean frequency of migraine attacks 
and tension-type headache attacks in the last 4 weeks at the end of phase 1 and of phase 2 
compared with the baseline and washout period, respectively26. Any adverse effects were 
documented and compared. In all stages of the trial, QoL as measured by the CHQ-PF50 
Dutch edition, and psychological functioning as measured by the CBCL Dutch edition, 
were analyzed as secondary outcome measures. 
Statistical Analysis
Sample size calculations were primarily based on calculations with regard to decrease in 
migraine frequency in the last 4 weeks of the riboflavin phases compared with the last 4 
weeks of the placebo phases26. For this primary outcome measure, a minimum number of 
20 patients was required for sufficient power; to allow for exploratory analyses we extended 
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this to 42 children. Statistical analysis of the CHQ-PF50 and CBCL data was performed 
according to the intention-to-treat principle. To evaluate the effect of riboflavin on the 
continuous outcome variables the t-test for independent observations was applied32. 
To statistically compare possible differences between the patients and healthy controls, 
data of our study population were compared with raw data of a group of 353 healthy 
children from the same region in which our study took place, who were previously 
investigated using the same questionnaire (Child Health Questionnaire CHQ-PF50, Dutch 
edition)9,28 by performing an analysis of covariance (ANCOVA) with adjustment for gender 
and age. For the CBCL data, we performed an analysis of variance (ANOVA) using the 
published data of a group of 1,241 healthy children (aged 6-11 years) in the Netherlands 
who were previously investigated using the same questionnaire (CBCL, validated Dutch 
version)30. All statistical testing took place at the 0.05 level of significance (two-tailed). 
Analyses were performed using the statistical programme SPSS 15.0 for Windows (SPSS 
Inc., Chicago, IL, USA).	
RESULTS
Demographics 
A total of 57 children were assessed for eligibility. Of these, 15 patients did not meet the	
inclusion criteria, or met one or more exclusion criteria, or the parents or child refused to 
participate in the trial, and were therefore not enrolled (Fig. 1).
Of the 42 children that were randomized, 20 were randomized to receive riboflavin during 
phase 1 and placebo during phase 2, whereas 22 children received placebo during phase 
1 and riboflavin during phase 2. In this latter group, during the placebo phase, one child 
was lost to follow-up, the parents of two children withdrew their consent for further 
participation, and one patient proved to be suffering from headache due to medication 
overuse (revealed after careful study of her baseline headache diary). Both treatment 
groups had comparable demographic and migraine features (Table 1).
Outcome data
The results concerning headache outcome have already been reported26. Briefly, no 
significant difference was found between the effects of riboflavin versus placebo in the 
prevention of migraine attacks, or in the severity or duration of the migraine attacks. 
A steady decrease in migraine frequency throughout the trial was found, both in the 
riboflavin-placebo group and in the placebo-riboflavin group.
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Fig. 1: The CONSORT* flow diagram showing the flow of participants.  
*CONSORT indicates Consolidated Standard of Reporting Trials. 
 
 
  
 
 
 
 
 
 
 
      Randomized  (n = 42) 
    Asessed for eligibility  
 (n = 57) 
Excluded (n = 15) 
· not meeting inclusion criteria (n = 2) 
· presence of exclusion criteria (n = 3) 
· refused to participate (n = 10) 
     Enrollment  (n = 42) 
     baseline period: 4 weeks 
Allocated to riboflavin 
           (n = 20)  
phase 1: 16 weeks  
Allocated to placebo 
         (n = 22) 
phase 1: 16 weeks 
Allocated to riboflavin 
            (n = 18) 
  phase 2: 16 weeks 
Allocated to placebo 
         (n = 20) 
phase 2: 16 weeks 
Washout (n = 20):  
        4 weeks 
Washout (n = 18):   
       4 weeks 
Discontinued intervention (n = 4) 
· refusal of further participation (n = 2) 
· presence of exclusion criteria (n = 1) 
· lost to follow-up (n = 1)  
Analyzed (n = 18)  Analyzed (n = 20) 
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Table 1: Baseline demographic and clinical characteristics
Characteristic Riboflavin-Placebo
(n = 20)
Placebo-Riboflavin
(n = 22)
Age in years, mean (± sd)
 
9.91 ± 1.89 9.50 ± 1.63
Male 12 (60%) 12 (54%)
Migraine with aura 9 (45%) 8 (36%)
Other headache types
   Nil other than migraine
   Tension-type headache
   Headache by ENT infections
   Other
8 (40%)
10 (50%)
1 (5%)
3 (15%)
15 (68%)
4 (18%)
0 (0%)
2 (9%)
Family history of migraine 16 (89%) 19 (95%)
Years since onset of migraine 
    (mean ± sd) 3.06 ± 1.73 2.80 ± 2.14
Frequency of migraine attacks per month 
(mean ± sd) 3.60 ± 3.10 3.48 ± 5.41
Duration of migraine in hours
    (mean ± sd) 2.45 ± 1.19 2.57 ± 1.54
Migraine prophylaxis used 
    in the past 2 (10%) 4 (18%)
Use of paracetamol as   
   symptomatic treatment 13 (65%) 17 (77%)
Use of ibuprofen as   
   symptomatic treatment 4 (20%) 6 (27%)
Use of sumatriptan as   
   symptomatic treatment 4 (20%) 5 (23%)
sd, standard deviation
During the trial no adverse effects were reported by parents or children26.
The QoL and CBCL outcome data are summarized in Tables 2a, 2b, 3a and 3b. 
No significant differences were found between placebo and riboflavin on all investigated 
generic QoL domains (Tables 2a and 2b) or on all CBCL scales (Tables 3a and 3b). Since 
there were no superior effects of riboflavin with regard to placebo (or vice versa) on any 
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of the QoL or CBCL outcomes, we concluded that the riboflavin condition in fact acted 
as a placebo with regard to these outcomes. Therefore, we collapsed the data of the 
riboflavin-placebo group with the placebo-riboflavin group to gain more statistical power 
for comparison with the data of healthy children, both at baseline and at the end of the 
trial. The results of these analyses are given in Tables 4 and 5.	
During the trial, an improvement of the generic QoL was observed in these combined 
data on the domains physical functioning, role/emotional/behavioural, role/physical, 
bodily pain, behaviour, mental health, self-esteem, general health perception, parental 
impact emotional, parental impact time, and family activities. No improvement was 
observed on the domains global health and family cohesion during the trial.	Furthermore, 
at the start of the trial, on all QoL domains a significant difference (p < 0.05) was found 
between the included children and healthy controls as measured by ANCOVA, in favour 
of the healthy controls. At the end of the trial the QoL on four domains (mental health, 
self-esteem, parental impact emotional and parental impact time) was within the range 
of healthy controls as measured by ANCOVA.      
 
With regard to psychological functioning, in the combined data of both the riboflavin-
placebo and the placebo-riboflavin group there was an improvement on all CBCL scales. 
Furthermore, at the start of the trial, on the CBCL subscales somatic complaints and 
thought problems and on the main scales internalizing behavior and total score, a 
significant difference (p < 0.05) was found between the included children and healthy 
controls as measured by ANOVA, in favour of the healthy controls. At the end of the trial 
the CBCL scores on the main scales internalizing behavior and total score were within 
the range of healthy controls. In addition, at the end of the trial, a significant difference 
(p <  0.05) in the score on the subscale somatic complaints was found in children with 
migraine versus healthy controls in favour of the healthy controls, despite improvement 
as measured by ANOVA. With regard to the subscale of aggressive behaviour and the main 
scale of externalizing behaviour, at the end of the trial the children with migraine had 
significantly favourable scores (p < 0.05) compared to healthy controls as measured by 
ANOVA.
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Table 4: Quality of life (CHQ-PF50), not distinguished by riboflavin or placebo,  
in comparison with healthy controls 
QoL-subscales   Period 1 baseline   Period 2 end
 
 Healthy Controls
  n           mean        sd   n           mean        sd  n            mean        sd
Global Health 41 59.351 26.36 38 57.011 23.13 353 85.72 16.27
Physical Functioning 41 80.731 25.63 38 91.231 19.05 353 99.08 4.25
Role/Emot/Behavioural 40 86.671 23.36 38 91.521 15.37 353 97.87 7.19
Role/Physical 40 70.001 27.79 38 86.401 20.45 353 95.75 15.61
Bodily Pain 41 52.191 21.85 38 63.951 17.64 353 85.67 17.24
Behaviour 41 64.001 11.13 38 67.261 9.15 353 78.54 13.06
Mental Health 41 76.462 14.54 37 81.35 15.53 353 81.40 12.10
Self-esteem 41 74.181 12.08 37 75.90 14.27 353 79.15 10.97
General Health Perception 41 66.951 18.96 38 68.731 18.49 353 82.87 13.44
Parental Impact Emotional 41 71.131 22.75 38 86.40 14.29 353 86.31 15.20
Parental Impact Time 41 83.741 23.58 38 95.02 7.62 353 93.96 13.02
Family Activities 41 79.171 14.31 38 85.962 13.95 353 91.52 11.94
Family Cohesion 41 33.541 19.04 38 31.581 19.00 353 72.22 19.41
n, number of patients; sd, standard deviation
1significant difference compared with healthy controls (p  <  0.01; two-sided) by two-way ANCOVA test
2significant difference compared with healthy controls (p  <  0.05; two-sided) by two-way ANCOVA test
Table 5: Psychological functioning (CBCL), not distinguished by riboflavin or placebo,  
in comparison with healthy controls 
Parameter    Period 1 baseline   Period 2 end
 
   Healthy Controls
  n         mean        sd   n          mean        sd    n               mean         sd
Total 40 31.412 21.75 35 19.10 15.49 1241 21.40 15.63
Withdrawn 40 1.90 2.74 35 1.17 1.74 1241 1.77 1.94
Somatic complaints 37 5.451 3.50 34 3.391 2.82 1241 0.89 1.44
Anxious/depressed 40 4.08 4.28 35 2.31 3.29 1241 2.53 3.11
Social problems 40 1.98 2.60 35 1.02 1.52 1241 1.39 1.89
Thought problems 40 1.171 1.28 35 0.40 0.77 1241 0.47 1.01
Attention problems 40 4.11 3.72 35 2.95 3.24 1241 3.09 2.90
Delinquent behaviour 40 0.93 1.27 35 0.63 1.11 1241 1.18 1.51
Aggressive behaviour 40 6.33 5.14 35 3.371 4.02 1241 6.40 5.31
Internalizing 37 11.561 8.47 34 6.74 6.09 1241 5.08 5.08
Externalizing 40 7.25 6.04 35 4.001 4.71 1241 7.57 6.32
n, number of patients; sd, standard deviation
1significant difference compared with healthy controls (p <  0.01; two-sided) by two-way ANOVA test
2significant difference compared with healthy controls (p <  0.05; two-sided) by two-way ANOVA test
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DISCUSSION
This is the first randomized, double-blind, placebo-controlled intervention study in 
children with headache or migraine in which generic QoL and psychological functioning	
have been used as outcome variables. Riboflavin was used as intervention medication. 
As previously reported, no significant difference was found for the effect of riboflavin in 
the dosage used versus placebo on improvement of mean migraine frequency, mean 
intensity or mean duration of migraine attacks26. In addition, based on the data yielded 
by the present study, we conclude that riboflavin has no superior effect versus placebo in 
children with migraine with regard to improvement of QoL and psychological functioning 
on all investigated life domains and psychological subscales. To gain maximal statistical 
power, we decided to collapse the data of the riboflavin-placebo group with those of 
the placebo-riboflavin group to analyze the effect of a structured prophylactic placebo 
intervention in combination with state-of-the-art symptomatic treatment in children with 
migraine on generic QoL and psychological functioning over a relatively long period of 9 
months. To do this, we decided to compare the data of our cohort with data from healthy 
controls, at the start and at the end of the trial.	
	
In this combined group, the QoL was significantly lower at baseline on all investigated life 
domains compared with healthy children. This is in line with other descriptive studies on 
generic QoL in children with headache or migraine at referral to a specialist5-9. On all but 
two life domains, the QoL improved during the trial. At the end of the trial, on four life 
domains the QoL was within the range of healthy controls, i.e. mental health, self-esteem, 
parental impact emotional, and parental impact time. This means that the effect of the 
headache attacks of a child with migraine on the emotional wellbeing of his/her parents 
is also susceptible to proper symptomatic treatment and placebo prophylactic treatment 
of the child. This placebo effect is well known in headache research; it might be induced 
by the sustained attention paid by physicians and research nurses to the burden placed 
on the child and/or its family. 
Interestingly, during the trial no improvement was seen on the QoL domains global health 
and family cohesion, in contrast to improvements on the other QoL domains. Regarding 
the domain global health, the poor QoL might persist because parents of children with 
migraine are inclined to believe that their child’s health is poor, irrespective of any 
improvement due to treatment. Regarding the domain family cohesion, the poor QoL 
might persist because the child’s headache represents a functional problem within the 
family (i.e. a symptom of a dysfunction of the family) and is therefore inclined to remain 
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poor after a treatment predominantly directed at improving the child’s headache only. 
Alternatively, the poor and treatment-resistant QoL on the domains global health and 
family cohesion might also be due to the fact that both are single-question domains. This 
means that there is a range of only 5 items for parents to assess their child’s health and 
the quality of the relations within their family, respectively; this is considerably less than 
the amount of variation available in the other QoL domains. Therefore, additional studies 
are needed to answer these important questions about the effect of treatment on internal 
family relations, as well as on parents’ perception of the health of their child with migraine. 
With regard to the association of the primary headache parameters (headache frequency, 
intensity and duration) and QoL, a post-hoc analysis showed that in general in all phases 
of the trial most QoL domains are inversely related, not only with headache frequency but 
also with duration of the headache attacks. 
With regard to psychological functioning, at baseline all CBCL scores in the combined 
group were within the range of healthy controls, with the exception of the subscales 
somatic complaints and thought problems and the main scale internalizing behaviour. 
This is in line with the descriptive studies of Galli et al.23 and Vanatta et al.21 who also used 
the CBCL as outcome variable. In the CBCL the subscale somatic complaints contains 8 
questions, 3 of which concern the symptoms of headache, nausea and vomiting29,30 (i.e. the 
hallmarks of migraine in children). Therefore, due to the nature of their disease, children 
with migraine are inclined to have a high score on this subscale. Moreover, the subscale 
somatic complaints is one of the three subscales that form the internalizing behaviour 
score (the others being the subscales withdrawn and anxious/depressed). Since there were 
no significant differences in scores on the subscales withdrawn and anxious/depressed in 
the children with migraine compared with healthy controls, either in the present study or 
in the study of Galli et al.23 and in the study of Vanatta et al.21 in the father’s CBCL report, 
we conclude that the deviant score on the main scale internalizing behaviour in children 
with migraine, in favour of healthy controls, has to be attributed to the nature of the 
disease and not to psychological dysfunctioning due to migraine. Therefore, based on 
the results of the present study and of Galli et al.23 and Vanatta et al.21, it seems justified to 
conclude that children with migraine do not exhibit more psychological dysfunctioning 
than healthy controls at referral to a specialist. This seems remarkable because several 
studies have demonstrated that adults with migraine exhibit more psychological 
dysfunctioning and/or psychiatric comorbidity than healthy controls, suggesting a shared 
genetic susceptibility to both migraine and psychopathology, especially anxiety disorders 
and depression33-36. However, if a shared genetic susceptibility between migraine and 
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psychopathology does exist, one would expect this also to be manifest in children with 
migraine. The results of the present study and of Galli et al.23 and Vannatta et al.21 seem 
to demonstrate the opposite. This suggests that the association between migraine and 
psychopathology in adults is more likely due to the long-term effect of a chronic disease on 
the mental state of migraineurs and is therefore not present in children with migraine who 
have the disease for a relatively short period. However, one may also argue that children 
are less susceptible for developing psychopathology in comparison with adults due to 
their relatively protected environment with fewer responsibilities and less stressors and, 
in addition, that developing symptoms of psychopathology due to a genetic susceptibility 
might take a considerable amount of time, and that for this reason in children with not-
longstanding migraine there is minimal or absent psychopathology.               
In addition, in the present study there was an improvement on all CBCL scales throughout 
the trial; by the end of the trial, scores were within normal range on the subscale thought 
problems and on the main scales internalizing behaviour and total score. At the end of 
the trial, despite improvement, only on the subscale somatic problems was the score still 
significantly deviant from that of healthy controls, in favour of the latter group. 
Interestingly, regarding the subscale aggressive behaviour and the main scale externalizing 
behaviour, at the end of the trial there was also a significant deviant score compared with 
healthy controls, but this time in favour of children with migraine. The subscale aggressive 
behaviour is one of the two subscales that form the externalizing behaviour score (the 
other being delinquent behaviour). Since there was no significant difference between the 
score on the subscale delinquent behaviour compared with healthy controls at the end 
of the trial, we conclude that the low score on the main scale externalizing behaviour is 
mainly due to the low score on the subscale aggressive behaviour. Therefore, based on the 
present study, we conclude that children with migraine are inclined to have significantly 
better scores versus healthy controls on the subscale aggressive behaviour and on the 
main scale externalizing behaviour after a proper symptomatic and placebo prophylactic 
treatment. 
With regard to the association of the primary headache parameters (headache frequency, 
intensity and duration) and psychological functioning, we performed a post-hoc analysis 
on the main CBCL-scales of internalizing and externalizing behaviour and total score 
showing that especially in phase 1 and phase 2 these were in general positively related 
with headache frequency and headache duration.
At the start of the present study the generic QoL was poor on all life domains compared 
with healthy controls, which is in line with similar descriptive studies5-9. However, with 
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regard to psychological functioning, no discrepancy with healthy controls was found 
at the start of the study with exception of the subscale thought problems, somatic 
complaints and the main scale internalizing behaviour. With regard to the deviant scores 
on the latter two scales, we conclude that this is mainly due to the nature of the disease 
itself which inevitably leads to high scores on both scales; this was also demonstrated in 
similar descriptive clinical studies concerning only psychological functioning in children 
with migraine23,21.  We therefore conclude that the QoL of children with migraine at 
referral to a specialist is poor, not because of psychological dysfunctioning, but rather as a 
consequence of the disease itself.   
Our study certainly has some limitations. It could be argued that improvements on the 
QoL domains and the CBCL scales might result from entry bias and regression toward 
the mean; e.g. inclusion of children with migraine at referral to a specialist implies that 
they are probably at their worst because migraine is typically a paroxysmal disease with 
periods of relatively frequent attacks, followed by periods with relatively infrequent 
attacks, so that the included children will be more inclined to improve than to deteriorate 
after consultation with a specialist. This phenomenon will undoubtedly have occurred in 
the present study. Moreover, as all children received proper symptomatic treatment and 
placebo prophylactic treatment in a structured manner, a placebo effect almost certainly 
occurred. In addition, it could be argued that improvements on the QoL domains and the 
CBCL scales are due to repeated testing, meaning that parents of the included children 
are inclined to give higher scores as they expect some results from the treatment. To 
gain more insight into these topics, we performed a PubMed search to find comparable 
pharmacological placebo-controlled, randomized intervention studies in children in 
fields other than headache research which used both psychological functioning and QoL 
as outcome parameters; however, none were found. 
Finally, a major limitation is that we did not use an intervention with a superior effect 
compared with placebo on the primary headache parameters headache frequency, 
headache intensity and duration of the headache attacks. If this was the case, and we 
would have demonstrated that this intervention had a concomitant superior beneficial 
effect on QoL and psychological functioning, this would give additional evidence that 
both outcomes are directly related to the burden of headache in children with migraine.    
The study also has strong points. This is the first randomized, double-blind, placebo-
controlled intervention study in children with headache or migraine in which generic 
QoL and psychological functioning are used as outcome variables. In addition, this is the 
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first clinical study in children with migraine in which both generic QoL and psychological 
functioning are used as outcome variable in the same cohort of patients, providing 
valuable additional information on the relationship between QoL and psychological 
functioning. 
		
Finally, we believe that measuring generic QoL and psychological functioning in 
pharmacological or non-pharmacological intervention studies in children with headache 
or migraine is an important concept, not only to observe if the intervention itself has 
a positive effect on QoL and psychological functioning, but also because numerous 
pharmacological interventions in this field (especially prophylactic interventions) may 
have an adverse effect on physical, social and psychological wellbeing. For example, 
anti-epileptic drugs are widely used as migraine prophylaxis in children. As these drugs 
may have a beneficial effect on headache frequency and intensity, they may also have a 
negative effect on mood, cognition or behaviour12. The net result of this combination may, 
however, be difficult to determine. The use of generic QoL and psychological functioning 
as outcome parameter may help to detect this, especially in smaller children who cannot 
yet adequately voice their improvements and/or their complaints and subsequently 
provide a reasonable judgement about the overall effect of treatment. Also for this reason, 
we recommend that future intervention studies in children with headache or migraine 
use generic QoL and psychological functioning as outcome parameter.  
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ABSTRACT 
Background: Little is known about the effects of sleep on migraine, especially in children. 
Objective: To assess the effect of sleep deprivation on headache attacks in children with 
migraine. The relationship between resting and sleeping and headache symptoms was 
also explored.
Methods: A prospective study using headache diaries. In 42 children with migraine, sleep 
pattern and duration were registered in the diaries by the parents.
Results: The study included 42 children (6 to 13 years) with migraine (mean age 9.69 years, 
24 male).	Only 6.2% of the headache attacks were preceded by the occurrence of one 
night in which the child slept less than usual. During attacks, resting decreased headache 
intensity in 76.0% of the attacks occurring after a preceding sleep deficit and in 54.4% 
of the attacks without preceding sleep deficit (p = 0.04). Sleeping decreased headache 
intensity in 84.0% of the attacks with a sleep deficit and in 63.6% of the attacks without 
preceding sleep deficit (p = 0.05). In case of a favourable effect of resting and sleeping on 
headache intensity, a significant decrease of headache duration was also found, compared 
with attacks with no effect of resting and sleeping on headache intensity (p < 0.001 and 
p = 0.021, respectively). 
Conclusions: In these young children, one night with less sleep was not an important 
precipitating factor of migraine attacks. Moreover, once a child is suffering from a 
headache attack, resting and sleeping resulted in a clinically relevant improvement of 
headache intensity and duration. 
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INTRODUCTION
In both children and adults a regular and undisturbed sleep is recommended as a 
treatment goal in many diseases and conditions, but especially in the case of headache 
disorders. As early as 1853 in his classic	Lehrbuch, Romberg wrote:	“The	attack	is	generally	
closed	 by	 a	 profound	 and	 refreshing	 sleep”1. Although sleeping has been the advised 
treatment for migraine attacks over the centuries, the functions of sleep have not yet been 
fully unravelled2. In fact, more is known about the adverse effects of sleep disturbances. 
A recent review showed that sleep disorders are associated with headaches and that 
variations in sleep duration (oversleeping/undersleeping) are commonly identified 
headache triggers3; however, because most of the included studies were of a retrospective 
or cross-sectional nature and were population based, they were correlative rather than 
causative.
Also in the paediatric clinical setting data are scarce. A few studies have shown that a 
variety of sleep disturbances/disorders are present in children and adolescents with 
migraine4-8. Although these studies show an association between sleep and migraine, 
their design does not allow causal inferences, which is of clinical interest to improve 
headache treatment. Another topic of clinical interest is whether sleeping actually does 
resolve migraine attacks. 
Therefore, we investigated	the effects of sleep in childhood migraine. The current study 
was designed within the context	 of	 a	 placebo-controlled, randomized, double-blind, 
crossover trial of riboflavin as a possible preventive drug9. 
The aim of the present study was to assess sleep as a potential	causative factor for migraine 
attacks in a paediatric outpatient department setting. The relation between resting and 
sleeping and headache symptoms was also explored.
MATERIAL and METHODS
Patients and procedure
A consecutive series of children with migraine (referred to the paediatric neurology 
departments of either a university children’s hospital or at the paediatric outpatient 
department of a general hospital) were asked to participate in a placebo-controlled, 
cross-over trial with riboflavin as the acting agent. 
The methodology, including the inclusion and exclusion criteria, procedure and design 
of this trial have been described in detail in our former paper, which also presents the 
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Consolidated Standard of Reporting Trials (CONSORT) flow diagram and CONSORT 
statement9. 
During the trial, the parents of the included children were asked to keep a detailed 
headache diary during all stages of the trial.
Measures
Headache diaries were analyzed in all phases of the trial. We introduced the term ‘deficit’ 
to describe the situation in which the diary reported the duration of sleep in the night 
preceding the headache attack as 1 or more hours less than the patient’s usual quantity 
of sleep. In the present study, the relation between sleep deficit and the occurrence of a 
migraine attack was the principal outcome measure. In order to exclude statistical bias 
due to the type of intervention and phase of the trial, sleep deficit was also related to 
these variables. Finally, we explored a possible relationship between sleep deficit and the 
type, intensity and duration of the headache attacks. All of these outcome measures were 
defined as secondary outcome measures in advance of the start of the trial, to be analysed 
in the present study.
Statistical Analysis
Sample size calculations were based on calculations with regard to a decrease in migraine 
frequency in the last 4 weeks of the riboflavin phases compared with the last 4 weeks of 
the placebo phases9. Thus, a minimum number of 20 patients were required to participate 
in the trial. To allow for dropouts, 30 patients were initially enrolled, which was later 
extended to 42 to allow further exploratory analyses9. 
Statistical evaluation of the headache diary data was performed using Statistical Package 
for the Social Sciences (SPSS 15.0) software (SPSS Inc., Chicago, IL, USA) in combination 
with Statistical Analysis Software (SAS 9.2, SAS Institute Inc, Cary, NC, USA). 
Chi-square tests were used for categorical date, and for continuous data t-tests for 
independent observations were used to compare headache diary variables. The level of 
statistical significance was set at p ≤ 0.05, two-tailed. The descriptive values are expressed 
as means, including standard deviations (sd) and percentages.
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RESULTS
Demographics
Baseline information on demographics and migraine features of the participants are 
presented in Table 1. Of the 57 recruited	children, 15 were not enrolled because they did 
not meet the inclusion criteria, or met one or more exclusion criteria, or because they or 
their parents declined to participate in the trial. Of the 42 remaining children, 20 were 
randomized to receive riboflavin during phase 1 and placebo during phase 2, and 22 
children received placebo during phase 1 and riboflavin during phase 2. In this latter 
group one child was lost to follow-up, the parents of two children withdrew their consent 
for further participation, and one patient proved to be suffering from headache due to 
medication overuse, which was discovered after careful study of her baseline headache 
diary. Both treatment groups had comparable demographic and migraine features.
During the entire trial a total of 504 headache attacks were reported and used for analysis.	
In total, 403 headache attacks had relevant data, i.e. 403 attacks reporting headache 
characteristics concerning the duration of sleep in the preceding night and duration of 
sleep in general. Of all recorded headache attacks, the mean intensity (on a scale from 
0-3) was 1.92 (sd 0.97). On average, the total duration of a single headache attack was 2 h 
and 48 (sd 81) min. 
Outcome data
To investigate the effects of sleep deficit on headache characteristics, we analysed the 
number of headache attacks that were preceded by a night in which the child slept 1 
or more hours less than usual. Of the 403 headache attacks available for	analysis, sleep 
deficit occurred in 25 attacks (6.2%; Table 2). In 21 of these 25 headache attacks (84.0%), 
sleep deficit ranged from 1-3 h, and in the remaining 4 headache attacks (16.0%) sleep 
deficit was more than 3 h. Because the present study is part of a placebo-controlled trial, 
the outcomes might be affected by the type of intervention received (i.e. riboflavin or 
placebo). Therefore, we compared the headache attacks with or without a preceding sleep 
deficit in the last 4 weeks of the riboflavin periods and of the placebo periods throughout 
the trial. However, no difference in the occurrence of a sleep deficit could be found on Chi-
square analysis between the two types of intervention (p = 0.75; Table 2).	The percentage 
of headache attacks in the placebo and the riboflavin periods is lower than the percentage 
of headache attacks in the baseline and the washout periods; this is due to the fact that 
the baseline and washout period had a combined duration of 8 weeks (Table 2).
Subsequently, we explored whether a preceding sleep deficit was related to the type 
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of headache attack. Of the headache attacks preceded by a sleep deficit, 88.0% were 
migraine attacks and 12.0% were non-migrainous headache attacks (Table 2). Of the 
headache attacks not preceded by a sleep deficit, 78.6% were migraine attacks and 21.4% 
were non-migrainous headache attacks. Because there was no significant difference 
between the subdivisions in both groups on Chi-square analysis (p = 0.32), we conclude 
that sleep deficit preceding a headache attack does not affect the type of headache 
attacks in children with migraine.
To measure the effects of a sleep deficit on headache characteristics, we analysed	 the 
relation between sleep deficit and pain intensity	and total headache duration. The reported 
values for intensity and duration of the headache attacks showed no significant difference 
compared to those not preceded by a sleep deficit; the mean values for intensity (on a 0-3 
scale) were 1.8 (sd 0.87)	and 1.9 (sd 0.97), respectively (p = 0.59; Table 2). The mean values 
for the total duration of the headache attacks were 2 h and 40 min (sd 1 h and 16 min), and 
2 h and 49 min (sd 1 h and 20 min), respectively (p = 0.58; Table 2). 
Finally, we explored the	potentially positive effects of resting and sleeping on headache 
attacks, to assess whether or not these were related to preceding sleep deficits (Tables 
3 and 4). Testing for significance took place with two-way ANOVA analysis. The total 
number of reported headache attacks during which resting or sleeping took place (i.e. 
504) exceeds the total number of reported attacks; this is because the parents indicated 
that both resting and sleeping had occurred	in a considerable number of attacks. Resting 
decreased the headache intensity in 76.0% of the attacks occurring after a preceding 
sleep deficit compared with 54.4% of the attacks without preceding sleep deficit (p = 0.04; 
Table 3). Sleeping decreased the headache intensity in 84.0% of the attacks with a sleep 
deficit compared with 63.6% of the attacks without a preceding sleep deficit (p = 0.05; 
Table 3). Without a decreasing effect of resting on headache intensity, the average total 
duration of the headache attacks was 3 h and 17 min.	With a decreasing effect of resting 
on headache intensity, the duration was reduced by 48 min. Without a decreasing effect 
of sleeping on the intensity of the headache attack an average total duration of 3 h and 15 
min was reported; with a decreasing effect of sleeping on the intensity of the headache 
attack, the attack was shortened by 39 min.	Both effects were highly significant (p <  0.001 
and p = 0.021, respectively; Tables 4a and 4b). The occurrence of a sleep deficit showed 
no relation with the effects of resting and sleeping on headache duration compared with 
attacks without a preceding sleep deficit (p = 0.19 and p = 0.63, respectively; Table 4b).
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DISCUSSION 
Sleep deprivation
During the trial it was found that 6.2% of the headache attacks were preceded by a night 
in which the parents reported that their child slept	at least 1 hour shorter than usual. This is 
much less than expected based on earlier reports on sleep disturbances and associations 
with headache4-8. We believe this is the first prospective study to explore the effect of 
sleep deprivation on headache in children with migraine, making comparison with other 
studies difficult. One study, in which parents of children with migraine were specifically 
asked if their child slept too little, yielded an answer of 42%8; however, this question was 
not used to identify sleep deprivation as a trigger factor for migraine attacks, and no 
definition of ‘too little’ was given. Consequently, we cannot readily relate	this finding to 
our results.
According to a recent population-based study of 480 Hispanic and Caucasian children 
(aged 6-11 years), there is a discrepancy between the parental report of sleep time by 
means of a questionnaire and objectively obtained polysomnographic evidence10. In that 
study, parents reported 578 min as the habitual total sleep time and 547 min as the total 
sleep time on the night of the recording, whereas using polysomnography a total sleep 
time of only 480 min was found (p	< 0.001). The authors warned clinicians that parents 
substantially overestimate the total sleep time of their children10. In a study by Vendrame 
et al., children (aged 9-15 years) with headache showed polysomnographic values of (on 
average) 390 min for total sleep time in the migraine group; however, that study lacked a 
control group of age-matched healthy children11. In the present study, parents reported a 
total sleep time of over 8 hours in 93.8% of the headache attacks. One explanation for the 
discrepancy between the total sleep times found by Vendrame et al. and our group is that 
the children with headache in the study of Vendrame were part of a specifically selected 
subgroup with a positive screening for sleep complaints. Additional explanations could 
be the difference in the mean age of the patients (11.5 versus 9.7 years, respectively) or 
over-estimation by the parents in the present trial of the total sleep time of their children. 
Our way of collection of sleep data has its flaws. Future research should also include data 
on baseline sleep patterns, nights of normal sleep and nights with oversleeping. However, 
even allowing for the limitations of not having polysomnographic values, and assuming 
that parental overestimation is a consistent factor, the present	study allows us to draw 
some conclusions based on the reported values. For example, in our trial, having a sleep 
deficit precedes only 6.2% of the headache attacks. One possibility for this rare occurrence 
of sleep deficit, preceding a headache attack in children with migraine, could be that the 
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trigger factor is not the deficit on the night preceding the attack but rather a sleep debt 
over multiple nights, particularly because	lack of sleep or bad quality of sleep is reported 
to precipitate headache attacks4,12. Future prospective studies should focus on this 
relationship, preferably using objective measurement tools (such as polysomnography) 
and using healthy, sex and age-matched children as controls.
No significant relationship was found between the occurrence of sleep deficit and the 
headache characteristics of pain intensity and headache duration. This allows concluding 
that a sleep deficit preceding a headache attack does not result in increased pain intensity 
or prolonged attack duration. An earlier cross-sectional study	in children with headache 
explored the parents’ perception of sleep duration as being too little or adequate during the 
preceding week on the one hand, and headache severity on the other8. The authors used 
the Headache Intake Questionnaire13 to measure pain severity and headache duration, 
and the Children’s Sleep Habits Questionnaire14 to measure total sleep duration, all on 
Likert-type scales. Headache duration was not related to the total sleep duration (in line 
with our findings), but the pain intensity of migraine attacks was inversely related to the 
parental report of sleep duration (p < 0.05)8. Based on this result, one could hypothesize 
that a prolonged sleep deficit could lead to more intense migraine attacks; however, our 
study shows no such relationship for one night of diminished sleep.
To elucidate the causative effects of sleep deficit on migraine attacks in children, future 
studies should use a prospective and intervention design rather than a cross-sectional 
one. To our knowledge only one case-controlled intervention study on children with 
migraine has explored the effect of improving sleep hygiene on primary headache 
parameters, providing evidence that a simple modification of sleep pattern will decrease 
migraine frequency and duration15. Whilst we specifically investigated the causal effects of 
a single night of sleep deficit, future studies should focus on other possible causal factors 
and mechanisms. These studies should be aware of the recently reported high placebo 
rate in trials on childhood migraine and should therefore be appropriately designed16. 
Resting and Sleeping
To the best of our knowledge, the effect of resting and sleeping after the start of a 
headache attack on headache intensity and duration in children with migraine has not 
yet been evaluated in intervention studies. Our study confirms the generally accepted 
positive effects of resting and sleeping on the intensity of headache attacks in children 
with migraine. Moreover, in case of a positive effect of resting and sleeping on headache 
intensity, headache duration decreased significantly compared with attacks with no 
effect of resting and sleeping on headache intensity. The effects of resting and sleeping 
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on headache intensity were significantly greater after a preceding sleep deficit (resting: 
p = 0.04, sleeping: p = 0.05), whereas the preceding sleep deficit had no effect on the 
reduction of headache duration by resting or sleeping (resting: p = 0.19, sleeping: p = 
0.63, respectively).	This might be explained by the fact that children with a preceding 
sleep deficit were inclined to sleep longer, because of their shortage of sleep, and since 
the duration of sleeping and resting was not an item in the headache diaries, a possible 
decreasing effect on the duration of the headache attacks might be masked by an increase 
of the duration of resting and sleeping themselves.	Therefore, precise documentation of 
these durations could be of added value. 
A limitation of the present study is that we did not specifically ask the question for which 
Romberg already seemed to know the answer, i.e. “Does sleeping end the attack?” We 
recommend that future studies explore this question. One prospective clinical study on 
sleep in relation to migraine attacks in children has demonstrated that one-third of the 
attacks ended in falling asleep17. 
Another point is the use of Likert-type scales to report headache intensity. Different 
scales are used in different studies; we used a 4-point scale (light, moderate, annoying, 
strong) whilst others used the scale from the Headache Intake Questionnaire used by 
Hershey et al.13 in which a 10-point severity scale was adapted to a 5-point faces scale 
for younger children. The International Headache Society guideline for controlled trials 
of drugs in migraine recommends the use of a 4-point Likert scale: 0 = no headache; 1 
= mild headache; 2 = moderate headache; 3 = severe headache18. We recommend use 
of this Likert scale whenever possible, with the visual analogue scale as the next best 
alternative18.
Clinical Advice
Although our results show that a single event of sleep deficit is at most a small factor 
among those triggering migraine attacks, we recommend focusing on the different 
aspects of sleep of our migraine patients. Whereas future research needs to define the 
importance of other aspects of sleep disturbances for the origin of migraine, the positive 
effects of changing bad sleeping habits on the frequency of migraine or headache attacks 
have been demonstrated15,19. Moreover, having slept less than usual has no relationship 
with the general advice to children to go to bed during a migraine attacks; in all situations 
we would strongly recommend going to bed. 
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CONCLUSIONS 
The present study has shown that one night with less sleep is not an important trigger 
factor for migraine attacks in children. It was also shown that resting and sleeping after 
the start of the headache attack is likely to decrease the intensity and duration of the 
attack in children with migraine. This effect on intensity is even more profound when 
there has been lack of sleep in the night preceding the headache attack. 
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Table 1: Baseline demographic and headache characteristics of the study population
Parameter Riboflavin-Placebo
(n = 20)
Placebo-Riboflavin
(n = 22)
Age, mean (sd) 9.91 (1.89) 9.50 (1.63)
Male 12 (60%) 12 (54%)
Headache
MA 
MoA
Only migraine
TTH
ENT infections
Other
9 (45%)
11 (55%)
8 (40%)
10 (50%)
1 (5%)
3 (15%)
8 (36%)
12 (64%)
15 (68%)
4 (18%)
0 (0%)
2 (9%)
Family history of migraine 16 (89%) 19 (95%)
Years since onset of migraine,
 mean	(sd)
3.06 (1.73) 2.80 (2.14)
Number of migraine attacks per month,
mean (sd)
3.60 (3.10) 3.48 (5.41)
Duration of migraine in hours,
mean (sd)
2.45 (1.19) 2.57 (1.54)
n, number of patients; MA, migraine with aura; MoA, migraine without aura; TTH, tension-type headache;  ENT, ear-nose-throat.
Table 2: Intervention and headache characteristics related to sleep deficit
Parameter No sleep deficit Sleep deficit Statistical analysis
riboflavin 26.5 % 32.0 % 0.75
placebo 16.7 % 12.0 %
baseline/washout 56.9 % 56.0 %
f 378 25 
migraine  78.6 %. 88.0 % 0.32
non-migrainous headache 21.4 % 12.0 %
f 378 25
intensity (0-3): mean (sd) 1.90 (0.97) 1.80 (0.87) 0.59
f 375 25
duration (hours): mean (sd) 2.82 (1.33) 2.67 (1.27) 0.58
f 341 24
f, number of reported headache attacks 
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Table 3: Effect of resting and sleeping on headache intensity:  without and with sleep deficit
Parameter No sleep deficit Sleep deficit Statistical analysis
Resting
decreasing effect on HI 54.4% 76.0% 0.04
no decreasing effect on HI          45.6% 24.0%
f 351 25
Sleeping
decreasing effect on HI 63.6% 84.0% 0.05
no decreasing effect on HI           36.4% 16.0%
f 330 25
f, number of reported headache attacks; HI, headache intensity 
Table 4a: Effect of resting and sleeping on headache intensity  and headache duration (hours): 
without and with sleep deficit
Parameter No sleep deficit Sleep deficit Total
f mean sd f mean sd f mean sd
Resting
decreasing effect on HI 167 2.01 1.34 18 2.28 2.43 185 2.49 1.33
no decreasing effect on HI          149 3.26 1.17 6 3.84 0.82 155 3.29 1.16
Sleeping
decreasing effect on HI 182 2.59 1.29 20 2.50 1.27 202 2.58 1.28
no decreasing effect on HI           115 3.25 1.27 4 3.50 1.00 119 3.25 1.26
f, number of reported headache attacks; HI, headache intensity
Table 4b: Statistical data on effect of resting and sleeping on headache intensity and headache 
duration: without and with sleep deficit
Source of variation dfnum dfdenom F-ratio p-value
Resting         deficit (D) 1 336 0.31 0.58
  rest (R) 1 336 14.47 < 0.001
D x R 1 336 1.77 0.19
Sleeping deficit (D) 1 317 0.36 0.81
sleep (S) 1 317 34.90 0.021
D x S 1 317 1.51 0.63
dfnum, degrees of freedom in numerator; dfdenom, degrees of freedom in denumerator 
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SUMMARY and DISCUSSION
As described in Chapter	1, the objectives of this thesis were: (1) To assess all literature 
concerning prophylactic treatment of migraine in children and adolescents; (2) To 
describe and evaluate	 the literature concerning the occurrence and manifestations of 
psychological (dys)functioning and/or psychiatric comorbidity in children and adolescents 
with migraine in clinical studies; (3) To evaluate generic health-related Quality of Life (QoL) 
in children and adolescents with primary headache at an outpatient department in a 
general hospital; (4) To	assess the efficacy of medium-dose riboflavin as a prophylactic 
drug in childhood migraine; (5) To study generic health-related	QoL and psychological 
functioning as outcomes in a prophylactic intervention study in children with migraine; 
(6)	In a prospective study	to investigate sleep deprivation as a potentially causative factor 
for headache attacks in childhood migraine, and to explore the effect of resting and 
sleeping after the start of the headache attack on headache symptoms. 
With regard to the first aim of the study, Chapter	2 presents the results of a systematic 
review of the available evidence for the efficacy of	prophylactic pharmacological treatment 
modalities in children and adolescents with migraine. 
The conclusion of this review is that only flunarizine is evidence-based effective as 
migraine prophylaxis in children and adolescents compared with placebo, and that 
there is conflicting evidence for the use of propranolol. Nimodipine, clonidine, L-5HTP, 
trazodone and papaverine showed no effect when compared with placebo. With regard to 
widely used drugs for migraine prophylaxis in children and adolescents, such as valproic 
acid and pizotifen, either no studies have been performed or they are methodologically	
inadequate. Therefore, evidence-based recommendations for these drugs are not possible.	
Generally,	because of the small number of studies and the methodological shortcomings, 
conclusions regarding effectiveness had to be drawn with caution. 
In addition, it appeared	 that headache improvement and adverse events are the two 
outcome measures most frequently used in the included trials. Although most studies 
described the adverse events as ‘mild’, the simple description of the kind and number of 
adverse events gave insufficient insight into the appreciation by the child of the severity 
of the adverse effect in relation to	 the beneficial effects of the intervention, especially 
since children are unable to verbalize such abstract concepts. Therefore, it was concluded 
that, in intervention studies in children with headache or migraine, not only clinical 
improvement and registration of adverse effects should be used as outcome, but also 
QoL and satisfaction of the intervention by the child and/or its parents. 
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Based on the conclusions of this review, it was decided to perform a prophylactic 
intervention study in children with migraine with headache frequency, intensity and 
duration as primary outcome and QoL as secondary outcome, measuring QoL on a 
broad number of life domains to acquire in-depth insight into the net combination of the 
beneficial and the adverse effects of the intervention. 
In addition, it was decided to use psychological functioning as secondary outcome 
because in several descriptive clinical studies, a substantial proportion of children and 
adolescents with migraine seemed to demonstrate psychological dysfunctioning and/
or psychiatric comorbidity to some extent1-11, raising the question whether this could be 
influenced by an intervention directed at reducing the migraine attacks. 
Until now, no systematic review has been performed (of clinical studies) regarding the 
occurrence of psychological dysfunctioning and/or psychiatric comorbidity in children 
and adolescents with migraine. Consequently, such a review was conducted and is 
described in Chapter	3. We performed an extensive literature search in Pubmed, PsycInfo, 
Embase and the Cochrane Database and screened the included studies for relevance and 
quality. Based on the best-evidence synthesis method of Slavin12, we concluded that there 
is strong evidence that children and adolescents with migraine in a clinical setting do not 
exhibit more withdrawn behaviour, do not have more thought problems, do not have 
more social problems, and do not exhibit more delinquent or aggressive behaviour than 
healthy children and adolescents. Furthermore, we found strong evidence that children and 
adolescents with migraine have more somatic complaints and exhibit more internalizing 
behaviour which, given the construct of the outcome measure used, is a consequence 
of the nature of their disease rather than a sign of psychological dysfunctioning. Finally, 
compared with healthy children and adolescents, we found limited evidence that children 
and adolescents with migraine in a clinical setting are more frequently diagnosed with 
an oppositional defiant disorder	but not more frequently diagnosed with ADHD, conduct 
disorder, dysthymia or depression. However, because the included studies and the method 
of assessing the evidence had the potential to cause bias, these conclusions require some 
caution. 
With reference to our third aim, in Chapter	4 we present an exploratory	study in children 
and adolescents with primary headache, referred to the outpatient paediatric department 
of a general hospital, with the purpose of measuring QoL at referral on a broad range of 
life domains. Another goal of this study was to become acquainted with the use of this 
type of QoL measurement tool in children and adolescents with headache in a clinical 
Chapter 8
134
Summary and Discussion
setting, in order to use it as outcome in the prophylactic intervention study in children 
with migraine. 
This study took place between October 2003 and October 2005 at the outpatient paediatric 
department of the Vlietland Hospital. All children and adolescents referred because of 
primary headache were investigated according to	protocol. QoL was measured using 
the Dutch version of the Child Health Questionnaire (CHQ-PF50 Dutch edition). On all 
but one subscale (i.e. self-esteem) the QoL of the children and adolescents with primary 
headache was decreased compared with a cohort of healthy children and adolescents, 
especially on the domains of mental health, parental impact time, and family cohesion. 
Compared with a historic control	cohort of children and adolescents with asthma, the 
QoL was significantly worse for our headache group on seven subscales and significantly 
better on one subscale (i.e. general health perception). Compared with a historic control	
cohort of children and adolescents with ADHD, the QoL was significantly worse on six 
subscales but significantly better on three subscales. There were no significant differences 
on any QoL subscale between children and adolescents with tension-type headache and 
children and adolescents with migraine.  
On the basis of this study we concluded that the QoL in children and adolescents with 
primary headache presenting at the outpatient paediatric department of a general 
hospital seems to be considerably diminished, and that there are no differences in QoL 
between children and adolescents with tension-type headache and those with migraine. 
In addition, we concluded that generic QoL, as measured with the CHQ, could be used as 
outcome in a prophylactic intervention study in children with migraine. 
As the QoL in children with migraine is poor at referral to a specialist, one may hypothesize 
that the poor QoL is due to the headaches the child is suffering from. From this perspective 
an intervention aiming at decreasing the headache attacks in frequency and/or in intensity 
is expected to have a concomitant beneficial effect on QoL. However, one might also 
hypothesize that the headaches the child is suffering from are an expression of a poor QoL 
whereas the poor QoL may primarily be attributed to other factors, such as psychological 
dysfunctioning, psychiatric comorbidity, and/or family or school problems. From that 
perspective an intervention aiming at decreasing the headache attacks in frequency and/
or in intensity, would not have a concomitant beneficial effect on QoL. Therefore, from 
a clinical point of view, performing a prophylactic intervention study in children with 
migraine with QoL as outcome, might also offer additional information to help address 
this issue. In other words, is the poor QoL in children with migraine due to the migraine 
itself or due to other factors? 
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In Chapter	5,	the results of the prophylactic intervention study in children with migraine 
are presented with regard to the primary outcomes, i.e. headache frequency and 
intensity. Riboflavin (vitamin B2) in a dosage of 50 mg per day was chosen as verum 
medication. Riboflavin had already been used as a prophylactic agent in studies on adults 
with migraine, including two open-label studies13,14 and two randomized controlled 
trials15,16. In these latter trials, riboflavin was proven effective with minimal adverse events. 
These adverse events were diarrhoea and polyuria (each occurring in	1 of 43 adults with 
migraine treated with riboflavin)15,16.  As riboflavin seemed to have the qualities of an ideal 
drug for migraine prophylaxis (low cost, superior effectiveness compared with placebo, 
and minimal adverse events) and since no intervention studies with riboflavin in children 
or adolescents with migraine as verum medication had been published at the start of 
our research, we decided to perform a randomized, placebo-controlled, double-blind, 
crossover trial in children with migraine with riboflavin as the acting agent. This trial 
eventually included 42 children (6 to 13 years) with migraine of which 14 children also 
suffered from tension-type headache. Following a 4-week baseline period, all children 
received riboflavin or	placebo for 16 weeks, and then placebo or	riboflavin for 16 weeks 
with a washout period of 4 weeks in between. The sequence of riboflavin and placebo was 
determined by randomization and blinded for both the patient and the parents, as well 
as for the investigators. The primary outcome measure was reduction in mean frequency 
of migraine attacks and episodic	 tension-type headache in the last four weeks of the 
riboflavin and placebo phase, compared with the preceding baseline or washout period. 
Secondary outcome measures were mean severity and mean duration of migraine and 
tension-type headaches in the last 4 weeks of the riboflavin and placebo phase, compared 
with the preceding baseline or washout period.
No significant difference in the reduction of mean frequency of migraine attacks in the 
last month of treatment was found between placebo and riboflavin (p = 0.44, two-tailed). 
However, a significant difference in reduction of mean frequency of episodic	 tension-
type headache was found in favour of the riboflavin treatment (p = 0.04, two-tailed). 
We concluded that in this group of children with migraine, there is no evidence that 
riboflavin has a prophylactic effect on migraine attacks. We also concluded that there is 
some evidence that riboflavin may have a prophylactic effect on episodic tension-type 
headaches in children with migraine.  
With regard to our fifth aim, Chapter	6 presents	a study among children with migraine 
on	the effect of riboflavin on QoL and psychological functioning as secondary outcome 
measures. Riboflavin did not	 have any superior effect compared to	 placebo with 
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regard to improvement of generic QoL (as measured with the CHQ) and psychological 
functioning (as measured with the Child Behaviour Checklist = CBCL-Dutch edition), on all 
investigated life domains and psychological subscales. Therefore, we collapsed the data 
of the riboflavin-placebo group with the placebo-riboflavin group to gain more statistical 
power for the comparison with the data of healthy children, both at baseline and at the 
end of the trial. In this collapsed group, at baseline the QoL was significantly worse on 
all 13 CHQ life domains compared with healthy controls. On the other hand, all CBCL 
baseline	scores were within the range of healthy controls with exception of the scales 
thought problems, somatic complaints and internalizing behaviour. The deviant scores on 
the latter two scales probably resulted from the migraine itself, given the construct of the 
CBCL, and were therefore not an indication of psychological dysfunctioning. 
Throughout the trial, in the collapsed group we saw	an improvement on 11 of the 13 QoL 
domains and on all CBCL scales, leading to normalization of scores on the QoL domains 
mental health, self-esteem, parental impact emotional and parental impact time, and on 
all deviant	CBCL scales, with the exception of somatic complaints. Additional evidence 
for the conclusion that the poor QoL in children with migraine at referral is primarily 
caused by the headache attacks themselves is found in the post-hoc analysis with regard 
to the association of the primary headache parameters (headache frequency, intensity 
and duration) and QoL, demonstrating that, in general, in all phases of the trial most QoL 
domains are inversely related, not only to headache frequency but also to	duration of the 
headache. 
The question posed above (i.e. is the poor QoL in children with migraine at referral to 
a specialist due to the headache attacks themselves or is this poor QoL due to other 
factors?) could therefore be answered in favour of the first hypothesis.	 In addition, we 
concluded that both QoL and psychological functioning can be used as outcome variables	
in intervention studies in children with migraine. Finally we concluded that, compared 
with placebo, riboflavin has no superior effect on improvement of QoL and psychological 
functioning in this group of children. 
Interestingly, there were two QoL life domains that did not improve during the trial. These 
were the domains global health and family cohesion. This might be due to the fact that 
both are single-question domains. This means that there is a range of only 5 answering 
alternatives	for parents to assess their child’s health and the quality of the relations within 
their family, respectively; this is considerably less than the amount of variation available 
in the other QoL domains. As to global health, another explanation might be that the 
poor QoL on this domain persisted because the parents of children with migraine are 
inclined to believe that their child’s health is poor, irrespective of any improvement due to 
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treatment. Therefore, additional studies are needed to address these important questions 
about the effect of treatment on internal family relations, as well as on parent’s perception 
of the health of their child with migraine. 
In addition, another point of interest regards the CBCL subscale aggressive behaviour 
and the CBCL scale externalizing behaviour. At the end of the trial there was a significant 
deviant score on both these scales compared with healthy controls, but in favour of 
children with migraine. The subscale aggressive behaviour is one of the two subscales 
that form the externalizing behaviour score, the other being delinquent behaviour. 
Since there was no significant difference between the score on the subscale delinquent 
behaviour compared with healthy controls at the end of the trial, we concluded that the 
low score on the main scale externalizing behaviour has to be attributed to	the low score 
on the subscale aggressive behaviour. This means that, while psychological functioning 
in children with migraine at referral to a specialist seems (in general) to be within normal 
limits, improvement is still possible after an intervention which decreases headache 
frequency, intensity and duration, eventually even resulting in superior scores on some 
aspects of psychological functioning in comparison with healthy children. This is also 
demonstrated by the post-hoc analysis with regard to the association of the primary 
headache parameters (headache frequency, intensity and duration) and the main CBCL 
scales of internalizing and externalizing behaviour and total score, showing that especially 
in phase 1 and phase 2 of the trial these parameters were generally positively related with 
headache frequency and headache duration.
   
Finally, in reference to our sixth aim, in Chapter	 7	 the effect of sleep deprivation as a 
causative factor on headache attacks in children with migraine, and (once a headache 
attack has started) the relationship between resting and sleeping on headache symptoms, 
is explored within the context of the prophylactic intervention study with riboflavin as 
verum medication (described in the previous two chapters). 
In this trial, only 6.2% of the headache attacks were preceded by the occurrence of one 
night with	less sleep	than usual. This had no effect on either headache intensity or duration. 
During the headache attacks, resting decreased headache intensity in 76.0% of the attacks 
occurring after a preceding sleep deficit and in 54.4% of the attacks without preceding 
sleep deficit (p = 0.04). Sleeping decreased headache intensity in 84.0% of the attacks 
with a sleep deficit and in 63.6% of the attacks without preceding sleep deficit (p = 0.05). 
In case of a favourable effect of resting and sleeping on headache intensity, a significant 
decrease of headache duration was also found, compared with attacks with no effect of 
resting and sleeping on headache intensity (p < 0.001 and p = 0.021, respectively). We 
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concluded that in these young children with migraine, one night with less sleep was not 
an important precipitating factor of migraine attacks. However, once a child was suffering 
from a headache attack, resting and sleeping resulted in a clinically relevant improvement 
of headache intensity and duration. 
Clinical implications and recommendations for future research
Based on the systematic review described in the second chapter of this thesis, we found 
that only flunarizine is proven evidence-based effective for childhood migraine. However, 
this treatment modality has the potential of serious adverse effects and is therefore	
contraindicated for use in children or adolescents in most European countries and the 
United States, thereby creating considerable uncertainty	 for physicians with regard to 
prescribing migraine prophylaxis in children and adolescents. Nevertheless, a broad 
variety and ever-increasing number of prophylactic drugs are being prescribed to them, 
stressing the need for high-quality research to evaluate the pharmacological prophylactic 
treatment of children and adolescents with migraine. Therefore more	 high-quality 
randomized controlled trials evaluating the most frequently used pharmacological 
prophylactic treatments should be performed. We also recommend that future high-
quality studies on existing and novel treatment modalities in children and adolescents 
with migraine should be conducted and reported according to the Consolidated 
Standards of Reporting of Trials (CONSORT) statement, as a substantial proportion of the 
published intervention studies in this field do not match these criteria and therefore do 
not provide sufficient evidence.  
Also, based on this systematic review, we recommend that in future intervention studies in 
children and adolescents with migraine not only should clinical improvement in headache 
and registration of adverse events be measured, but also secondary outcomes such as 
QoL, satisfaction of the intervention by the child and/or its parents, and psychological 
functioning, to broaden the outcome area to get a more complete picture of the effects 
of the intervention.	
This holds true especially for treatment modalities which have the potential of adverse 
effects on mood, cognition and behaviour such as anti-epileptic drugs, which are widely 
used for migraine prophylaxis. Using these outcomes in intervention studies in children 
with migraine can provide an answer regarding the clinically relevant question with 
regard to the combined result of the beneficial and adverse effects of these interventions 
We also conclude, based on the systematic review of the literature concerning 
psychological functioning and psychiatric comorbidity in children and adolescents with 
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migraine that for the involved specialist, in general, it does not seem necessary to refer 
a child with migraine to a child psychologist or a child psychiatrist. However, since the 
number of studies included in this review was limited, and both the included studies and 
the method of assessing the evidence had the potential to cause bias, additional studies 
are needed to further	 elucidate the occurrence of psychological dysfunctioning and 
psychiatric comorbidity in children and adolescents with migraine. In future studies it is 
preferable that both the mother and father complete the questionnaires independently	
or, if this is not feasible, the parent who completes the questionnaire should clearly state 
if he or she is the mother or the father of the child. Subsequently, separate statistical 
analysis for mother’s and father’s reports should be performed and described. Relatively 
large samples of both children and healthy controls should be included, preferably more 
than 25 in each group. A concealed selection strategy should be employed, preferably 
in sample selections of children from different hospitals, selected in a randomly ordered 
fashion. Validated outcome measures should be used which preferably have been used 
in previous studies in this field in order to consolidate and/or generate further evidence. 
Finally, appropriate statistical analyses should be	 performed on the most important 
outcome measures.     
The generic QoL in children and adolescents with primary headache is poor at referral 
to a paediatric outpatient department in a general hospital on nearly all life domains, 
and comparable to	or worse than the QoL of	children with Attention Deficit Hyperactivity 
Disorder (ADHD) or asthma. However, the statistical comparison method had several 
shortcomings because we could only compare our data with the published QoL data of 
groups of children with asthma or ADHD from different countries	and studied	in a different 
time period. Also, we found no statistically significant differences in QoL on all life domains 
between children with tension-type headache or migraine. This has clinical consequences 
as it implies that the most important factor in referral might be	 the perception of the 
referring physician of the burden placed on the child and its family as induced by the 
headache, and not the type of headache itself.	This stresses the need for using generic QoL 
as outcome in daily practice for a physician, specialized in treatment of these children, in 
order to objectively evaluate the effect of his or her treatment on the child and its family. 
Finally, and also relevant from a clinical point of view, this study clearly showed that a 
child with primary headache, severe enough to consult a specialist, places a heavy burden 
on its parents and brothers and sisters, implying that the specialist, to whom this child is 
referred, should inquire about the consequences of the headaches, not only for the child 
itself, but also for its parents and family and should do so consistently during treatment 
and follow-up.
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In the fifth chapter of this thesis the results of a prophylactic placebo-controlled crossover 
trial in children with migraine with riboflavin in a daily dosage of 50 mg are presented. 
Unlike in adults, we could not find evidence of a superior effect of riboflavin compared 
with placebo. This might be due to the dosage used as a recent study showed17. In this 
retrospective study, 41 children or adolescents with migraine were treated with 200 mg 
or 400 mg riboflavin on a daily basis for three to six months, eventually demonstrating 
that 68.4% of the included children had a reduction of 50% or more in the frequency 
of all headache attacks without any serious adverse effects17. However, this study was 
retrospective,	 no placebo group was included and treatment was not concealed, all 
of which are essential for assessing study quality. Future  studies should be placebo-
controlled, randomized, double-blind trials according to the CONSORT statement. The 
dosage of riboflavin should be at least 200 mg but preferably	400 mg on a daily basis. 
We did find some evidence that riboflavin may have a prophylactic effect on episodic	
tension-type headaches in children with migraine. To investigate if riboflavin indeed 
has a primary effect on tension-type headache in children or adults, placebo-controlled, 
randomized, double-blind trials according to the CONSORT statement in children or adults 
with primary tension-type headache with and without migraine should be performed. 
Nevertheless, from a clinical point of view, based upon our study and given the lack of 
evidence-based effective prophylactic treatment modalities without adverse events in 
children with migraine, we consider it justified to prescribe riboflavin, in the dosage as 
described in our study, for a period of at most four months, in children with migraine who	
also suffer from tension-type headaches. 
In the study described in the sixth chapter of this thesis we found that riboflavin in fact 
acted as a placebo on all investigated QoL domains and CBCL subscales throughout the 
trial. During the trial the QoL improved on 11 of the 13 life domains and on all CBCL scales, 
resulting in normalization of scores on 4 of 13 life domains and on all but 1 CBCL scale. This 
has clinical implications, as this study shows	that QoL in children with migraine at referral 
to a specialist is poor, not due to psychological dysfunctioning, but due to the disease 
itself. One could argue that referral of a child with migraine to a child psychologist or 
child psychiatrist should, preferably, be considered	after some period of proper treatment. 
However, this is the first intervention study in children with migraine in which QoL and 
psychological functioning have been used as outcome, therefore providing only moderate 
evidence for this assertion. In order to develop this to an evidence-based guideline, more 
comparative studies are needed.	However, we have shown that QoL in children with 
migraine does not improve on the life domains of global health and family cohesion, 
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despite improvement of the headache attacks. From this perspective, when consultation 
of a child psychologist or child psychiatrist is eventually deemed as necessary in the 
treatment of a child with migraine, the involved psychologist or psychiatrist might explore 
and (if necessary) try to adjust the QoL on these particular life domains. This implies the 
need to explore how the parents perceive their child with migraine, and perhaps to try 
and alter that image. For example, instead of seeing their child as being (more-or-less 
consistently) sick and helpless, parents might see their child as having a relatively mild 
condition with a good prognosis when simple life rules are adopted and combined with 
proper pharmacological treatment. In addition, when required, the quality of the internal 
relationships within the family of the child with migraine might be altered to promote a 
more cohesive and beneficial situation. 
      
Finally, we found that a single night of less sleep is not an important migraine trigger 
in childhood migraine. It was also found that, in case of a headache attack, resting and 
sleeping resulted in a clinically relevant decrease of intensity and duration of the attack, 
compared with not resting and sleeping at all. Resting and sleeping had a more profound 
impact with regard to decrease of headache intensity and duration when the child had 
slept less than usual the previous night. These findings have clinical relevance because 
they provide moderate evidence that a shortage of sleep in children with migraine will 
not  automatically provoke a headache attack, and that resting and sleeping are sensible 
actions when a headache attack has started in children with migraine, especially when 
the child has slept less than usual in the night preceding the headache attack. However, 
few studies have focused on sleep and sleeping behaviour in children with migraine. More 
prospective studies are needed to further unravel the relationship between sleep and 
headache in children with migraine.
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SAMENVATTING in het NEDERLANDS 
In dit proefschrift worden de resultaten gepresenteerd die betrekking hebben op  het 
onderzoek dat uitgevoerd is naar migraine bij kinderen.
De doelstellingen van dit proefschrift worden in hoofdstuk 1 toegelicht. Deze zijn: 
1. het beoordelen van alle wetenschappelijke literatuur met betrekking tot de 
effectiviteit van profylactische medicatie bij kinderen en adolescenten met 
migraine, dat wil zeggen medicatie die gegeven wordt om migraineaanvallen te 
voorkómen bij deze doelgroep (hoofdstuk 2), 
2. het beschrijven en beoordelen van alle wetenschappelijke literatuur met 
betrekking tot het vóórkomen en de uitingen van psychisch (dys)functioneren 
en/of psychiatrische comorbiditeit bij kinderen en adolescenten met migraine 
(hoofdstuk 3), 
3. het onderzoeken en evalueren van de kwaliteit van leven (KvL) bij kinderen en 
adolescenten met primaire hoofdpijn die verwezen worden naar een polikliniek 
kindergeneeskunde in een algemeen ziekenhuis (hoofdstuk 4), 
4. het beoordelen van de werking van riboflavine als profylactische medicatie bij 
kinderen met migraine (hoofdstuk 5),
5. het onderzoeken en evalueren van KvL en psychologisch functioneren als 
uitkomstmaten in een trial waarbij tevens gekeken wordt naar het effect van 
een profylactische behandeling op hoofdpijnklachten bij kinderen met migraine 
(hoofdstuk 6), 
6. in een prospectieve studie bestuderen in hoeverre slaaptekort een potentieel 
oorzakelijke factor kan zijn voor hoofdpijn en migraine aanvallen in de 
kinderjaren en onderzoeken wat het effect is van rusten en slapen na het begin 
van de hoofdpijn aanval op de hoofdpijn symptomen (hoofdstuk 7). 
In hoofdstuk	2 worden de resultaten beschreven van de systematische literatuurstudie 
ten aanzien van de effectiviteit van profylactische medicatie bij kinderen en adolescenten 
met migraine. De conclusie van deze studie is dat alleen flunarizine effectief is als 
migraineprofylacticum bij deze doelgroep in vergelijking met placebo. Daarnaast werd 
tegenstrijdig bewijs gevonden voor een superieur effect van propranolol ten opzichte van 
placebo als profylactische medicatie. 
Medicatie zoals nimodipine, clonidine, L-5HTP, trazodon en papaverine toonden geen 
superieur effect in vergelijking met placebo. Ten aanzien van het gebruik van medicatie 
Samenvatting in het Nederlands
161
Ch
ap
te
r 1
0
zoals valproïnezuur en pizotifeen – middelen die op grote schaal gebruikt worden voor 
de profylaxe van migraine bij kinderen en adolescenten - bleek dat er ofwel geen studies 
zijn uitgevoerd naar de effectiviteit hiervan ofwel dat deze studies methodologisch 
ontoereikend waren. Om die reden zijn met wetenschappelijk bewijs onderbouwde, 
zogenaamde evidence-based (EB), aanbevelingen voor deze middelen niet mogelijk. 
Concluderend kan gezegd worden dat vanwege het geringe aantal studies en de 
methodologische tekortkomingen, conclusies over effectiviteit van profylactische 
medicatie bij kinderen met migraine met de nodige voorzichtigheid moeten worden 
getrokken.
Uit deze literatuurstudie bleek verder dat hoofdpijnverbetering en bijwerkingen als meest 
voorkomende uitkomstmaten worden gebruikt. Hoewel in veel studies de bijwerkingen 
als mild worden beschreven, geeft het eenvoudig weergeven van het soort, het aantal 
en de ernst van de bijwerkingen onvoldoende inzicht in de waardering door het kind 
van de bijwerking(en) in combinatie met het gunstige effect van het geneesmiddel. Dit 
is met name het geval bij jonge, prepuberale kinderen, omdat juist deze kinderen niet 
of onvoldoende in staat zijn om dergelijke abstracte begrippen goed te verwoorden. 
Daarom werd geconcludeerd dat, in studies bij kinderen met hoofdpijn of migraine, niet 
alleen klinische verbetering en de registratie van bijwerkingen van de geneesmiddelen 
moet worden gebruikt als uitkomstmaat, maar ook andere uitkomstmaten 
zoals KvL en tevredenheid met de behandeling door het kind en/of de ouders. 
Op basis van de conclusies van deze studie werd besloten om een profylactische 
interventie- studie uit te voeren bij kinderen met migraine waarbij de frequentie, de 
intensiteit en duur van hoofdpijn als primaire uitkomstmaten werden genomen en KvL 
als secundaire uitkomstmaat waarbij het effect op KvL zou worden onderzocht op een 
groot aantal levensdomeinen om zodoende tot een optimale evaluatie te komen van de 
positieve en de negatieve effecten van de interventie.
 
Daarnaast werd ook besloten om ‘psychologisch functioneren’ te gebruiken als 
secundaire uitkomstmaat, dit omdat uit verschillende klinische studies duidelijk werd dat 
een aanzienlijk deel van de kinderen en adolescenten met migraine psychologische en/of 
psychiatrische problemen vertonen1-11 wat  de   vraag    opriep    of    een interventie, gericht op 
vermindering van de migraineaanvallen, kan leiden tot een verbetering van deze psychische 
comorbiditeit. Verder viel op dat er geen systematisch literatuuronderzoek was uitgevoerd 
ten aanzien van het optreden van psychologisch dysfunctioneren en/of psychiatrische 
problematiek bij kinderen en adolescenten met migraine in klinische studies. Besloten 
werd daarom een dergelijke literatuurstudie op te zetten en uit te voeren. De resultaten 
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hiervan worden beschreven in hoofdstuk	3. Een systematisch literatuuronderzoek werd 
uitgevoerd in Pubmed, PsycINFO, Embase en de Cochrane Database. De geincludeerde 
studies werden onderzocht op relevantie en kwaliteit. Op basis van de “best-evidence 
synthesis” methode van Slavin12 werd vastgesteld dat er sterke aanwijzingen zijn dat 
kinderen en adolescenten met migraine in een klinische setting in vergelijking met 
gezonde kinderen en adolescenten niet meer teruggetrokken gedrag vertonen, niet 
meer cognitieve problemen vertonen, niet meer sociale problemen hebben en niet 
vaker delinquent of agressief gedrag vertonen. In een aantal studies werden sterke 
aanwijzingen gevonden dat kinderen en adolescenten met migraine meer somatische 
klachten en meer internaliserend probleemgedrag vertonen wat, gezien de opzet van 
deze studies en de gebruikte vragenlijsten, veel meer een gevolg is van de aard van hun 
ziekte dan een teken van psychologisch dysfunctioneren. Tenslotte liet dit systematische 
literatuuronderzoek zien dat kinderen en adolescenten met migraine in een klinische 
setting in vergelijking met gezonde kinderen en adolescenten vaker gediagnosticeerd 
worden met een oppositionele gedragsstoornis (Oppositional Defiant Disorder = ODD), 
maar niet vaker gediagnosticeerd worden met een aandachtstekort/hyperactiviteitstoornis 
(Attention Deficit Hyperactivity Disorder  =  ADHD), antisociale gedragsstoornis (Conduct 
Disorder = CD), dysthymie of depressie. Echter, omdat de onderzochte studies en de 
gebruikte methode van beoordeling potentieel bias met zich mee kunnen brengen 
dienen deze conclusies met enige terughoudendheid te worden geïnterpreteerd. 
   
In hoofdstuk	4 worden de resultaten beschreven van de studie waarin de KvL bij kinderen en 
adolescenten met primaire hoofdpijn, verwezen naar een polikliniek kindergeneeskunde 
in een algemeen ziekenhuis, werd onderzocht. Het primaire doel van deze studie was 
het vaststellen van de KvL op een groot aantal levensdomeinen. Ook werd in deze 
studie onderzocht in hoeverre KvL als uitkomstmaat gebruikt kon worden in de nog op 
te zetten profylactische interventie studie bij kinderen met migraine. Deze studie vond 
plaats tussen oktober 2003 en oktober 2005 op de polikliniek kindergeneeskunde van 
het Vlietland Ziekenhuis. Alle kinderen en adolescenten die werden verwezen door hun 
huisarts met primaire hoofdpijn werden volgens protocol onderzocht. De KvL werd 
gemeten met behulp van de Nederlandse versie van de Child Health Questionnaire (CHQ-
PF50 Nederlandse editie). Uiteindelijk werden 70 kinderen in deze studie opgenomen. Er 
bleek bij hen overwegend sprake te zijn van migraine of spierspanningshoofdpijn, of een 
combinatie van deze beide vormen van primaire hoofdpijn. 
Uit de studie bleek dat de KvL van kinderen en adolescenten met primaire hoofdpijn op 
alle levensgebieden was verminderd in vergelijking met de KvL van gezonde kinderen 
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en adolescenten, met name op het levensdomein mental health (geestelijke gezondheid 
zoals de ouders die inschatten), parental impact time (de tijd die ouders extra aan het kind 
moeten besteden als gevolg van de hoofdpijn) en family cohesion (de kwaliteit van de 
onderlinge relaties in het gezin). Alleen het domein self esteem (gevoel van eigenwaarde 
van de kinderen in de perceptie van de ouders) was niet verminderd in vergelijking met 
gezonde kinderen. In vergelijking met een historisch controle cohort van kinderen en 
adolescenten met astma, was de KvL van de groep kinderen met hoofdpijn significant 
slechter op zeven levensdomeinen en significant beter op één domein (general health 
perception = gezondheid van het kind zoals gezien door ouders).  In vergelijking met een 
historische controle groep van kinderen en adolescenten met ADHD, was de kwaliteit van 
leven significant slechter op zes levensdomeinen, en significant beter op drie domeinen. 
Er waren geen significante verschillen in KvL op elk levensdomein tussen kinderen en 
adolescenten met spierspanningshoofdpijn en kinderen en adolescenten met migraine. 
Geconcludeerd werd op basis van deze studie dat de KvL van kinderen en adolescenten met 
primaire hoofdpijn op een polikliniek kindergeneeskunde van een algemeen ziekenhuis 
aanzienlijk verminderd is in vergelijking met gezonde kinderen en dat er geen verschil is 
in KvL tussen kinderen en adolescenten met spierspanningshoofdpijn en kinderen met 
migraine. Daarnaast werd geconcludeerd dat KvL, zoals gemeten met de CHQ, gebruikt kan 
worden als uitkomstmaat in een profylactische interventie studie bij kinderen met migraine. 
De vraag is waarom de KvL slecht is bij kinderen met primaire hoofdpijn die naar een 
specialist verwezen worden. Een verklaring kan zijn dat de slechte kwaliteit van leven 
het gevolg is van de hoofdpijn van het kind. Vanuit dit perspectief zal een behandeling 
gericht op vermindering van de hoofdpijn aanvallen in frequentie en/of in intensiteit 
ook een gunstig effect hebben op de KvL. Echter, een andere mogelijkheid is dat de 
hoofdpijn waaraan het kind lijdt juist een uitdrukking is van een slechte KvL waarbij deze 
slechte KvL het gevolg is van andere factoren, zoals psychologisch dysfunctioneren en/of 
psychiatrische problematiek en/of  problemen in de familie en/of problemen op school. 
Vanuit dat perspectief zal een behandeling, gericht op vermindering van de hoofdpijn 
aanvallen in frequentie en/of in intensiteit, juist geen gunstig effect op de KvL hebben. 
Vanuit een klinisch oogpunt kan het uitvoeren van een profylactische interventie studie 
bij kinderen met migraine, met KvL als uitkomstmaat, aanvullende informatie opleveren 
die inzicht geeft op dit punt. Met andere woorden, is de slechte KvL bij kinderen met 
migraine het gevolg van migraine zelf of is dit het gevolg van andere factoren? 
In hoofdstuk	5 worden de resultaten beschreven van het profylactisch geven van riboflavine 
bij kinderen met migraine waarbij gekeken werd  naar primaire uitkomstmaten, dat wil 
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zeggen naar het effect op hoofdpijn-frequentie en -intensiteit. Riboflavine (vitamine B2) in 
een dosering van 50 mg per dag was gekozen als verum-medicatie. Riboflavine is al eerder 
gebruikt als profylacticum in studies bij volwassenen met migraine in twee “open-label” 
studies13,14 (dat wil zeggen zonder placebocontrole groep) en twee gerandomiseerde 
gecontroleerde trials (met een placebocontrole groep)15,16. In deze twee laatste studies 
bleek riboflavine effectief te zijn met minimale bijwerkingen. Deze bijwerkingen waren 
diarree en vaker plassen, elk optredend bij 1 van 43 volwassenen met migraine behandeld 
met riboflavine. Aangezien riboflavine een ideaal medicament leek te zijn voor de 
profylaxe van migraine (lage kosten, superieure effectiviteit in vergelijking met placebo en 
minimale bijwerkingen), en omdat er geen interventie studies met riboflavine bij kinderen 
of adolescenten met migraine bekend waren toen dit onderzoek begon, werd besloten 
om een gerandomiseerde, placebogecontroleerde, dubbelblinde, cross-over studie bij 
kinderen met migraine uit te voeren met riboflavine als verum medicatie. In deze trial werden 
uiteindelijk 42 kinderen (6 tot 13 jaar) met migraine opgenomen, waarvan 14 kinderen 
tevens last hadden van spierspanningshoofdpijn. Na een 4-weekse observatieperiode 
(baseline periode) kregen alle kinderen dagelijks 50 mg riboflavine of  placebo gedurende 
16 weken (eerste fase). Daarna kregen de kinderen in de tweede fase een placebo indien 
zij in de eerste fase riboflavine hadden gekregen of dagelijks 50 mg riboflavine indien 
zij in de eerste fase placebo hadden gekregen. Tussen de eerste en tweede fase zat een 
“uitwasperiode” (wash-out periode) van 4 weken. De volgorde van eerst riboflavine en 
daarna placebo of eerst placebo en daarna riboflavine werd bepaald door randomisatie. 
Zowel de patiënten als hun ouders, evenals de onderzoekers, waren niet op de hoogte 
van de randomisatiecode gedurende de trial. De primaire uitkomstmaat was de reductie 
in gemiddelde frequentie van migraine- en spierspanningshoofdpijn-aanvallen in de 
laatste vier weken van de riboflavine- en placebo-fase, in vergelijking met de voorgaande 
baseline of wash-out periode. Secundaire uitkomstmaten waren ernst en de duur van de 
migraine- en spierspanningshoofdpijn-aanvallen in de laatste 4 weken van de riboflavine 
en placebo fase, in vergelijking met de voorgaande baseline of wash-out periode. 
Er werd geen significant verschil gevonden in de vermindering van de gemiddelde 
frequentie van migraine-aanvallen in de laatste maand van de behandeling tussen 
placebo en riboflavine (p = 0,44, tweezijdig). Wel werd er een significant verschil gevonden 
in vermindering van de gemiddelde frequentie van spierspanningshoofdpijn-aanvallen 
in het voordeel van de riboflavine behandeling (p = 0,04, tweezijdig). Geconcludeerd 
werd dat er geen bewijs is dat riboflavine in de gebruikte dosering een profylactisch 
effect op migraine-aanvallen heeft bij deze groep kinderen met migraine. Verder 
werd geconcludeerd dat er enig bewijs is dat riboflavine in de gebruikte dosering een 
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profylactisch effect heeft op spierspannings-hoofdpijn-aanvallen bij kinderen met migraine. 
 
Hoofdstuk	6 geeft de resultaten weer van de studie bij kinderen met migraine ten aanzien 
van het effect van riboflavine op KvL en psychologisch functioneren als secundaire 
uitkomstmaten. Riboflavine bleek geen superieur effect te hebben ten opzichte van 
placebo voor wat betreft verbetering van de  KvL (zoals gemeten met de CHQ) en voor 
het psychologisch functioneren (zoals gemeten met de Child Behaviour Checklist = CBCL-
Dutch edition) op alle onderzochte levensdomeinen van de KvL en alle (sub)schalen van 
de CBCL. Om meer statistische power te verkrijgen voor de vergelijking met gezonde 
kinderen, zowel bij aanvang als aan het einde van de trial, werd besloten om de gegevens 
van de riboflavine-placebo-groep met de placebo-riboflavine groep samen te voegen. In 
deze samengevoegde groep bleek in de baseline periode dat de KvL significant slechter 
was op alle 13 onderzochte levensdomeinen in vergelijking met gezonde kinderen. 
Verder waren in de baseline periode de scores op alle CBCL (sub)schalen binnen het 
bereik van gezonde controles met uitzondering van de subschalen thought problems 
(een maat voor het cognitief functioneren), somatic complaints (lichamelijke klachten) 
en de hoofdschaal internalizing behaviour (internaliserend gedrag, dat wil zeggen de 
neiging van het kind om problemen en spanningen om te zetten in lichamelijke klachten 
en “terugtrekgedrag”). De afwijkende scores op de twee laatste schalen zijn waarschijnlijk 
veel meer het gevolg van de migraine zelf, gezien de bijbehorende vragen en de 
samenstelling van de CBCL, en veel minder een gevolg van psychologisch dysfunctioneren. 
Gedurende de trial werd in de samengevoegde groepen een verbetering op 11 van de 
13 KvL levensdomeinen gezien evenals op alle CBCL (sub)schalen, met als gevolg een 
normalisering van de KvL scores op de domeinen mental health (geestelijke gezondheid 
zoals de ouders die inschatten), self esteem (gevoel van eigenwaarde), parental impact 
time (de tijd die ouders extra aan het kind moeten besteden als gevolg van de hoofdpijn), 
parental impact emotional (het effect dat de hoofdpijn van het kind heeft op de emoties 
van de ouders), en een normalisering van alle afwijkende CBCL schalen, met uitzondering 
van de subschaal Somatic complaints (lichamelijke klachten). Aanvullende ondersteuning 
voor de conclusie dat de slechte KvL bij kinderen met migraine, verwezen naar een 
specialist, waarschijnlijk primair wordt veroorzaakt door de hoofdpijn zelf werd ook 
gevonden in de post-hoc analyse met betrekking tot de samenhang van de primaire 
hoofdpijnparameters (hoofdpijn frequentie, intensiteit en duur) en KvL, waaruit bleek dat 
in alle fasen van de trial de scores op de meeste KvL-domeinen omgekeerd evenredig 
waren met de frequentie en duur van de hoofdpijnaanvallen. 
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De vraag zoals hierboven gesteld  (is de slechte KvL bij kinderen met migraine bij 
verwijzing naar een specialist te wijten aan de hoofdpijn zelf of is de slechte KvL een 
gevolg van andere factoren ?) - kon derhalve beantwoord worden in het voordeel 
van de eerste hypothese. Bovendien kon geconcludeerd worden dat zowel KvL als 
psychologisch functioneren gebruikt kunnen worden als uitkomstvariabelen in 
interventie studies bij kinderen met migraine. Ten slotte werd geconcludeerd dat 
riboflavine ten opzichte van placebo geen superieur effect heeft op verbetering 
van KvL en verbetering van psychologisch functioneren in deze groep kinderen. 
Er waren twee KvL domeinen die niet verbeterden tijdens de trial. Dit waren de domeinen 
global health (algemene gezondheid van het kind) en family cohesion (kwaliteit van de 
onderlinge relaties in het gezin). Dit zou te maken kunnen hebben met het feit dat beide 
domeinen “enkele vraag domeinen” zijn in de gebruikte CHQ vragenlijst. Dit betekent 
dat er voor de ouders een reeks van slechts vijf alternatieven was om respectievelijk 
hun inschatting van de gezondheid van hun kind en de kwaliteit van de relaties binnen 
hun gezin weer te geven. Dit is aanzienlijk minder dan de variabiliteit van de andere KvL 
domeinen.
Een  andere verklaring kan zijn dat de slechte KvL op het domein global health blijft 
bestaan gedurende de trial omdat ouders van kinderen met migraine geneigd zijn er 
van uit te gaan dat de gezondheid van hun kind slecht is, ongeacht verbetering door 
behandeling. Daarom zijn aanvullende studies nodig om de vragen ten aanzien het effect 
van behandeling op onderlinge familierelaties, en op de perceptie van de ouders van de 
gezondheid van hun kind met migraine, te beantwoorden, 
Een ander belangrijk punt in dit verband is de CBCL subschaal agressive behaviour 
(agressief gedrag) en de CBCL hoofdschaal externaliserend gedrag (dat wil zeggen, 
de neiging van het kind om problemen en spanningen om te zetten in agressief en 
delinquent gedrag). Aan het einde van de trial werd een significant afwijkende score 
op beide schalen in vergelijking met gezonde controles gevonden ten gunste van de 
kinderen met migraine. De subschaal agressive behaviour is een van de twee subschalen 
die de basis vormen van de hoofdschaal externaliserend gedrag. De andere subschaal 
is delinquent gedrag. Aangezien er geen significant verschil was tussen de score op de 
subschaal delinquent gedrag in vergelijking met gezonde controles aan het eind van 
de trial, werd geconcludeerd dat de lage score op de CBCL hoofdschaal externaliserend 
gedrag moet worden toegeschreven aan de lage score op de subschaal agressief gedrag. 
Dit betekent dat, hoewel het psychologisch functioneren bij kinderen met migraine bij 
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verwijzing naar een specialist (in het algemeen) binnen de normale grenzen lijkt, er nog 
verbetering mogelijk is na een interventie waardoor hoofdpijn frequentie, intensiteit en 
duur afnemen, waarbij uiteindelijk zelfs significant betere scores mogelijk zijn op sommige 
aspecten van psychologisch functioneren in vergelijking met gezonde kinderen.
Dit wordt ook aangetoond door de post-hoc analyse met betrekking tot de samenhang van 
de primaire hoofdpijnparameters (hoofdpijnfrequentie, intensiteit en duur) en de scores op 
de belangrijkste CBCL hoofdschalen internaliserend gedrag, externaliserend gedrag en de 
totale score, waaruit blijkt dat met name in fase 1 en fase 2 van de trial deze parameters over 
het algemeen positief evenredig zijn met frequentie en duur van de hoofdpijnaanvallen 
     
Ten slotte wordt in hoofdstuk	 7 de prospectieve studie besproken waarin onderzocht 
werd in hoeverre slaaptekort een oorzakelijke factor is voor hoofdpijnaanvallen bij 
kinderen met migraine, en wat het effect is van rusten en slapen na het begin van de 
hoofdpijn aanval op de hoofdpijn symptomen. Een en ander werd onderzocht binnen 
de context van de riboflavinetrial zoals beschreven in de vorige twee hoofdstukken. 
Uit deze studie bleek dat slechts 6,2% van de hoofdpijnaanvallen voorafgegaan werd door 
een nacht met minder slaap dan normaal. Een voorafgaand slaaptekort had geen effect 
op de intensiteit of de duur van de  hoofdpijn. Tijdens de hoofdpijnaanval gaf rusten een 
vermindering van de hoofdpijn intensiteit in 76,0% van de aanvallen die ontstonden na 
een voorafgaand slaaptekort en in 54,4% van de aanvallen zonder voorafgaand slaap 
tekort (p = 0,04). Door te gaan slapen verminderde de hoofdpijn intensiteit in 84,0% van 
de aanvallen met een voorafgaand  slaaptekort en in 63,6% van de aanvallen zonder 
voorafgaand slaap tekort (p = 0,05). In het geval van een gunstig effect van rusten en 
slapen op hoofdpijn intensiteit, werd ook een significante daling van hoofdpijnduur 
gevonden, in vergelijking met aanvallen waarin geen effect van het rusten en slapen op 
hoofdpijnintensiteit was gezien (p < 0,001 en p = 0,021, respectievelijk). Concluderend 
kunnen we stellen dat in deze groep jonge kinderen met migraine een nacht minder 
slapen geen belangrijke uitlokkende factor is voor een migraine aanval. Echter, wanneer 
een kind een hoofdpijnaanval heeft, dan zal rusten en slapen hoogstwaarschijnlijk 
resulteren in een klinisch relevante verbetering van de intensiteit en duur van de hoofdpijn. 
   
Chapter 10
168
Samenvatting in het Nederlands
Klinische implicaties en aanbevelingen voor toekomstig onderzoek 
Op grond van de systematische literatuurstudie, zoals beschreven in het tweede hoofdstuk 
van dit proefschrift, kan worden geconcludeerd  dat alleen flunarizine effectief is voor de 
behandeling van migraine bij kinderen. Echter, in de meeste Europese landen en in de 
Verenigde Staten is flunarizine gecontraïndiceerd bij kinderen of adolescenten vanwege 
de ernstige bijwerkingen. Hierdoor is er onzekerheid bij artsen met betrekking tot het 
voorschrijven migraineprofylactica bij kinderen en adolescenten. Desondanks wordt aan 
deze groep patiënten toch een grote variëteit en een toenemend aantal profylactische 
geneesmiddelen voorgeschreven. Dit betekent dat er een noodzaak is voor het verrichten 
van gerandomiseerde, placebogecontroleerde interventiestudies van hoge kwaliteit bij 
kinderen en adolescenten met migraine om het effect van deze migraineprofylactica te 
evalueren. 
Wij raden daarom aan dat toekomstige studies ten aanzien van bestaande en nieuwe 
migraineprofylactica bij kinderen en adolescenten moeten worden uitgevoerd en 
gerapporteerd volgens de vigerende hoge kwaliteitsnormen voor trials (= CONSORT 
statement). Bovendien zijn we op basis van deze literatuur studie van mening dat in 
de toekomst bij interventie studies bij kinderen en adolescenten met migraine niet 
alleen klinische verbetering van de hoofdpijn en de registratie van bijwerkingen wordt 
gemeten, maar ook secundaire uitkomstmaten zoals KvL en psychologisch functioneren, 
zodat een volledig beeld van de effecten van de interventie verkregen kan worden. Dit 
geldt met name voor het vaststellen van mogelijke nadelige effecten van de interventie 
op stemming, cognitie en gedrag zoals veroorzaakt kan worden door onder andere de 
anti-epileptica die op grote schaal worden gebruikt voor de profylaxe van migraine. 
Door het gebruiken van deze uitkomstmaten kan in toekomstige interventiestudies bij 
kinderen met migraine een antwoord worden gegeven op de klinisch relevante vraag wat 
het gecombineerde resultaat is van de gunstige en nadelige effecten van de interventie.
 
Daarnaast concluderen we, op basis van de systematische literatuurstudie ten aanzien 
van het psychologisch functioneren en psychiatrische comorbiditeit bij kinderen en 
adolescenten met migraine, dat het voor de behandelend specialist in het algemeen 
niet nodig is om een kind met migraine door te verwijzen naar een kinderpsycholoog 
of een kinderpsychiater. Echter, omdat het aantal opgenomen studies in dit onderzoek 
beperkt was en omdat de methode voor bepaling van het wetenschappelijk bewijs de 
potentie had om bias te veroorzaken, is het aan te raden om aanvullende studies uit te 
voeren om meer inzicht te krijgen in het voorkomen van psychologisch dysfunctioneren 
en psychiatrische comorbiditeit bij kinderen en adolescenten met migraine. In 
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toekomstige studies is het verder wenselijk dat zowel de moeder als de vader de 
vragenlijsten onafhankelijk van elkaar invult. Indien dit niet mogelijk is het wenselijk dat 
de ouder die de vragenlijst invult aangeeft of hij of zij de moeder of de vader van het 
kind is. Vervolgens dienen afzonderlijke statistische analyses voor de vragenlijsten van 
moeder en vader te worden uitgevoerd en beschreven. Relatief grote groepen kinderen 
en gezonde controles dienen te worden opgenomen in toekomstige studies in dit veld, 
bij voorkeur meer dan 25 in elke groep. Een “verborgen selectiestrategie” moet worden 
toegepast, bij voorkeur in de vorm van steekproeven van kinderen met migraine uit 
verschillende ziekenhuizen, geselecteerd in een willekeurige volgorde. Gevalideerde 
uitkomstmaten dienen te worden gebruikt die bij voorkeur zijn toegepast in eerdere 
studies op dit gebied om zo meer wetenschappelijk bewijs te genereren. Tenslotte dienen 
adequate statistische analyses worden uitgevoerd op de belangrijkste uitkomstmaten. 
 
De KvL bij kinderen en adolescenten met primaire hoofdpijn is slecht bij verwijzing 
naar een polikliniek kindergeneeskunde in een algemeen ziekenhuis op bijna alle 
levensdomeinen en vergelijkbaar of slechter met de KvL van kinderen met ADHD of 
astma. Echter, de statistische vergelijkingsmethode voor wat betreft deze laatste twee 
groepen had een aantal tekortkomingen. Immers, de gegevens van onze studie konden 
alleen worden vergeleken met de gepubliceerde KvL gegevens van groepen van kinderen 
met astma of ADHD die bovendien afkomstig waren uit een ander land en onderzocht 
waren  in een andere periode. Verder waren er geen statistisch significante verschillen in 
KvL tussen kinderen met spierspanningshoofdpijn of migraine op alle levensdomeinen. 
Dit heeft klinische consequenties omdat dit betekent dat de belangrijkste factor voor 
de verwijzing van kinderen met hoofdpijn naar een specialist de perceptie is van de 
verwijzend (huis)arts ten aanzien van de impact van de hoofdpijn voor het kind en zijn 
familie, en niet zozeer het type hoofdpijn. Dit onderstreept ook het belang voor het 
gebruik van generieke KvL criteria als uitkomstmaat  in de dagelijkse praktijk van een arts, 
gespecialiseerd in de behandeling van deze kinderen, om objectief te evalueren wat het 
effect is van zijn of haar behandeling op het kind en zijn familie. Ten slotte maakt deze 
studie duidelijk dat een kind met primaire hoofdpijn, ernstig genoeg om een specialist 
te raadplegen, een zware last legt op ouders en broertjes of zusjes.  Dit betekent dat de 
specialist, naar wie dit kind wordt verwezen, niet alleen moet informeren naar de gevolgen 
van de hoofdpijn voor het kind zelf, maar ook voor de ouders en de rest van het gezin en 
dit ook consequent moet blijven doen tijdens de behandeling en follow-up. 
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In het vijfde hoofdstuk van dit proefschrift worden de resultaten van een profylactische 
placebo-gecontroleerde cross-over trial bij kinderen met migraine met riboflavine in 
een dagelijkse dosering van 50 mg beschreven. In tegenstelling tot bij volwassenen, 
konden we geen bewijs vinden voor een superieur effect van riboflavine ten opzichte 
van placebo. Dit kan te maken hebben met de gebruikte dosering zoals een recente 
studie laat zien17. In deze retrospectieve studie werden 41 kinderen en adolescenten 
met migraine dagelijks met 200 mg of 400 mg riboflavine behandeld gedurende drie 
tot zes maanden. Uit deze studie bleek dat 68,4% van de geincludeerde  kinderen een 
vermindering had in de frequentie van hoofdpijn aanvallen van 50% of meer, zonder 
ernstige bijwerkingen17. Echter, deze studie was retrospectief van opzet, er was geen 
placebo-groep en de behandeling was niet geblindeerd, parameters die stuk voor stuk 
essentieel zijn voor een hoge kwaliteit van onderzoek. Toekomstige studies naar het 
effect van riboflavine bij kinderen met migraine dienen derhalve placebogecontroleerde, 
gerandomiseerde, dubbelblinde trials te zijn conform het CONSORT statement. 
De dosering van riboflavine dient tenminste 200 mg of 400 mg dagelijks te zijn. 
In onze trial werden aanwijzingen gevonden dat riboflavine een profylactisch effect kan 
hebben op de episodische spierspanningshoofdpijn bij kinderen met migraine. Dit is nog 
niet eerder beschreven, ook niet bij volwassenen. Echter, om definitief vast te stellen of 
riboflavine inderdaad een primair effect heeft op episodische spierspanningshoofdpijn bij 
kinderen of volwassenen dienen placebogecontroleerde, gerandomiseerde dubbelblinde 
studies te worden uitgevoerd bij kinderen en volwassenen met spierspanningshoofdpijn 
met of zonder migraine conform het CONSORT statement. Desalniettemin, vanuit 
een klinisch perspectief, gebaseerd op onze studie en gegeven het gebrek aan 
wetenschappelijk bewezen effectieve migraine profylactica zonder bijwerkingen, lijkt het 
ons gerechtvaardigd om riboflavine schrijven in de dosering zoals beschreven is in onze 
trial voor kinderen met migraine die tevens last hebben van spierspanningshoofdpijn, 
voor een periode van ten hoogste vier maanden.
In de studie zoals beschreven in het zesde hoofdstuk van dit proefschrift werd 
aangetoond dat riboflavine in feite optrad als een placebo op alle onderzochte aspecten 
van de KvL en de CBCL (sub)schalen gedurende de hele trial. Tijdens de trial verbeterde 
de KvL in 11 van de 13 KvL domeinen en op alle CBCL (sub)schalen. Dit resulteerde in 
normalisatie van de scores op 4 van de 13 KvL domeinen en alle CBCL (sub)schalen 
op één na. Dit heeft klinische consequenties omdat deze trial laat zien dat de KvL bij 
kinderen met migraine bij verwijzing naar een specialist slecht is, waarbij dit niet komt 
door psychologisch dysfunctioneren, maar door de ziekte zelf. Men zou daarom kunnen 
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stellen dat het doorverwijzen van een kind met migraine naar een kinderpsycholoog of 
kinderpsychiater bij voorkeur moet worden overwogen bij uitblijven van verbetering na 
een bepaalde periode van medicamenteuze behandeling. Echter, deze trial is de eerste 
studie bij kinderen met migraine waarin KvL en psychologisch functioneren zijn gebruikt 
als uitkomstmaat voor behandeling, wat derhalve beperkt bewijs geeft voor deze stelling. 
Om tot definitief wetenschappelijk bewijs te komen en deze stelling te ontwikkelen tot 
een richtlijn zijn meer vergelijkbare studies nodig. 
Aangetoond is verder dat de KvL bij kinderen met migraine niet verbetert op het domein 
global health (algemene gezondheid van het kind) en family cohesion (kwaliteit van de 
onderlinge relaties in het gezin) ondanks verbetering van de hoofdpijn aanvallen. Vanuit dit 
perspectief, wanneer een kind met migraine wordt verwezen naar een kinderpsycholoog 
of kinderpsychiater, kan de betrokken psycholoog of psychiater deze KvL domeinen 
verkennen en (zo nodig) proberen aan te passen. Dit betekent dat hij of zij onderzoekt 
hoe de ouders hun kind met migraine in figuurlijke zin zien, en zo nodig probeert dat 
beeld te veranderen, bijvoorbeeld door in plaats van het zien van hun kind als min of meer 
ziek en hulpeloos, de ouders te leren hun kind te zien als een kind dat een betrekkelijk 
milde aandoening heeft met een goede prognose indien eenvoudige leefregels worden 
toegepast gecombineerd met een adequate medicamenteuze behandeling. Daarnaast
 kan, indien nodig, de kwaliteit van de verhoudingen binnen de familie van het kind met migraine 
worden aangepast om een meer samenhangende en gezonde gezinssituatie te bevorderen. 
        
Tenslotte werd vastgesteld dat een nacht minder slaap niet een belangrijke uitlokkende 
factor is voor het krijgen van hoofdpijn bij kinderen met migraine. Wel werd vastgesteld 
dat, indien er sprake is van een hoofdpijnaanval, rust en slapen resulteren in een klinisch 
relevante vermindering van de intensiteit en de duur van de hoofdpijnaanval, vergeleken 
met het in het geheel niet gaan rusten of slapen. Rusten en slapen had meer effect op 
de vermindering van  de intensiteit en de duur van de hoofdpijn wanneer het kind de 
voorgaande nacht minder dan gewoonlijk had geslapen. Deze bevindingen zijn klinisch 
relevant omdat ze beperkt bewijs leveren dat een tekort aan slaap bij kinderen met 
migraine niet automatisch een hoofdpijn aanval hoeft uit te lokken en dat rusten en slapen 
verstandige maatregelen zijn wanneer een hoofdpijn aanval begonnen is bij kinderen 
met migraine, vooral wanneer het kind minder heeft geslapen dan normaal in de nacht 
voorafgaande aan de hoofdpijn aanval. Er zijn echter weinig studies uitgevoerd waarbij 
onderzocht is wat het effect is van slaap bij kinderen met migraine. Meer prospectieve 
studies zijn nodig om verder de relatie tussen slaap en hoofdpijn bij kinderen met 
migraine op te helderen.
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Dankwoord
DANKWOORD
Op de eerste plaats wil ik de kinderen en ouders bedanken die hebben deelgenomen 
aan de studies zoals nu verschenen in dit proefschrift. Ik hoop dat dankzij hun deelname 
aan dit onderzoek er meer inzicht is ontstaan in wat het betekent om op jonge leeftijd 
migraine te hebben, zowel voor het kind als zijn of haar familie.  
Verder ben ik een aantal personen veel dank verschuldigd.
Geachte professor Arts, beste Willem-Frans, dank voor het mogelijk maken dat ik 
onderzoek kon gaan doen en voor het vertrouwen wat jij steeds in mij hebt gehouden. 
Onze eerste ontmoeting vond plaats in 2000, kort nadat ik in het Vlietland Ziekenhuis was 
gaan werken. Jij maakte het toen mogelijk dat ik een part-time aanstelling kon krijgen op 
de afdeling kinderneurologie om zo de werkwijze van de afdeling kinderneurologie van 
het EMC en de kinderneurologen persoonlijk goed te leren kennen. Nadat ik enige tijd bij 
jou op deze manier werkzaam was, zijn wij gezamenlijk gaan kijken naar een onderwerp 
voor onderzoek en kwamen we uit op hoofdpijn bij kinderen. Jij hebt mij hiervoor 
geïntroduceerd bij professor Passchier. Samen met hem en later de andere betrokkenen 
bij dit onderzoek hebben wij hard gewerkt om deze promotie mogelijk te maken. Steeds 
heb jij mij gesteund en ben je achter mij blijven staan, ook als het tegenzat. Voor het 
uiteindelijk doen slagen van dit project is jouw grote ervaring als kinderneuroloog 
naast je expertise als wetenschapper van doorslaggevend belang geweest in alle fasen 
van het onderzoek. Ik ben er buitengewoon gelukkig mee dat ik met dit project mijn 
onderzoekskwaliteiten heb kunnen laten zien en verder heb kunnen ontwikkelen. Zonder 
jouw hulp was dit niet mogelijk geweest. 
Geachte professor Passchier, beste Jan, ook jou wil ik bijzonder bedanken voor de hulp 
en ondersteuning die jij me hebt geboden tijdens het gehele promotietraject. Je input 
in de ontwikkelingsfase van de studies, je begeleiding tijdens deze studies, je visie op 
de data-analyses en jouw deskundige aanvullingen en correcties voor de verschillende 
hoofdstukken zijn maar een klein deel van de zaken die jij hebt ingebracht. Ook heb ik 
het bijzonder gewaardeerd dat jij er nooit een probleem van maakte als ik  jou belde of 
mailde om een aspect van een artikel te bespreken waar ik mee worstelde of als er andere 
zaken waren met betrekking tot het onderzoek waar ik graag overleg over wilde hebben. 
Vrijwel altijd lukte het je om mij snel terug te bellen of snel terug te mailen (zelfs als je in 
het buitenland verbleef!) waardoor  het onderzoek zijn vaart behield.   
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Geachte doktor Van Duivenvoorden, beste Hugo, ook jou ben ik veel dank verschuldigd 
voor je hulp en ondersteuning. Deze was veel breder dan alleen de ondersteuning 
ten aanzien van de statistiek. Niet alleen heb je mij geholpen met aspecten van het 
onderzoek zoals het maken van keuzes uit de data en de verschillende statistische 
analyse methoden,  ook heb je waardevolle adviezen gegeven voor het schrijven van de 
artikelen waar ik veel aan heb gehad. Gaandeweg het promotietraject ben ik jou dan ook 
veel meer gaan beschouwen als copromotor dan als statisticus. Ook heb ik genoten van 
onze gesprekken en discussies tussen de bedrijven door over de actualiteit, geneeskunde 
en gezondheidszorg, Frankrijk en vele andere zaken. Het is zonder meer passend dat jij 
uiteindelijk ook officieel mijn copromotor bent geworden!  
Geachte mevrouw Dijkstra, beste Natascha, aan jouw inspanningen als 
researchverpleegkundige heb ik bijzonder veel te danken.  Jij en ik zijn in 2005 tegelijkertijd 
begonnen aan de studies waar uiteindelijk het grootste gedeelte van het proefschrift op 
is gebaseerd. Niet alleen zorgde je ervoor dat de data op een correcte manier werden 
ingevoerd in de vele databases, ook was je inbreng onmisbaar in de vele overlegmomenten 
met Hugo toen wij de databases en de statistische software aan het opzetten waren 
en vervolgens de data gingen analyseren. Verder heb jij nog met vele andere hand- en 
spandiensten je het vuur uit de sloffen gelopen voor het onderzoek. Ik ben heel blij voor 
je dat je, mede dankzij je inspanningen als researchverpleegkundige voor dit project, nu 
al weer enige tijd een baan als gespecialiseerd kinderneurologieverpleegkundige hebt op 
de polikliniek kinderneurologie van het Havenziekenhuis, een plek waar je alleen al door 
je expertise op het gebied van kinderhoofdpijn meer dan op je plaats bent.
Geachte collega Locher, beste Heiko, jij kwam in een relatief laat maar wel cruciaal stadium 
bij het project waarbij ook jouw inbreng van grote waarde is geweest. Je hebt een 
belangrijke bijdrage geleverd in de data-analyse van de riboflavinetrial maar met name 
was je inbreng essentieel bij het uitvoeren van het systematische literatuuronderzoek 
naar het voorkomen van psychische comorbiditeit bij kinderen met migraine en de studie 
over de effecten van slaap op hoofdpijnklachten bij kinderen met migraine. Het is dan ook 
zonder meer terecht dat jij mede-auteur bent geworden van de publicaties voortkomende 
uit de riboflavinetrial en tweede auteur van deze laatste twee publicaties. Ik ben blij dat 
jij, mede door jouw inspanningen voor dit onderzoek, er in bent geslaagd een promotie- 
en opleidingsplaats voor KNO-arts te verwerven, iets wat jij heel graag wilde. Jij bent nu 
gestart met je eigen promotieonderzoek op de afdeling KNO in het LUMC. Doe je voordeel 
met de opgedane kennis door je medewerking aan dit project en aarzel niet om te bellen 
voor advies of als je nog een keer een (race)fietstochtje naar het Woudt wil maken !    
175
Ch
ap
te
r 1
0
Dankwoord
Verder wil ik ook bedanken Brigitte de Bie, Evelyne van Boeckel, Bert den Exter, Esther 
Hentzen-Alders, Sandra Kenter, Coby Langendoen, Arjan Pijning en Lia van Wijk, mijn 
collega-kinderartsen in het Vlietland Ziekenhuis. Ik wil hen met name bedanken voor 
het doorverwijzen van hun hoofdpijnpatiëntjes en het vertrouwen wat zij steeds in mij 
hebben gehad om dit onderzoek succesvol af te ronden tot een promotie.    
Speciaal dank ben ik verschuldigd aan Sjaan Scholten, polikliniekassistente op de 
polikliniek Kindergeneeskunde van het Vlietland Ziekenhuis. Beste Sjaan, jij was vanaf het 
begin betrokken bij het onderzoek. Dankzij jouw “hoofdpijnschriftje” (dat overigens nu 
nog steeds dienst doet) was het mogelijk om een goede systematiek in het onderzoek 
aan te houden. Ook veel dank voor het punctuele uitreiken, verzamelen en categoriseren 
van de vele formulieren die de ouders van de patiënten steeds moesten invullen voor de 
studies zoals in dit proefschrift beschreven. Daarnaast heb jij ook nog veel andere hand- 
en spandiensten geleverd voor het onderzoek. Ik heb dat zeer gewaardeerd.
In het bijzonder wil ik noemen Gerrit-Jan van Zoelen, voorzitter van de Raad van Bestuur 
van het Vlietland Ziekenhuis. Beste Gerrit-Jan, wij spraken elkaar voor het eerst toen jij 
zes weken was aangesteld en ik bij je kwam omdat het onderzoek dreigde vast te lopen. 
Jij heb het toen mogelijk gemaakt dat de voorwaarden werden gecreëerd om de verdere 
voortgang van het onderzoek te waarborgen. Hiervoor mijn grote dank.   
Verder ben ik blij met de inspanningen die Adrie Noteboom van de Afdeling EAD van 
het Vlietland Ziekenhuis heeft verricht. Adrie,  jij was de grootboekrekeninghouder voor 
de riboflavinetrial en jij hebt dit keurig gedaan. Ook veel dank voor het regelen van de 
benodigde stukken voor de accountantsverklaring (en wat was ik blij dat deze uiteindelijk 
werd afgegeven!). Ook wil ik bedanken Adrie Pelgrim van het CKCL laboratorium. Adrie, 
dank voor je inspanningen. 
Ook wil ik bedanken alle verpleegkundigen, secretaresses en andere medewerkers van 
de kinderafdeling van het Vlietland Ziekenhuis voor hun steeds aanwezige interesse in 
dit onderzoek.
     
Wat ik bijzonder op prijs stelde was de belangstelling voor dit onderzoek van Corien 
Catsman, Renee de Coo, Liesbeth Smit, Marie-Claire de Wit, Liesl Rehbock, Hannerieke 
van den Hout en Rinze Neuteboom, collega-kinderneurologen in het EMC en het 
Havenziekenhuis. Ook dank voor het doorverwijzen van de hoofdpijnpatiëntjes en de 
adviezen die ik van hen mocht ontvangen.
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Arianne Verhagen van de afdeling Huisartsgeneeskunde van het EMC wil ik bedanken 
voor haar vriendelijke uitnodiging om lid te worden van de “Werkgroep Kinderhoofdpijn”. 
Arianne, door mijn lidmaatschap hiervan en het intensief meewerken aan de 
gerealiseerde publicaties heb ik veel geleerd op het gebied van systematisch “evidence 
based” literatuuronderzoek. Deze ervaring kwam mij goed van pas bij het schrijven van 
mijn “eigen” systematische literatuurstudie ten aanzien van psychische comorbiditeit bij 
kinderen met migraine, wat uiteindelijk heeft geleid tot een publicatie in Pediatrics. 
Ook een woord van dank voor de medewerkers van de afdeling Medische Psychologie 
en Psychotherapie van het EMC, waar ik ook enige tijd een eigen werkkamer had. In het 
bijzonder wil ik Margreet Langendoen en Miranda Spek, afdelingssecretaresses, bedanken 
voor de nodige hand- en spandiensten die zij geleverd hebben voor het onderzoek.
Ook wil ik bedanken de kinderartsen, neurologen en kinderneurologen die patiëntjes 
naar mij hebben doorverwezen voor de riboflavinetrial. In het bijzonder collega P. de Laat, 
J. Samijn, A. van Rossum, R. van der Lee, D. Kamphuis, B. Koop and C. de Korte. Ook wil 
ik bedanken Loes Visser and Hong San Lau, ziekenhuisapothekers in respectievelijk het 
Erasmus MC en het Vlietland Ziekenhuis, voor het regelen, opslaan en verstrekken van de 
riboflavine- en placebocapsules voor de riboflavinetrial. Veel dank hiervoor, dit was een 
van de aspecten van het onderzoek dat werkelijk uitstekend verliep.
Niet in de laatste plaats ben ik Laraine Visser dankbaar, die door haar “native speaker 
activiteiten” gewaarborgd heeft dat de correcte Engelse spelling en grammatica steeds 
is gebruikt. Bedankt hiervoor, geen enkele referee of editor heeft hierover opmerkingen 
gemaakt! 
Tenslotte wil ik graag nog diegenen in mijn persoonlijke leven bedanken die mij zoveel 
steun hebben gegeven in de afgelopen jaren.
Ik wil mijn vrienden door de jaren heen, Franc Petrus, Jonathan en Sontje Go, Erwin en 
Carola Melger, Patrick en Uraida van Wonderen, Paul en Martine Staneke, Inge en Arthur 
de Jong, Benjamin Go, Fay ten Berge en Rosseel van den Broek, Lennie en Ton van Osch, 
Joop en Mihaela Plaisier, Maarten en Betty Derickx en Mikel Kors bedanken voor hun 
steun in de afgelopen jaren maar vooral ook voor hun begrip omdat ik me weer eens 
moest afmelden voor een van hun verjaardagen of een festiviteit anderszins vanwege het 
onderzoek. Jonathan en Franc, fantastisch dat jullie paranimf zijn op de promotie! 
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Mijn broer Niek Bruijn, zijn vrouw Ignia en mijn zus Lydie-Anne Bruijn wil ik ook bedanken 
voor hun steeds aanwezige interesse en belangstelling voor mijn onderzoek.
Lieve mama, wij weten allebei dat het bereiken van deze promotie voor mij heel veel 
betekent. Het zou ook veel betekend hebben voor mijn vader en jouw man, Simon Bruijn, 
die helaas veel te vroeg is overleden. Ten tijde van zijn overlijden was ik net begonnen 
aan mijn opleiding tot kinderarts en moest het sindsdien zonder hem doen. Dat is voor 
ons niet altijd even makkelijk geweest, met name in de zware en verdrietige periode na 
zijn overlijden. Ons leven heeft zich verder ontwikkeld sindsdien. Het bereiken van deze 
mijlpaal was niet mogelijk geweest zonder je aandacht en toewijding naar mij en later ook 
naar Christine en de kinderen. Mama, heel veel dank en een hartelijke omhelzing voor jou. 
Allerliefste Christine, dit lange dankwoord wil ik bij jou laten eindigen omdat ik bovenal 
dankzij jou deze klus heb kunnen klaren. Ik wil je bedanken voor je steun naar mij toe 
terwijl ik met mijn promotie bezig was en vooral voor je regelmatige benadrukken dat er 
meer in het leven is dan werken en promoveren. Jij hield me gelukkig met beide benen 
op de grond als ik weer eens over een probleem of een formulering in een artikel zat na 
te denken. In de loop van dit promotietraject hebben wij drie kinderen gekregen, Simon, 
Niek en Anna, van wie ik zielsveel houd en waar ik je nog veel dankbaarder voor ben. 
Ik hoop dat wij samen met onze kinderen nog veel mooie en goede momenten zullen 
beleven. Ik kijk uit naar de jaren die nog voor ons liggen en hoop dat ik jou daarin dezelfde 
zorg en steun kan verschaffen die jij mij en de kinderen al zo lang en zo liefdevol geeft.  
Jacques Bruijn
Zomer 2010
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CURRICULUM VITAE
Jacques Bruijn werd geboren op 4 augustus 1965 te Haarlem. Na het basisonderwijs 
ging hij naar het Triniteitslyceum te Overveen. Hij beëindigde aldaar zijn gymnasium-ß 
opleiding in mei 1983 en begon aansluitend met de opleiding Geneeskunde aan de 
Vrije Universiteit van Amsterdam. In september 1990 slaagde hij cum laude voor zijn 
artsexamen. Hierna ging hij werken als AGNIO op de afdeling Kinderneurologie van het 
Universitair Medisch Centrum Utrecht (hoofd prof. dr. O. Van Nieuwenhuizen) waarna hij 
van juli 1991 tot februari 1992 werkzaam was als AGIO op de afdeling Oogheelkunde 
van het Academisch Ziekenhuis van de Vrije Universiteit te Amsterdam (hoofd prof. dr. K. 
Tan). Omdat de kindergeneeskunde en kinderneurologie bleven trekken solliciteerde hij 
naar een opleidingsplaats voor kinderarts in het opleidingscluster Nijmegen. In februari 
1992 begon hij hiermee op de afdeling Kindergeneeskunde van het Canisius Wilhelmina 
Ziekenhuis te Nijmegen (hoofd dr. P. Van Wieringen). In mei 1993 ging hij werken op de 
afdeling Kindergeneeskunde (hoofd prof. dr. R.C.A. Sengers) van het Universitair Medisch 
Centrum Nijmegen (UMCN).  In het kader van het ontwikkelen van kinderneurologie als 
subspecialisatie werkte hij in totaal 9 maanden op de afdeling kinderneurologie van het 
UMCN (hoofd prof. dr. F. Gabreëls) en deed hij onderzoek op het echografielaboratorium 
van deze afdeling. Tevens werkte Jacques van februari 1996 tot februari 1997 als arts-
assistent op de afdeling Neurologie van het UMCN (hoofd prof. dr. G. Padberg). Hij 
beëindigde zijn opleiding in februari 1998. Hierna ging hij werken als chef de clinique op 
de afdeling Kindergeneeskunde van het Sint Maartens Gasthuis te Venlo. In december 
1999 maakte hij de overstap naar de afdeling Kindergeneeskunde van het Vlietland 
Ziekenhuis in Schiedam waar hij nog steeds werkzaam is.
Vanaf februari 2001 tot februari 2003 had Jacques een part-time aanstelling op de afdeling 
Kinderneurologie van het EMC-Sophia Kinderziekenhuis (hoofd prof. dr. W.F. Arts). In 
augustus 2002 werd hij geregistreerd als kinderneuroloog NVKN (Nederlandse Vereniging 
voor Kinderneurologie). Naast de algemene kinderneurologie en gedragsneurologie heeft 
Jacques kinderhoofdpijn als aandachtsgebied. In het kader van dit laatste aandachtsgebied 
verrichte hij de studies waaruit dit proefschrift uiteindelijk is voortgekomen. 
Verder heeft Jacques als aandachtsgebied acute kindergeneeskunde. Hij werd in oktober 
1999 geregistreerd als Pediatric Advanced Life Support (PALS)-instructeur en in maart 
2005 als European Pediatric Life Support (EPLS)-instructeur bij de Stichting Spoedeisende 
Hulp Kindergeneeskunde (SHK). Van december 2000 tot oktober 2005 was hij course-
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director voor de PALS. In oktober 2004 werd hij geregistreerd als Newborn Life Support 
(NLS)-instructeur.
Jacques is lid van het Pediatric Subcomittee van de International Headache Society. 
Hij was lid van de commissie Protocollen en Consensus (voorzitter dr. C. Lincke) van 
de Nederlandse Vereniging van Kinderartsen (NVK) en van de NVK-werkgroep
 “Pijnherkening en Behandeling bij kinderen” (voorzitter dr. R. Van Lingen). Als lid van deze 
laatste werkgroep stelde hij onder meer de richtlijn “Diagnostiek en Behandeling van 
Kindermigraine” op. Hij is verder lid van de werkgroep Kinderhoofdpijn (voorzitter Dr. G. 
Hageman) en de werkgroep Gedragsneurologie (voorzitter drs. F. Visscher) van de NVKN.
Jacques is in 1996 getrouwd met Christine. Samen hebben zij twee zonen, Simon en Niek, 
en een dochter, Anna.
